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Abstract 
 
  
 The biosynthesis of tetrapyrolles in eukaryotes and the -subclass of purple 
photosynthetic bacteria is controlled by the pyridoxal 5’-phosphate (PLP)-dependent 
enzyme, 5-aminolevulinate synthase (ALAS).  Aminolevulinate, the universal building 
block of these macromolecules, is produced together with Coenzyme A (CoA) and 
carbon dioxide from the condensation of glycine and succinyl-CoA.  The three-
dimensional structures of Rhodobacter capsulatus ALAS reveal a conserved active site 
serine that moves to within hydrogen bonding distance of the phenolic oxygen of the PLP 
cofactor in the closed, substrate-bound enzyme conformation, and simultaneously to 
within 3-4 angstroms of the thioester sulfur atom of bound succinyl-CoA.  To elucidate 
the role(s) this residue play(s) in enzyme activity, the equivalent serine in murine 
erythroid ALAS was mutated to threonine or alanine.  The S254A variant was active, but 
both the SCoAmK  and kcat values were increased, by 25- and 2-fold, respectively, suggesting 
the increase in turnover is independent of succinyl-CoA-binding.  In contrast, substitution 
of S254 with threonine results in a decreased kcat, however the Km for succinyl-CoA is 
xi 
unaltered.   Removal of the side chain hydroxyl group in the S254A variant notably 
changes the spectroscopic properties of the PLP cofactor and the architecture of the PLP-
binding site as inferred from circular dichroism spectra.  Experiments examining the rates 
associated with intrinsic protein fluorescence quenching of the variant enzymes in 
response to ALA binding show that S254 affects product dissociation.  Together, the data 
led us to suggest that succinyl-CoA binding in concert with the hydrogen bonding state of 
S254 governs enzyme conformational equilibria.    
  As a member of the -oxoamine synthase family, ALAS shares a high degree of 
structural similarity and reaction chemistry with the other enzymes in the group.   
Crystallographic studies of the R. capsulatus ALAS structure show that the alkanoate 
component of succinyl-CoA is bound by a conserved arginine and a threonine.  To 
examine acyl-CoA-binding and substrate discrimination in murine erythroid ALAS, the 
corresponding residues (R85 and T430) were mutated and a series of CoA substrate 
analogs were tested.  The catalytic efficiency of the R85L variant with octanoyl-CoA was 
66-fold higher than that calculated for the wild-type enzyme, suggesting this residue is 
strategic in substrate binding.  Hydrophobic substitutions of the residues that coordinate 
acyl-CoA-binding produce ligand-induced changes in the CD spectra, indicating that 
these amino acids affect substrate-mediated changes to the microenvironment of the 
chromophore.  Pre-steady-state kinetic analyses of the R85K variant-catalyzed reaction 
show that both the rates associated with product-binding and the parameters that define 
quinonoid intermediate lifetime are dependent on the chemical composition of the acyl-
CoA tail.  Each of the results in this study emphasizes the importance of the relationship 
between the bifurcate interaction of the alkanoic acid component of succinyl-CoA and the 
xii 
side chains of R85 and T430.  
 From the X-ray crystal structures of Escherichia coli 8-amino-7-oxonoanoate 
synthase and R. capsulatus ALAS, it was inferred that a loop covering the active site 
moved 3-6 Å between the holoenzymic and acyl-CoA-bound conformations.  To 
elucidate the role that the active site lid plays in enzyme function, we shuffled the portion 
of the murine erythroid ALAS cDNA corresponding to the lid sequence (Y422-R439), 
and isolated functional variants based on genetic complementation in an ALA-deficient 
strain.  Variants with potentially greater enzymatic activity than the wild-type enzyme 
were screened for increased porphyrin overproduction.  Turnover number and the 
catalytic efficiency of selected functional variants with both substrates were increased for 
each of the enzyme variants tested, suggesting that increased activity is linked to 
alterations of the loop motif.  The results of transient kinetics experiments for three 
isolated variants when compared to wild-type ALAS showed notable differences in the 
pre-steady-state rates that define the kinetic mechanism, indicating that the rate of ALA 
release is not rate-limiting for these enzymes.  The thermodynamic parameters for a 
selected variant-catalyzed reaction indicated a reduction in the amount of energy required 
for catalysis.  This finding is consistent with the proposal that, in contrast to the wild-type 
ALAS reaction, a protein conformational change associated with ALA release no longer 
limits turnover for this variant enzyme. 
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Chapter One 
 
Introduction 
 
The central function of heme:  biogenesis, chemistry and health 
Living organisms utilize tetrapyrroles in many important cellular processes.  
Heme, a ferrous metallated tetrapyrolle, serves a crucial role as a prosthetic group in 
cytochromes and globins, proteins responsible for respiration (1).  As a cofactor, heme is 
a component of reactions catalyzed by various enzymes including: catalases, peroxidases 
and the cytochrome P-450s (2, 3).  Heme also modulates both steps of the central dogma 
of molecular biology.  Transcription is affected via a signal transduction cascade, 
whereby heme activates transcriptional repressors such as Bach-1 (4, 5).  Message 
translation is highly regulated through the phosphorylation of eucaryotic translation 
initiation factor 2A (eIF2α) by a number of heme-dependent kinases (6-9). 
Hierarchically, among eucaryotes and the α-subclass of purple photosynthetic 
bacteria, the heme biosynthetic pathway consists of eight enzymes (Figure 1.1).  The 
biosynthesis begins with the condensation of glycine and succinyl-CoA and concludes 
with the chelation of ferrous iron by protoporphyrin IX (10).  Among cells with 
organelles, all eight enzymes are nuclear encoded; however, the enzymes are distributed 
in both the cytosol and mitochondria (11).  Porphyrias, congenital disorders characterized 
by the accumulation of porphyrins and porphyrin precursors, occur when gene-derived 
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defects are present among the pathway enzymes (12).  Aberrant iron metabolism and 
associated disorders stem from additional enzymatic deficiencies (13).   
The catabolism of heme is a tightly regulated process involving heme oxygenase 
and biliverdin reductase, which together degrade heme to carbon monoxide, iron and 
bilirubin (14).  Heme, present in hemoproteins, is degraded to bile pigments by the action 
of heme oxygenase (15, 16).  Typical inducers of heme oxygenase include:  heme, 
endotoxin, heavy metals and hypoxia (17-19).  The role of these molecules and 
circumstances in the generation of reactive oxygen species has been documented, 
suggesting that the action of the rate-limiting step of heme degradation is potently 
cytoprotective (20).  Several disease states are associated with defects in heme 
breakdown, including atherosclerosis and cancer, as well as a number of inflammatory, 
autoimmune, and degenerative diseases (21, 22). 
 The enzymes of the heme biosynthetic and degradation pathways have been 
crystallized.  These three-dimensional structures provide the framework for identifying 
structural components of both the molecular basis of heme-related disease and catalysis.  
This introduction describes each enzyme of these pathways in terms of structure and 
function with the congenital disorder at each step addressed.  The focus of this 
dissertation is on aminolevulinate synthase, the enzyme on which my theses are based.   
Enzymes in the heme biosynthesis pathway 
Aminolevulinate synthase 
5-Aminolevulinate synthase (EC 2.3.1.37) (ALAS), is the first, and key regulatory 
enzyme of heme biosynthesis in non-plant eucaryotes and the α-subclass of purple 
photosynthetic bacteria (Figure 1.1) (23).  ALAS catalyzes the Claisen-like condensation 
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of glycine and succinyl-Coenzyme-A to yield coenzyme-A (CoA), carbon dioxide (CO2) 
and 5-aminolevulinate (ALA) (23).  For the remaining monera, and in all plants, ALA is 
synthesized from an alternative pathway involving the five carbon skeleton of glutamate 
(24, 25).  Interestingly, the photosynthetic phytoflagellate Euglena gracilis synthesizes 
ALA via both pathways, with non-plastid heme synthesized from glycine or the Shemin 
pathway, and chloroplast heme coming from glutamate-derived ALA (26).    
 The ALAS-catalyzed reaction takes place in the mitochondria of non-plant 
eucaryotes (11).  This reaction is tightly regulated, and the rate of reaction determines the 
anabolic production of downstream metabolites in the pathway (27, 28).  Mammalian 
genomes contain two genes which code for two isoforms of ALAS.  The gene encoding 
the non-specific, or housekeeping form of ALAS (ALAS1), which is constitutively 
expressed in all tissues, has been localized to chromosome band 3p21 (29).  The erythroid 
specific form of the enzyme (ALAS2) is encoded by a gene located on the X-
chromosome at band Xp11.21 (30).  The nucleotide sequences of the two genes are 
notably different; however, the two protein isoforms share significant similarity (29, 31).  
Mitochondrial import of ALAS is determined by an N-terminal transit sequence, which is 
cleaved prior to enzyme maturation (32).  ALAS2 from Rattus rattus shows a ~9 kDa 
difference in monomeric molecular weight after the presequence is clipped (33).   
Heme and iron regulate both gene expression and sub-cellular localization of 
ALAS.  Mammalian ALAS proteins contain heme regulatory motifs (HRM) which 
consist of a conserved dipeptide, Cys-Pro (32).  By way of HRMs, depleted intracellular 
heme pools inhibit the mitochondrial translocation of ALAS1 (34).  Plentiful heme on the 
other hand in differentiating erythrocytes does not contribute to
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mitochondrial import of the ALAS2 enzyme (34).  Transcription of the ALAS1 gene is 
upregulated by peroxisome proliferator-activated coactivator 1α (PGC-1α) (35), through 
promoter-mediated interactions with both nuclear regulatory factor 1 (NRF-1) and the fox 
head family member FOX01 (36).  Transcription of the ALAS2 gene is regulated by 
erythroid-specific factors including GATA-binding protein 1 (globin transcription factor 
1), a protein which is chiefly responsible for the activation of globin production in red 
cells (37).  The resultant ALAS2 transcript contains a 5' iron regulatory element (IRE) 
which binds with the IRE-binding protein (IRP) in iron-poor conditions, rendering 
translation impossible (38).  Under iron-rich conditions, the IRP-1 contains an Fe-S 
cluster (38).  The incorporation of this prosthetic group within the protein restricts 
formation of the IRE-IRP-1 complex, permitting message translation by the ribosome 
(38).  Ultimately, it is the bioavailability of iron that is the chief modulator of ALAS2 
production in vivo (39). 
The reaction catalyzed by ALAS is markedly similar to those of 2-amino-3-
ketobutyrate-CoA ligase (KBL), 7-amino-8-oxononanoate synthase (AONS), and serine 
palmitoyl transferase (SPT) (40-43).  Based on structure and function, ALAS is classified 
as a fold-type I pyridoxal-5’-phosphate (PLP)-dependent enzyme and as a member of the 
α-oxoamine synthase subfamily; AONS, KBL and SPT represent the closest structural 
relatives, with the enzymes of the subfamily sharing a Cα RMSD of 1.5 Å (44).  KBL 
catalyzes the degradation of threonine (45), AONS, the committed step in biotin 
biosynthesis (46) and SPT, the first step of sphingolipid biosynthesis (47).  In all cases 
the reduced coenzyme is liberated and the aminoketone product of the enzyme-catalyzed 
reaction is further metabolized.  Enzymes in the α-oxoamine synthase family function as 
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homodimers, with each monomer containing a PLP cofactor at the subunit interface (44).  
In ALAS, there is one active site per subunit, comprised of residues from adjacent 
monomers at the dimeric boundary (48).   
 The three-dimensional structure of ALAS from Rhodobacter capsulatus has been 
solved (49).  The bacterial protein exists as a homodimer, where each monomer consists 
of three domains.  The N-terminal domain, discrete from the remainder of the enzyme, is 
defined by an alpha-helix and an anti-parallel beta-sheet.  The catalytic domain contains a 
core parallel beta-sheet flanked by alpha helices.  The C-terminal domain independently 
interacts with the N-terminal domain through three alpha-helices and with the central 
core domain of the enzyme via a three-stranded, anti-parallel beta-sheet.  The orientation 
of the PLP cofactor can be considered to occur through interactions with three specific 
protein moieties.  First, the phosphate group is bound tightly via 6 hydrogen bonds 
(where three are intrasubunit, and three intersubunit).  Second, pi-stacking interactions 
between the conjugated systems of the cofactor and a conserved active site histidine also 
stabilize the position of PLP.  Third, hydrogen bonding between a conserved aspartate 
residue and the pyridinium nitrogen enhance the electron withdrawing properties of the 
cofactor.  This PLP microenvironment and adjacent C-terminal domain delimit the 
substrate-binding channel, connecting the solvent exposed surface of the enzyme with the 
hydrophobic core of the enzyme, where the acyl-CoA-binding cleft is located (49). 
Studies focused on the role conserved amino acids play in the reaction catalyzed 
by murine ALAS revealed several notable findings.  First, the catalytic lysine (K313) 
(ALAS2 numbering), essential for enzyme activity and involved in forming a Schiff-base 
linkage with the PLP cofactor, has been elucidated (50).  An aspartate residue (D279) 
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involved in enhancing the electron withdrawing capacity of the PLP cofactor was also 
found (51).  Recognition of the carboxyl group of the glycine substrate and binding of the 
PLP cofactor were found to be dramatically affected when mutations were made to 
arginine residues, R149 and R439 (52-54).  More recently, an active site histidine 
(H282), was reported to modulate the orientation and electronics of the PLP cofactor 
(55).   
The ALAS chemical mechanism  (Scheme 1.1) is complex and involves: binding 
of glycine (I); transaldimination with the active site lysine (K313) to yield an external 
aldimine (II); abstraction of the pro-R proton of glycine (III); condensation with succinyl-
CoA (IV) and CoA release to generate an α-amino-β-ketoadipate intermediate (V); 
decarboxylation resulting in an enol-quinonoid rapid equilibrium (VI); protonation of the 
enol to give an aldimine-bound molecule of ALA (VII); and ultimately release of the 
product (ALA) (VIII) (28).  Transient kinetic analyses have indicated that the rate-
determining step of the ALAS-catalyzed reaction is product release or a conformational 
change leading to product release (27, 28).  The latter of the two possibilities is supported 
by the observation that the ALAS-catalyzed reaction rates, when measured with a variety 
of acyl-CoA derivatives, are comparable (56).   
The proposed model of ALAS catalysis, based on kinetic data obtained in both the 
steady- and pre-steady-states involves transition between “open” and “closed” 
conformations of the enzyme (28).  The binding of the second substrate, succinyl-CoA, to 
ALAS increased the ALAS-catalyzed reaction rate over 250,000 times (57).  This finding 
led to the proposal that part of the intrinsic binding energy of succinyl-CoA is utilized to  
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Scheme 1.1.  The chemical mechanism of ALAS.  The individual steps are: binding of 
glycine (I); transaldimination with the active site lysine (K313, murine erythroid ALAS 
numbering) to yield an external aldimine (II); abstraction of the pro-R proton of glycine 
(III); condensation with succinyl-CoA (IV) and CoA release to generate an α-amino-β-
ketoadipate intermediate (V); decarboxylation resulting in an enol-quinonoid rapid 
equilibrium (VI); protonation of the enol to give an aldimine-bound molecule of ALA 
(VII); and ultimately release of the product (ALA) (VIII).   
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favor the conversion of the population of equilibrium conformers to a population of 
“closed” conformational species.  This inter-conversion between the two conformational 
states is associated with progression of the reaction and ultimately to restoration of the 
open conformation, which is concomitant with ALA release.   
Mutations found in the ALAS2 gene can lead to sideroblastic anemia (58).  
Sideroblastic anemias are a group of disorders where the circulating erythrocytes appear 
hypochromic and the marrow is encumbered by ringed sideroblasts (59).  The nuclei of 
these sideroblastic cells are surrounded by iron-laden mitochondria (60), and thus the 
designation of ringed sideroblasts.  Diminished ALAS2 activity in red blood cells is the 
main reason why retained iron is a hallmark of a defect in heme biosynthesis (61).   
The most common form of inherited sideroblastic anemia is X-linked 
sideroblastic anemia (XLSA), a sex-linked, congenital disorder (61).  Hemizygous males 
present the most severe symptoms including:  fatigue, disorientation and both hepato- and 
splenomegaly (62, 63).  The toxicity of excess iron has been well-documented and leads 
to heart disease, liver and kidney failure (62, 63).  Specifically, potent oxidation of the 
cellular milieu by iron-burdened transferritin leads to decreased cell life via generation of 
reactive oxygen species (60, 64, 65).  
The majority of ALAS2 mutations leading to pathological conditions (e.g., 
XLSA) are missense and are manifested in regions of the protein responsible for 
interactions between the enzyme and its cofactor (49, 66).  In fact, these variants which 
turn over ALA with less efficiency are, to some extent, responsive to pyridoxine 
administration (61).  Other cases, in which the stability or processing of the enzyme is 
perturbed, are refractory to this line of therapy (67).  Advances regarding protein-protein 
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interactions between ALAS and the succinyl-CoA synthetase reveal that abrogation of 
this association may be responsible for the pathological presentation of the defect (49, 
68).   
Until recently, all of the enzymes of the heme pathway in mammals, except 
ALAS, were recognized to have a porphyrin-associated disorder when defective (69).  
Now, ALAS2 gene deletions have been identified in eight families with the following 
genetic manifestations c.1706-1709 delAGTG (p.E569GfsX24) or c.1699-1700 delAT 
(p.M567GfsX24) (70).  The corresponding gene product is a truncated form of the 
erythroid-specific ALAS enzyme (ALAS2), which may be responsible for increased 
circulating concentrations of protoporphyrin IX.  Consequently, these variants 
demonstrate the first instance of an erythroid ALAS-related porphyria, X-linked 
dominant protoporphyria.  With this finding, several features of the biochemical 
mechanism of this mode of disease require further research.  First, since the experiments 
were performed on lysates of bacterial cells harboring the expression plasmid for the 
truncated proteins and not with deletion-variants purified to homogeneity, the opportunity 
for other proteins and metabolites affecting the reaction cannot be ruled out.  Next, while 
the investigators measured ALAS activity in addition to the concentration of reaction 
products and downstream heme pathway intermediates (71), they did not identify whether 
the stability of the enzyme or its message was unchanged.  Certainly, elimination of a 
protein sequence of this magnitude could potentially affect protein degradation rates as 
well as message turnover.  Thorough biochemical experiments are required to elucidate 
the complete nature of this intriguing finding.    
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Porphobilinogen synthase  
The means by which ALA exits the mitochondrion of eukaryotic cells remains to 
be elucidated.  Once in the cytosol, 2 molecules of ALA are asymmetrically condensed 
by the metalloenzyme porphobilinogen synthase (EC 4.2.1.24; PBGS or ALA 
dehydratase (ALAD)) (Figure 1.1) (72).  The formation of porphobilinogen (PBG), a 
monopyrrole, is the first common step of tetrapyrrole biosynthesis among all living 
organisms.  PBGS isolated from different organisms, from bacteria to humans, share a 
high degree of sequence identity (73).  These enzymes are large, exhibiting homo-
octameric quaternary structure, and molecular masses in excess of 280 kDa (74).  The 
crystal structure for human PBGS has been determined (75).  Each of the four compact 
homodimers embrace one another using an N-terminal arm, resulting in tetragonal 
trapezohedral (422) symmetry.  With respect to oligomerization, PBGS is an example of 
a prototypical morpheein ensemble (76).  Morpheeins are the building blocks of a group 
of polypeptides in which a monomer of an enzyme can exist in multiple conformations.  
Each monomeric conformation affects quaternary structure differently, and the result is 
an oligomer of distinctive functionality (77). 
 Catalysis by PBGS begins with the formation of independent Schiff base bonds 
between 2 conserved active site lysine residues and the substrates (78, 79).  The 
destination of the ALA molecule within the monopyrrole dictates the nomenclature of the 
active site.  The A-site refers to one half of the active site that binds ALA destined for 
inclusion as the acetyl component of PBG, while the propionyl-coordinating half of PBG 
derives from P-site ALA.  P-site ALA binds before A-site ALA.  Homo-bond formation 
(C-C) occurs when A-site ALA (C3 position) links with ALA in the P-site (C4) position 
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via an aldol addition (78).  Hetero-bond formation (C-N) follows whereby the P-site 
substrate amino group attacks the A-site Schiff base.  The resultant Schiff-base exchange 
and liberation of the A-site catalytic lysine permit the energetically favorable steps of 
aromatization and product release (78).  The role of metal ions in the reaction catalyzed 
by PBGS has been an item of contention.  Three-dimensional structures obtained with a 
series of substrate and product analogs have been completed, and the role of an active-
site zinc has been partially addressed (78, 80).  A PBGS structure from Pseudomonas 
aeruginosa shows that a magnesium ion can be replaced by a zinc ion through the 
introduction of cysteine residues to the metal binding site (78).  This suggests that the 
direct involvement of magnesium ions in the mechanism of magnesium binding to 
PBGSs, is relatively plastic.  Nevertheless, the functionality of metal ions in the 
mechanism of PBGS remains to be fully elucidated.    
 Mutations that occur in the PBGS or ALAD gene result in a rare recessive 
autosomal disorder called ALAD porphyria (81).  Less than ten cases have been reported 
that are consequence of a defective gene product (82).  In addition to the inherited nature 
of the disease, heavy divalent metal ions can also illicit symptoms associated with PBGS 
deficiency (83).  Over 80% of the lead found in the human body is bound to ALAD (84).  
It has been proposed that ALAD porphyria is a disease where pathology stems from 
defects in conformer equilibrium (85).  Gel filtration data obtained using variants 
encoded by aberrant genes show that oligomerization of mutated enzymes occurs in a 
manner that favors the less active hexameric state.  These hexamers, resulting from eight 
porphyria-associated variants, may be the first example of a morpheein-based 
conformational disease.  Diminished enzyme activity leads to the accumulation of ALA.  
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Symptoms associated with the poor porphobilinogen production include: intermittent 
acute neurovisceral attacks and a propensity toward poisoning by lead (86).  Inhibition of 
this enzyme by succinylacetone, a metabolite found in among individuals with hereditary 
tyrosinemia type I, also causes pathological conditions similar to those of lead poisoning 
and congenital ALAD (80, 87). 
Porphobilinogen deaminase  
A cytosolic polymerization reaction where four molecules of PBG are linked is 
catalyzed by porphobilinogen deaminase (EC 4.3.1.8; PBGD) or hydroxymethylbilane 
synthase) (Figures 1.1 and 1.2).  The physiologically relevant reaction product is the 
linear tetrapyrrole hydroxymethylbilane (HMB) a.k.a. pre-uroporphyrinogen (74).  HMB 
is exceedingly unstable and can undergo spontaneous cyclization to form the non-
physiological isomer uroporphyrinogen I (88).  PBGD sequences are highly conserved 
throughout evolution and among diverse phyla; to date, all isolated enzymes contain a 
unique cofactor, dipyrromethane (89).  PBGD functions as a monomer and the human 
crystal structure was recently solved (90).  Human PBGD consists of 344 residues with a 
molecular weight of ~37 kDa.  The three-dimensional structural analysis shows that the 
monomeric protein is organized into three equal-sized domains.  Domain I houses most 
of the catalytic and substrate-binding residues, while domain II is responsible for cofactor 
binding.  The dipyrromethane cofactor is covalently linked to a loop of residues 
comprising domain III and is perched at the opening of the active site cavity, now known 
to be delimited by cleft formed by domains I and II (90).  A novel mechanism defines the 
generation of the unique dipyrromethane cofactor (91).  During turnover, the enzyme first 
binds HMB, then deaminates and polymerizes 2 molecules of PBG to form a
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Figure 1.2.  The X-ray crystal structure of porphobilinogen deaminase from Homo 
sapiens.  (PDB code: 3ecr) The monomeric protein is organized into three equal-sized 
domains, which are comprised of both α-helices (green) and β-sheets (rust) (A).  Perched 
at the top of the enzyme is the unique dipyrromethane cofactor (depicted as sticks in CPK 
color format) (B). 
A 
B 
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hexapyrrole.  Subsequently, PBGD cleaves the distal tetrapyrrole and releases HMB.  A 
thioether linkage to an active site cysteine retains the dipyrrole cofactor for the lifetime of 
the enzyme (91).  
  Acute intermittent porphyria (AIP) is due to an autosomal dominant pattern of 
inherited mutations of the PBGD gene leading to diminished enzyme activity (12).  
Hundreds of PBGD mutations have been identified, with acute attacks of porphyria 
affecting 1:100000 individuals, with presentation more common in women than men 
(92).  However, only recently was a poly-deletion mutant identified in exon 15 of the 
PBGD gene (93).  The deletion occurs in a conserved region of the protein where other 
disease causing mutations have been discovered (94).  This particular defect clearly has a 
more substantial negative effect on catalysis, as the ALA concentration identified in the 
urine of the patient was 100 times that of normal (92).  Symptoms of AIP include 
abdominal pain and other neurovisceral and circulatory disturbances, ultimately resulting 
in tachycardia (95).  A majority of the mutations identified in the human PBGD gene 
perturb carboxylate binding between conserved arginines and the cofactor or substrate 
(96).  However, recently, some of the mutations documented in patients suffering from 
AIP were found to be located distal from the active site (94). 
Uroporphyrinogen III synthase  
HMB serves as the substrate for the fourth enzyme of the heme biosynthetic 
pathway, uroporphyrinogen III synthase (EC 4.2.1.75) (UROS) (Figure 1.3).  UROS 
catalyzes closure of the tetrapyrrole macrocycle by inverting the D-ring of HMB (74).  
All identified UROS enzymes function as a monomer with a molecular weight of ~30 
kDa (97-100).  UROS proteins from all kingdoms of life are similar with respect to 
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Figure 1.3.  The three-dimensional structure of human uroporphyrinogen III 
synthase. (PDB code: 1jr2)  The functional monomer contains two unambiguous 
domains connected by a short β-ladder (yellow).  Each domain is characterized by a β-
sheet core (magenta) surrounded by α-helices (teal). 
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molecular mass; however significant sequence deviations have been observed (101).  
Specifically, the sequence similarity between mammalian and bacterial UROS is less than 
22%.  Notably, recent three-dimensional studies on UROS from the gram-negative 
eubacterium Thermus thermophilus identified significant conformational information 
(102).  In these experiments eight crystallographically unique UROS structures 
(consisting of apoenzymic, ligand-bound and product-bound forms) were overlaid.  From 
these maps, significant enzyme flexibility was observed, including a snapshot of the 
product-bound enzyme in the closed conformation (102). The X-ray crystal structure of 
human UROS revealed that the enzyme contains two unambiguous domains connected 
by a short β-ladder (103).  Each domain is characterized by a β-sheet core surrounded by 
α-helices.  The substrate binding cleft is located at the domain interface and delimited by 
a series of evolutionarily conserved residues.   
 The UROS-catalyzed reaction proceeds by way of a spirocyclic pyrrolenine 
intermediate (104).  This intermediate occurs after a rearrangement of the A-ring of 
HMB, which results in the concomitant loss of the C20 hydroxyl group and the formation 
of a carbocation at C20.  C16 of the D-ring is then susceptible to electrophilic attack and 
the spirocyclic pyrrolenine intermediate is generated.  Subsequently, azafluvene is 
formed permitting cyclization and D-ring inversion to yield the product 
uroporphyrinogen III.  From the structural data, it was inferred that the interactions of the 
A and B ring carboxylate groups with both structural domains of UROS are the chief 
modulators of the closed enzyme conformation (104).  The C and D rings demonstrate 
increased flexibility, a characteristic consistent with the sterically-mediated acts of 
catalytic cyclization and D ring inversion.  Biological relevance of all porphyrins is 
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demarcated by asymmetry about the D-ring of tetrapyrolles.  Without enzymatic 
conversion, HMB spontaneously cyclizes to a toxic dead end product, which in patients 
with UROS deficiency results in accumulation of uroporphyrinogen I (105). 
 Mutations to the UROS gene manifest as a rare form of porphyria called 
congenital erythropoietic porphyria (CEP) (105).  The defective enzyme is inherited as an 
autosomal recessive trait.  In CEP or Günther disease, HMB is non-enzymatically 
converted to uroporphyrinogen I and is subsequently catalyzed by the fifth enzyme of the 
heme biosynthetic pathway to coproporphyrin I (105).  Recently, a thorough study was 
conducted where 25 missense mutations were cloned into expression vectors, and the 
respective proteins were purified to homogeneity and characterized (106).  Kinetics 
experiments indicated that most mutated enzymes had significantly decreased activity, 
while others maintained reaction rates comparable to those of the wild-type enzyme.  
This suggested that mechanisms besides turnover may be responsible for the pathology 
observed in CEP.  Located in α-helix 3, perched above the active-site, a conserved active 
site cysteine was the focus of experiments related to enzyme structure.  Significantly, 
unfolding experiments performed on variants of this cysteine residue may be crucial for 
proper folding and turnover of uroporphyrinogen III (106).   
Coproporphyrin I is the causative agent of erythrodontia or red staining of the 
teeth (105).  Patients are either homozygous for a single polymorphism or are compound 
heterozygotes for a variant form of the enzyme (105).  In one particular case, CEP was 
diagnosed in a patient with a mutation-free form of the enzyme (107).  The causative 
agent for this pathology was faulty transcription, a defect which was linked to a mutation 
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in the erythroid-specific GATA1 transcription factor.  These particular data provide 
evidence that the functional responsiveness of erythroid specific promoters is different. 
Uroporphyrinogen decarboxylase  
 
The acetate side chains of uroporphyrinogen III are decarboxylated in four 
successive steps by uroporphyrinogen decarboxylase (EC 4.1.1.37; UROD), leaving the 
four methyl groups characteristic of the product coproporphyrinogen III (Figure 1.1) (74, 
108).  UROD exists as a homodimer, with a monomeric molecular mass of ~40 kDa (109, 
110).  Unlike most decarboxylases, UROD activity is independent of a prosthetic group 
or cofactor (111-113).  Sequence similarity among isolated UROD proteins is low; 
however common structural features have been identified between the human and plant 
enzymes (109, 114).  Three-dimensional studies have shown that the monomer contains a 
single domain characterized by a distorted (β/α) barrel, with the active site housed at the 
end of a deep cleft, delimited by the C-terminal loops of the barrel.  Evolutionarily 
conserved residues line the cleft, and several invariant basic residues are crucial for 
binding the propionate groups of the substrate (109, 110).  A dynamic active site loop 
located at the head of the active site undergoes conformational changes to allow substrate 
entry and reorganization of the catalytic cleft (109, 115). 
 After the asymmetric D-ring of uroporphyrinogen III is decarboxylated, 
sequential removal of the acetate groups proceeds in a clockwise manner (114, 116, 117).  
To accomplish this, sequential decarboxylation requires the 180o reorientation of the 
intermediate, a process whereby the substrate is flipped around its C10-C20 axis.  
Controversy exists as to the mechanism by which the remaining steps take place.  Several 
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theories state that the dimeric structure of UROD implies a dimer-dependent catalysis 
(114, 116).  Since each subsequent decarboxylation only requires a 90o rotation, it has 
been postulated that the two monomers collaborate during the decarboxylation of a single 
uroporphyrinogen substrate.  It has been proposed that the dimeric organization of UROD 
protects the reactants from solvent exposure, allowing the reaction intermediates to be 
passed and chemically modified between each monomer (114, 116).  Further, analysis of 
UROD compared with another cofactorless decarboxylase, orotidine 5'-monophosphate 
decarboxylase (ODCase), indicates that a protonated basic residue assists the transition of 
the polar carboxylate groups from water to the comparatively less polar hydrophobic core 
by stabilizing the post-scission carbanion (118). Alternatively, based on the structure for 
the human UROD bound to coproporphyrinogen, the UROD-catalyzed reaction may take 
place at a unique site on the enzyme surface (117).   
 Mutations in the human gene are responsible for the familial form of porphyria 
cutanea tarda (PCT) (119).  The disease has been classified into three sub-types.  Type I 
PCT has decreased hepatic UROD activity, but normal erythrocyte UROD activity (119).  
Type II PCT has decreased UROD activity both in red cells and hepatocytes (119). Type 
III PCT is similar to type II, but erythrocyte UROD activity is normal (119).  PCT is an 
autosomal dominant trait; however symptoms are rarely present in heterozygotes.  
Recently, three children from the same family presented with symptoms associated with 
early onset PCT (120).  Analysis of the UROD gene for all three probands indicated two 
novel missense mutations and one previously identified polymorphism, giving these 
patients an unique and previously unidentified compound heterozygote genotype (120). 
 Dermatitic photosensitivity is the hallmark symptom of PCT (119); a clinical 
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manifestation which shows a marked increase in intensity among individuals with co-
morbidities such as: hepatitis, HIV infection, or proclivity to imbibe (86).  Instances 
where severe symptoms occur at early onset are indicative of an accessory condition 
named hepatoerythropoietic porphyria (HEP).  HEP is frequently diagnosed in 
homozygotes or among individuals with compound heterozygosity (121, 122).   
Coproporphyrinogen oxidase  
The antepenultimate enzyme of the heme biosynthetic pathway catalyzes the 
sequential oxidative decarboxylation of rings A and B to form protoporphyrinogen IX 
(Figure 1.1).  Coproporphyrinogen oxidase (EC 1.3.3.3; CPO) in humans is oxygen-
dependent, found in the intermembranous space of mitochondria and produces 
coproporphyrinogen III, carbon dioxide and hydrogen peroxide (123, 124).  The enzyme 
is targeted to the organelle by way of an unusually long leader sequence of 110 amino 
acids (125, 126).  Oxygen-dependent CPOs are found in all eucaryotes and a select group 
of aerobic procaryotes (127).  Sequence similarity among the oxygen-dependent enzymes 
is high, and to date a requirement for prosthetic groups or cofactors has not been 
identified (127).  The human enzyme exists as a homodimer, with a monomeric mass of 
~37 kDa (Figure 1.4A) (128).  CPO contains an elaborate subunit interface with multiple 
conserved residues, suggesting a role of dimeric assembly in stabilizing the catalytically 
competent conformers of the enzyme.  Each monomer is composed of a central anti-
parallel β-sheet flanked by α-helices.  The active site, delimited on both sides by the β-
sheet and helices, elegantly houses the substrate while minimizing contacts with the 
solvent.  At the head of the active site, an α-helix acts as a lid to modulate the solvation-
state of the active-site cleft (128).   
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Figure 1.4.  The X-ray crystal structures of coproporphyrinogen III oxidase.  Each 
monomer of the dimeric human enzyme (PBD code: 2aex) is composed of a central anti-
parallel β-sheet (red) flanked by α-helices (green) (A).  The E. coli enzyme (PDB code: 
1olt) functions as a dimer (monomer shown) (B) and contains a catalytically essential S-
adenosyl-L-methionine cofactor and a [4S-4S] cluster (C). 
 
B 
A 
C 
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 Oxygen-independent CPOs are remarkably different from CPOs with oxygen 
requirements.  CPO from Escherichia coli is a complex monomer of ~53 kDa (Figure 
1.4B) (129).  The enzyme, a member of the “Radical SAM” family of proteins, utilizes a 
particularly labile [4Fe-4S] cluster to facilitate electron transfer to S-adenosyl-L-
methionine (SAM) (Figure 1.4C).  As an oxidizing agent, SAM accepts one electron from 
the substrate in one catalytic turnover; and an as yet unidentified substrate accepts 
another electron.  The identity of this acceptor molecule is of particular interest because 
anaerobes do not utilize oxygen, the physiological electron depository for the product of 
the aerobic reaction.  With respect to the mechanism of catalysis, the anaerobic 
conversion of coproporphyrinogen III to protoporphyrinogen IX is only partially 
understood (130, 131), although two of the steps are well documented.  These steps are 
the generation of the 5'-deoxyadenosyl radical from the reductive cleavage of SAM and 
the radical-mediated proton abstraction from the B-carbon of the propionate side chain.  
A recent study, centered upon the conserved histidines of human CPO, suggests that 
catalysis can occur despite alterations to these evolutionarily selected residues (132).  
Further work by the same group using substrate analogs where the C and D rings were 
modified to replace alkyl groups with the ring 13- and 17-propionate moieties led the 
investigators to postulate that the propionate side chains of rings C and D play a 
significant role in both substrate binding and turnover (133).  Be that as it may, the order 
of ring decarboxylation and how the processive reorganization of the substrate takes 
place (i.e., the manner in which the substrate rotates) remains to be elucidated. 
 Mutation in the human CPO gene are associated with hereditary coproporphyria 
(HCP), an acute condition of the liver (134).  While the disease is inherited in an 
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autosomal dominant manner, variable penetrance of the trait is observed (12).  Most of 
the disease-causing mutations have been mapped to portions of the enzyme proposed to 
be responsible for maintaining enzyme stability (135).  Work done by Stephenson et al. 
involving three invariant amino acids found in human CPO led to the identification of 
their roles in both the deprotonation of the substrate and bifurcate interactions between 
the carboxylate tail of the substrate and two arginine residues (136).  However, only one 
arginine residue (Arg401) has been reported to be mutated in porphyric patients, 
suggesting that the pathological basis of HCP may be more complex.  The most 
prominent biochemical feature of HCP is a marked increase in excreted 
coproporphyrinogen III; concentrations are typically 10–200 times higher compared with 
controls (137).  A severe variant form of HCP is known as harderoporphyria.  This 
disorder is characterized by earlier onset of neurovisceral attacks compared to HCP, and 
massive excretion of a tricarboxylated porphyrin (harderoporphyrin) in the feces (138). 
Protoporphyrinogen oxidase 
Protoporphyrinogen IX is aromatized to protoporphyrin IX by the penultimate 
enzyme of the heme biosynthetic pathway, protoporphyrinogen oxidase (EC 1.3.3.4; 
PPO) (Figure 1.1) (139).  This step of the pathway constitutes a branch point whereby 
protoporphyrin IX is supplied to produce chlorophyll or heme.  PPOs from diverse phyla 
require FAD as a cofactor (140).  This cofactor is coordinated by the macromolecule via 
a highly conserved N-terminal dinucleotide binding motif (GXGXXG) (141).  Human 
PPO exists as a homodimer, with a single cofactor per dimer (142).  Conversely, PPO of 
the facultative anaerobe Bacillus subtilis is a monomer of ~52 kDa (143).  Structural 
information has been deduced from the crystal structure of PPO from Nicotiniana 
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tabacum (144).  This enzyme exists as a loosely associated dimer with three defined 
monomeric domains.  The domains are responsible for FAD-, protoporphyrinogen IX-, 
and membrane-binding.  The active site of PPO is located between the FAD- and the 
substrate-binding domains.  Mutations associated with the human condition, variegate 
porphyria (VP) have been mapped using the plant model with notable success (145).   
 A binding mechanism for the PPO-catalyzed reaction has been proposed based on 
experimental results obtained with the INH (4-bromo-3-(5'-carboxy-4'-chloro-2'-fluoro-
phenyl)-1-methyl-5-trifluoromethyl-pyrazol) and acifluorfen inhibitors (144, 146).  The 
pyrazole ring of INH serves as an A ring model, which is coordinated in the active site by 
pi-stacking interactions with a conserved phenylalanine residue.  Ring B of the 
macrocycle substrate is stabilized by hydrophobic interactions provided by the side 
chains of two highly conserved leucine residues.  Oxidation of the C20 methylene bridge 
between rings A and D occurs by way of the FAD cofactor.  Next, imine-enamine 
tautomerizations initiate all hydride transfers from C20.  The three remaining oxidation 
reactions involving FAD generate three hydrogen peroxide molecules.  Curiously, the 
candidates for the catalytic base involved in this reaction are not evolutionarily conserved 
(144).  As such, a potential base which could execute proton abstraction from the 
substrate is the FADH--derived peroxide anion.   
PPO deficiency causes VP (147).  Missense, nonsense, and splice site mutations 
have been identified as the root of VP in most cases (145).  The disorder, inherited as an 
autosomal dominant trait, is highly prevalent in South Africans of European descent 
(148).  A founder mutation attributed to a missense mutation at position 59 (R59W) has 
been traced to an immigrant from the 17th century and results in a PPO with reduced 
 26
catalytic activity (148).  The genetic drift of the abnormal gene has resulted in very high 
prevalence; as many as twenty thousand South Africans may carry this gene (149).  VP 
presents as acute neurovisceral attacks and/or dermatitic photosensitivity.  It is the 
variability observed in pathological presentation of the disorder that is the basis of the 
nomenclature of the disease (86).  Sudden death associated with the acute visceral attacks 
of VP, highlight the importance of identifying silent carriers of mutated genes (150).  
Efforts to examine the mechanism of presentation and drift of the disorder are underway 
by a team at Harvard University (151).  Their work involving a genetic screen of 
hematopoeitic chordate mutants, identified a zebrafish (Danio rerio) variant that showed 
defective PPO activity (151).  This montalcino (mno) variant presented with hypochromic 
anemia and porphyria, which was partially ameliorated when human PPO mRNA was 
microinjected into mno embryos.  Rescue of the mno phenotype by overexpression of 
human PPO suggests functional conservation of the enzyme across chordates.  
Consequently, mno appears an excellent model for investigation of PPO and a valuable 
tool for identification of therapeutic agents of VP.  Increased plasma porphyrin in VP is 
detected by monitoring fluorescence emission at 626–628 nm, upon excitation at 405 nm 
(152).  Other porphyrias including EPP and PCT are marked by fluorescence emission 
peaks 636 nm and 618–622 nm, upon excitation at 405 nm, respectively (153).  
Incidentally, patients with a rare homozygous form of the disorder have a notable 
increase in red cell Zn-protoporphyrin (154).  
Ferrochelatase  
Ferrochelatase (EC 4.99.1.1) (FC) is the last enzyme in the heme biosynthetic 
pathway, and it catalyzes the insertion of ferrous iron into protoporphyrin IX to yield 
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protoheme (Figure 1.1) (155, 156).  In vivo, the enzyme associates with the inner 
membrane of the mitochondrial matrix (155).  The penultimate enzyme of the pathway, 
PPO, has been proposed to interact with FC directly, by transferring protoporphyrinogen 
IX to the FC active site (155).  However, experiments with isolated mitochondria have 
shown complexation between the two enzymes is not required for heme biosynthesis 
(157).  Nevertheless, modeling based on the three-dimensional structure of PPO with FC 
suggests early work on the topic is likely correct (144).  Three X-ray crystal structures for 
FC have been solved (158-160).  FC from humans, the yeast Schizocassharomyces pombe 
(161) and the Gram-negative oligotroph Caulobacter crescentus  (161) contain a [2Fe-
2S] cluster.  Curiously B. subtilis FC is devoid of this prosthetic group, and exists as a 
monomer (160).  The function of these iron-sulfur centers is largely unknown. 
 Human FC is dimeric, and each monomer is defined by two domains (Figure 1.5) 
(158).  The domains, structurally unrecognizable from each other, are composed of a 
four-stranded parallel β-sheet delimited by an α-helix in a β-α-β motif (a Rossmann-type 
fold).  A gene duplication event has been proposed based on the topological similarities 
shared between the two domains.  A porphyrin binding model has been proposed based 
on the three-dimensional structure of N-methyl-protoporphyrin bound-ferrochelatase and 
and metallation kinetics using this inhibitor (160, 162).  The substrate-binding cleft is 
deep within the macromolecule and is interdomain in nature.  Metal binding and catalysis 
likely take place within this region and involve several evolutionarily conserved residues.  
Sub-cellular localization studies with mammalian FC show that the active site is 
positioned near the membrane-associating side of the enzyme (163).  This interaction 
includes formation of an active site access tunnel, which permits substrate association
 28
 
Figure 1.5.  The three-dimensional structure of ferrochelatase from Homo sapiens 
(PBD code: 1hrk).  The 2Fe-2S cluster is coordinated by four cysteine residues.  This 
prosthetic group is located at the subunit interface of the functional dimer.
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and product release; a scenario mediated by the conserved hydrophobic residues which 
partially define the site of catalysis.  
The FC-catalyzed reaction is characterized by two key steps:  the binding of the 
substrate (protoporphyrin IX) and its subsequent metallation with ferrous iron (164).  
Distortion of the tetrapyrrole macrocycle is proposed to occur after its binding to the 
active site cleft of FC (165).  This step has been identified as a defining feature of 
ferrochelatase-catalyzed metallation. In fact, resonance Raman spectroscopic studies 
showed that in the absence of metal, murine ferrochelatase is able to induce saddling of 
the porphyrin substrate (166).  Additionally, quantum mechanical calculations of 
porphyrin binding to B. subtilis ferrochelatase permitted Sigfridsson and Ryde (2003) to 
describe a tilted pyrrole ring, according to a tetrapyrrole conformation which requires less 
energy for the insertion of metal (167).  In short, most investigators believe that the 
microenvironment of the active site controls the planarity of the porphyrin, which in turn 
affects metallation efficiency (165). 
 Chelatases catalyze the insertion of a metallic cation into a porphyrin to generate 
a variety of metallated tetrapyrroles (168).  Concerning the role of ferrochelatase in the 
generation of metallated tetrapyrroles, several theories exist.  Proponents of one theory 
suggest that a channel is involved in shuttling metal ions from solution to the active site 
(169, 170).  Several conserved residues in bacterial ferrochelatase appear important in 
facilitating this process.  An active site histidine residue (H183) is required for metal 
chelation (171), and together with a pair of nearby amino acids (glutamate and serine), 
define an internal metal-binding site (162, 169).  It has been suggested that this inner 
coordination site is linked to a second solvent-exposed metal binding site (169, 172).  
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This proposed channel is defined by conserved acidic amino acids comprising a π-helix.  
While the function of this helix remains unclear, hypotheses regarding the regulatory 
nature of this motif have been suggested (169, 172).  The mechanism by which 
metallation takes places requires further research, however a notable theory regarding 
iron delivery to FC exists.  Frataxin, as a monomer is a small protein, localized to the 
mitochondrion and plays a role in mitochondrial iron detoxification (173).  As an 
oligomer, frataxin can be as large as a trimer to greater than a 48-mer (174).  Based on 
the structures solved for frataxin oligomer with iron bound, as well as in vitro assays 
proving protein-protein interactions between this protein and FC, it is proposed that 
frataxin delivers ferrous iron to FC (165, 175).  Certainly, the channeling of metal atoms 
by way of a chaperone-ferrochelatase complex has the advantages of minimizing Fenton 
chemistry between the substrate and the aqueous environment.  Understanding the 
relationship between iron-delivery and heme synthesis represents an intriguing future 
direction of ferrochelatase-related research.  
 Mutations in the FC gene result in a congenital disorder called, erythropoietic 
protoporphyria (EPP) (176).  EPP is transmitted as an autosomal dominant trait; however 
evidence suggests that a second defective copy is necessary for pathological presentation 
(177, 178).  Accumulation of protoporphyrin is localized to reticulocytes, and is a 
significant component of bile (12).  Patients with protoporphyrin-rich bile often show 
cholestasis, cirrhosis and remarkably fluorescent gall stones (12).  Of all the porphyrias, 
EPP results in the greatest dermatitic photosensitivity.  Most EPP patients function with 
FCs that turnover substrate at a rate less than 20% of that of the wild-type protein (12).  
While this diminished activity likely stems from mutations in the protein; a common 
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wild-type FC allelic variant has been identified and shows a marked reduction in 
expression (179).  This decreased protein availability may be a reason why the disorder is 
not observed as exclusively dominant in nature.  The overproduction of protoporphyrin is 
also linked to acute liver damage, highlighting the necrotic effects of excess 
protoporphyrin, a circumstance noted in the treatment of several cancers (177, 180).    
 
Enzymes in the heme degradation pathway 
Heme oxygenase 
Heme oxygenase (EC 1.14.99.3; HO) (Figure 1.6) has 3 isoforms (14). The first, 
HO-1, is a highly inducible 32-kDa protein, that catalyzes the first and rate-limiting step 
in the degradation of heme from red blood cells, yielding equimolar quantities of 
biliverdin IXa, carbon monoxide (CO), and iron (Figure 1.2) (181).  Biliverdin (through 
the action of biliverdin reductase) is converted to bilirubin, and iron is sequestered into 
ferritin (181).  Interestingly, HO-1 utilizes heme as both a prosthetic group and a 
substrate (182). The second isoform of hemoxygenase, HO-2, a constitutively 
synthesized 36-kDa protein, is generally unresponsive to any of the inducers of HO-1 
(181). The third isoform, HO-3, also catalyzes heme degradation, but much less so when 
compared with HO-2 (183).  Although heme is the typical HO-1 inducer, others include 
endotoxin, heavy metals, oxidants, and hypoxia (182). A common feature of several of 
these inducers is their ability to generate reactive oxygen species, suggesting that HO-1 
provides potent cytoprotective effects (21).  These products have physiological and 
pathological functions which include protection from oxidative stress, a circumstance 
linked to:  atherosclerosis and cancer, as well as a number of inflammatory, autoimmune,  
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Figure 1.6.  The enzymes and intermediates of the heme catabolic pathway.  
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and degenerative diseases (20, 184, 185).  Further, the heme catabolic pathway is of 
major importance to the degradation of the globins and other hemoproteins, many of 
which are affective stressors of the aforementioned disordered states.   
 Mammalian HO-1 proteins share a high degree of sequence similarity.  Among 
eucaryotes, a conserved C-terminal hydrophobic tail of ~20 residues appears to function 
in anchoring HO-1 to the microsomal membrane.  A number of conserved histidine 
residues are most likely to be important in heme binding (186).  Human HO-1 is notably 
similar to bacterial HO with respect to sequence.  Several bacterial HOs, including that 
from Neisseriae meningitides, have been crystallized and require an NADH reductase for 
enzymatic activity (187).  These enzymes function as water-soluble monomers of ~25 
kDa.  In procaryotes, HOs function to release iron to the environment, a process which 
increases microbial survival and pathogenesis, and mitigates heme toxicity (187).  The X-
ray crystal structure of human HO-1 reveals many structural similarities to the bacterial 
proteins (188).  Human HO exhibits a mostly helical content.  Heme is found between 
two buried α-helices (189).  An evolutionarily conserved histidine in the proximal helix is 
the axial ligand for the substrate (189).  On the opposite side, an α-helix stretches over 
the active site and the heme molecule, by way of a glycine-rich loop, and terminates in a 
distal polar pocket.  The α-meso edge of heme is pointed toward the protein interior and 
is swaddled by a series of conserved hydrophobic residues.  Conformational 
heterogeneity is observed in the HO-1-heme complex and is likely due to flexibility of 
the distal pocket, a component of the enzyme which is proposed to contribute to the 
opening and closing of the active site (189). 
 34
 The HO-1 reaction mechanism involves three oxygenation steps (16, 190).  In the 
first step, the α-meso heme position is oxidized by diatomic oxygen (O2) in the presence 
of NADPH to yield α-hydroxyheme.  Subsequently, the α-hydroxyheme intermediate is 
further oxidized by O2 to release CO and verdoheme.  Finally, verdoheme is oxidized by 
O2 in the presence of NADPH to produce biliverdin and Fe3+. Among cyanobacteria, 
algae and plants, HO is ubiquitously expressed and plays a key role in the synthesis of 
photon-accepting chromophores for use in photosynthesis or light-sensing (191).  
Specifically both cyanobacteria and algae use the HO catabolic product biliverdin as a 
precursor for synthesis of phycobilin, the main photoreceptor for photosynthesis.  
Transcriptional regulation of the HO-1 gene involves activators such as Nrf2 and 
repressors such as the heme-binding protein Bach-1 (192).  Both the activating and 
repressing factors require heterodimerization with the small Maf proteins including 
MafK, MafF or MafG, which bind to the Maf recognition elements (MAREs) in HO-1 
gene enhancers; a circumstance which allows modulation of HO-1 gene expression (192).  
To date, no congenital disorder has been identified associated with mutations in the HO 
gene. 
Biliverdin reductase 
The conversion of biliverdin to bilirubin is controlled by biliverdin reductase (EC 
1.3.1.24; BVR) (Figure 1.6 (193, 194), an enzyme that reduces the C10 bridge of 
biliverdin.  BVR is evolutionarily conserved among all metazoa; however a homolog 
exists in red algae (195, 196).  Protein sequence comparison among diverse phyla shows 
a high degree of conservation.  Among mammalian species, BVR is greater than 80% 
identical, a degree of similarity bolstered by a series of sequence features (197).  BVRs 
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contain a leucine zipper motif (bzip), an adenine dinucleotide-binding motif, a 
serine/threonine kinase domain, two Src homology (SH2)-binding domains and a 
Zn/metal-binding motif (198-200).  The reductase activity of BVR requires NADH as a 
substrate at acidic pH; however, NADPH is utilized in the basic range (201).   
 While the structural basis for the unique cofactor/pH-dependence activity profile 
is unclear, site-directed mutagenesis and X-ray crystallography have provided insight into 
which residues are responsible for much of the reductase activity (202).  An N-terminal 
domain, complete with a Rossman fold, was identified from the three-dimensional 
structures of BVR with and without the cofactor bound (203).  In the rat crystal, 
extensive interactions between the enzyme termini occur by way of a β-sheet (203).  
Several point mutations to residues involved in defining the conserved binding domains 
of the enzyme (adenine dinucleotide, S/T kinase domain, “oxidoreducatse domain”) 
abolish reductase activity (204).  Most of these mutations have nearly the same negative 
impact on activity with both NADPH and NADH.  In contrast, the loss of S44, which 
results in a 400% increase in only the NADH-dependant activity, is due to reduced 
hindrance to NADH binding and NAD release (199).  With respect to NADH-derived 
enzyme activity, the BVR-catalyzed reaction is accelerated in human renal carcinoma 
(205). The significance and cause of this increase in activity is ambiguous; however, 
attenuation of this effect would be a valid therapeutic target. 
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Content of the dissertation 
  
This dissertation focuses on three aspects of the ALAS-catalyzed reaction.  First, 
the interconversion of ALAS between two forms, namely “open” and “closed”, is 
addressed with respect to hydrogen bonding interactions between the enzyme and the 
cofactor.  Second, substrate specificity related to succinyl-CoA is examined through 
molecular interactions between two conserved residues (Arg85 and Thr430 in murine 
ALAS) and the chemical nature of the acyl-CoA-derived tail. Third, the rate-determining 
step of the enzyme-catalyzed reaction is addressed in the context of the conformational 
mobility of an active site loop.  The conclusions set forth in each chapter are related to 
the advancement of knowledge regarding not only the ALAS-catalyzed reaction, but 
reactions catalyzed by members of the α-oxoamine synthase subfamily and PLP-
dependent enzymes as a group. 
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Chapter Two 
 
Serine-254 enhances an induced fit mechanism in murine 5-aminolevulinate 
synthase 
Abstract  
5-Aminolevulinate synthase (EC 2.3.1.37) (ALAS), is a homodimeric pyridoxal 
5'-phosphate (PLP)-dependent enzyme and catalyzes the initial step of the heme 
biosynthetic pathway in animals, fungi, and some bacteria.  This reaction involves the 
condensation of glycine and succinyl-Coenzyme A to produce 5-aminolevulinate (ALA), 
Coenzyme A (CoA) and carbon dioxide.  The X-ray crystal structures of Rhodobacter 
capsulatus ALAS reveal a conserved active site serine that moves to within hydrogen 
bonding distance of the phenolic oxygen of the PLP cofactor in the closed, substrate-
bound enzyme conformation, and simultaneously to within 3-4 angstroms of the thioester 
sulfur atom of bound succinyl-CoA.  To evaluate the potential roles of this residue in 
enzymatic activity, the equivalent serine in murine erythroid ALAS was mutated to 
alanine or threonine.  The S254A variant is active, but both the SCoAmK  and kcat values are 
increased, by 25- and 2-fold, respectively, suggesting unusual functional complexity.  In 
contrast, the S254T mutation results in a significant decrease in kcat without 
altering SCoAmK .  Circular dichroism spectroscopy reveals that removal of the side chain 
hydroxyl group in the S254A variant dramatically alters the PLP microenvironment as 
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well as the responsiveness of this microenvironment to succinyl-CoA binding.  Protein 
fluorescence stopped-flow experiments confirm that the mutations differentially alter the 
rates of conformational responsiveness to ALA binding.  Taken together the data support 
the postulate that this serine residue is important for formation of a competent catalytic 
complex by coupling succinyl-CoA binding to enzyme conformational equilibria.  
Similar functions of this residue may be postulated for the other α-oxoamine synthases. 
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Introduction 
5-Aminolevulinate synthase (EC 2.3.1.37; ALAS) is a homodimeric PLP-
dependent enzyme that catalyzes the first and key regulatory enzyme of the heme 
biosynthetic pathway in non-plant eucaryotes and the α-subclass of purple bacteria, 
involving the condensation of glycine and succinyl-CoA to produce CoA, carbon dioxide, 
and ALA (1).  Animal genomes encode two highly conserved but differentially expressed 
ALAS genes, a housekeeping and an erythroid-specific (eALAS) gene (2).  In humans, 
mutations in the eALAS gene can result in X-linked sideroblastic anemia, (3) a 
hypochromic and microcytic anemia characterized by iron accumulation within 
erythroblast mitochondria (4).  Approximately one-third of XLSA patients are pyridoxine 
responsive.  In these patients mutations in ALAS are commonly observed in the PLP-
binding site (5, 6). 
The ALAS chemical mechanism (Scheme 2.1) is complex and involves a high 
degree of stereoelectronic control, with individual steps including: binding of glycine (I); 
transaldimination with the active site lysine (K313, murine eALAS numbering) to yield 
an external aldimine (II); abstraction of the pro-R proton of glycine (III); condensation 
with succinyl-CoA (IV) and CoA release to generate an α-amino-β-ketoadipate 
intermediate (V); decarboxylation resulting in an enol-quinonoid rapid equilibrium (VI); 
protonation of the enol to give an aldimine-bound molecule of ALA (VII); and ultimately 
release of the product (ALA) (VIII) (7).  This mechanistic complexity is manifested 
structurally as an enzyme with an unusually high degree of sequence conservation, as 
exemplified by the observation that the catalytic core of human  eALAS and R. 
capsulatus ALAS are 49% identical and 70% similar (8).   
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Scheme 2.1.  The role Ser-254 plays in the chemical mechanism of ALAS. 
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PLP-dependent enzymes are classified based on structural and mechanistic 
similarities (9).  ALAS is evolutionarily related to transaminases and is grouped within 
class II of the fold type I PLP-dependent enzyme superfamily, for which the prototypical 
enzyme is generally considered to be aspartate aminotransferase (10-12).  ALAS is most 
closely related to the three other members of the α-oxoamine synthase subfamily, each of 
which catalyze reactions between small amino acids and CoA esters to generate 1,3-
aminoketones, while also sharing high structural similarity (13, 14).  Studies have 
demonstrated that aspartate aminotransferase exists in two predominant conformational 
forms, “open” and “closed”, and reactions catalyzed by PLP-dependent enzymes have 
been postulated to occur in a closed conformation, consistent with the induced fit 
hypothesis, where electrostatic and hydrophobic interactions between the substrates, 
cofactor, and amino acids comprising the active site provide the energetic impetus to 
stabilize this catalytically optimal conformation (15, 16).   
Prior to solution of an ALAS crystal structure, kinetic data led investigators to 
propose that ALAS transitions between open and closed conformations during the 
catalytic cycle (7, 17).  Steady-state kinetic experiments demonstrate that the kinetic 
mechanism is ordered, with glycine binding before succinyl-CoA, yet in transient kinetic 
studies binding of succinyl-CoA accelerates the apparent rate at which glycine binds to 
ALAS by over 250,000-fold (18).  This enhancement might occur by utilization of part of 
the intrinsic binding energy for succinyl-CoA to shift the enzyme conformer equilibrium 
towards a closed conformation wherein transaldimination of glycine with the PLP 
cofactor is rapid (17, 18).  Return to the open conformation is considered to be the key 
step limiting ALA release and the overall catalytic rate.   
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The crystal structures of Rhodobacter capsulatus ALAS in holoenzymic and 
substrate-bound forms adopt open and closed conformations, respectively, further 
supporting the hypothesis that enzyme dynamics play a crucial role during the ALAS 
catalytic cycle (8).  While the structure in general collapses slightly around the bound 
substrates, a more conformationally mobile loop of amino acids located between two β-
sheets at the subunit interface closes directly over the channel leading approximately 20Å 
down into the deeply recessed active site (Figure 2.1) (8).  A conserved threonine at the 
apex of the mobile loop forms a strong hydrogen bond (~2.5Å) with the carboxylate tail 
of succinyl-CoA in the substrate-bound structure and appears to simultaneously provide 
molecular recognition for succinyl-CoA while helping to lock this substrate into optimal 
position for catalysis.  Closer comparison of the active site structures reveals that, 
coincident with these changes, the side chain of S189 migrates from non-covalently 
associating with the peptide macroskeleton to within hydrogen bonding distance of the 
PLP phenolic oxygen, as well as the sulfur atom of succinyl-CoA (8, 19, 20).  These 
interactions suggest that this serine may be an important determinant in conformer 
equilibrium and catalysis by providing orientational binding energy between the cofactor 
and substrate, while stabilizing a closed Michaelis complex conformation.  The 
conservation of this residue in ALAS and the other α-oxoamine synthases suggests an 
important functionality that may be general to these enzymes (Figure 2.2).  Here we 
present experiments aimed at probing the role of this serine in catalysis by murine 
eALAS.  We have generated and purified the positionally equivalent S254A and S254T 
variants and investigated the effects of these mutations on the kinetic and spectroscopic 
properties of the enzyme.  The results support the postulate that S254 is a key 
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multifunctional residue that couples succinyl-CoA binding to enzyme conformational 
equilibria and catalysis.   
Figure 2.1.  Structural models for murine erythroid ALAS based on the R. 
capsulatus crystal structures. (A) Michaelis complex modeled by alignment of open 
holoenzyme and closed glycine and succinyl-CoA bound monomeric structures.  Serine-
254 is hidden by the succinyl-CoA ester in this view from the perspective of the adjacent 
subunit, which has been removed.  The active site loop is shown in yellow cartoon for the 
open and closed conformations, while all other structural features are for the closed 
conformation.  (B) Serine-254 in the open conformation.  (C) Serine-254 in the closed 
conformation with succinyl-CoA bound.     
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Figure 2.2.  Multiple sequence alignment of phylogenetically diverse members of the 
α-oxoamine synthase family in the region of murine eALAS serine-254.  The amino 
acid sequences were retrieved from public databases (NCBI) and aligned using 
CLUSTAL W (21).  The conserved serine residue is high-lighted in cyan.  The amino 
acid numbering in red refers to that of murine erythroid ALAS (mALAS2).  Represented 
proteins are: M. mus. AL2, Mus musculus erythroid ALAS (156255176); H. sap. AL2, 
Homo sapiens erythroid ALAS (28586); H. sap. AL1, Homo sapiens housekeeping 
ALAS (40316939); S. cer. ALA, Saccharomyces cerevisiae ALAS (151942209); R. cap. 
ALA, Rhodobacter capsulatus ALAS (974202); A. nig. AON, Aspergillus niger AONS 
(61696868); A. tha. AON, Arabidopsis thaliana AONS (42573269); M. mar. AON, 
Methanococcus maripaludis AONS (1599054); E. col. AON, Escherichia coli AONS 
(85674759); H. sap. KBL, Homo sapiens KBL (3342906); C. kor. KBL, Candidatus 
korarchaeum cryptofilum (17017433); E. col. KBL, Escherichia coli KBL (169753078); 
H. sap. SPT, Homo sapiens SPT (4758668); A. tha. SPT, Arabidposis thaliana SPT 
(17221603); S. cer. SPT, Saccharomyces cerivisiae SPT (706828), E. col. SPT, 
Escherichia coli SPT (170517920).  
                                                     254 
M. mus. AL2       NDPGHLKKLLEKSDPK---------TPKIVAFETVHSMDGAICPLEELCD 
H. sap. AL2       NDPDHLKKLLEKSNPK---------IPKIVAFETVHSMDGAICPLEELCD 
H. sap. AL1       NDVSHLRELLQRSDPS---------VPKIVAFETVHSMDGAVCPLEELCD 
S. cer. ALA       NDLNELEQLLQSYPKS---------VPKLIAFESVYSMAGSVADIEKICD 
R. cap. ALA       NDVAHLRELIAADDPA---------APKLIAFESVYSMDGDFGPIKEICD 
A. nig. AON       SCPRSLEDVLRREVEGDE-MVRNGKKNVFLVIESIYSMDGDIAPIREFVE  
A. tha. AON       CDMYHLNSLLSNCKMKR----------KVVVTDSLFSMDGDFAPMEELSQ 
M. mar. AON       NNTVDLIEIL-EKN-KN-------YENKFIVTDAVFSMDGDIAPVGELKK 
E. col. AON       NDVTHLARLLASPCPGQ----------QMVVTEGVFSMDGDSAPLAEIQQ 
H. sap. KBL       LDMADLEAKLQEAQKH---------RLRLVATDGAFSMDGDIAPLQEICC 
C. kor. KBL       CDLADLEDKL-RQVHKK-------YNKILIITDGVFSMDGDIAPLDGITK 
E. col. KBL       NDMQELEARLKEAREAG-------ARHVLIATDGVFSMDGVIANLKGVCD 
H. sap. SPT       NNMQSLEKLLKDAIVYGQPRTRRPWKKILILVEGIYSMEGSIVRLPEVIA 
S. cer. SPT       GDMVGLEKLIREQIVLGQPKTNRPWKKILICAEGLFSMEGTLCNLPKLVE 
A. tha. SPT       NTPGHLEKVLKEQIAEGQPRTHRPWKKIIVVVEGIYSMEGEICHLPEIVS 
E. col. SPT       NDAKDLERRMVRLGER--------AKEAIIIVEGIYSMLGDVAPLAEIVD 
                       *   :                  .:  :  .** *    :  .  
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 Materials 
Reagents.  The following were purchased from Sigma-Aldrich Chemical 
Company (St. Louis, MO): ampicillin, DEAE-Sephacel, Ultrogel AcA-44, -
mercaptoethanol, PLP, bovine serum albumin, succinyl-CoA, ALA-hydrochloride, -
ketoglutaric acid, -ketoglutarate dehydrogenase, HEPES-free acid, MOPS, tricine, 
thiamine pyrophosphate, NAD+, and the bicinchoninic acid protein determination kit.  
Glucose, glycerol, glycine, disodium ethylenediamine tetraacetic acid dihydrate, 
ammonium sulfate, magnesium chloride hexahydrate, and potassium hydroxide were 
acquired from Fisher Scientific (Pittsburgh, PA).  Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis reagents were acquired from Bio-Rad.  Xba I, Bam HI restriction 
enzymes, Vent DNA Polymerase, and T4 DNA ligase were from New England Biolabs 
(Ipswich, MA).  Oligonucleotides were synthesized by Integrated DNA Technologies 
(Coralville, IA). 
Methods 
Mutagenesis. The pGF23 expression plasmid encoded the full-length sequence for 
the murine, mature eALAS (22).  Site-directed mutagenesis for the S254A and S254T 
mouse ALAS variants was performed on the whole plasmid pGF23 using a previously 
described method (23).  The mutagenic oligonucleotides for S254A and S254T were:  5’-
GAG ACT GTT CAT GCC ATG GAT GGT GCC-3’ and 5’-GAG ACT GTT CAT ACC 
ATG GAT GGT GCC-3’, respectively, with the introduced codon substitutions 
underlined. The PCR-generated DNAs were sequenced between the Blp I and Bam HI 
restriction enzyme sites to confirm the presence of the intended mutation. The products 
 60
were then digested with Blp I and Bam HI and subcloned into pGF23 that was digested 
similarly.   
Protein purification, SDS-PAGE, protein determination and steady-state analysis. 
Recombinant murine eALAS and the S254 variants were purified from DH5 
Escherichia coli bacterial cells containing the overexpressed protein as previously 
described (22).  Purity was determined by SDS-PAGE (24) and protein concentration 
determined by the bicinchoninic acid method using bovine serum albumin as the standard 
(25).  All protein concentrations are reported on the basis of a subunit molecular weight 
of 56 kDa.  Enzymatic activity was determined by a continuous spectrophotometric assay 
at 30oC (26).   
Structural analyses.  The protein data base files 2BWN, 2BWO, and 2BWP, 
corresponding to the holoenzyme, succinyl-CoA-bound, and glycine-bound R. capsulatus 
ALAS crystal structures, were used as templates to model the PLP-binding core of the 
murine eALAS (8). Hydrogen bond determinations were accomplished using 
Deepview/Swiss-PdbViewer software (27, 28). 
Spectroscopic measurements. All spectroscopic measurements were performed 
with dialyzed enzyme in 20 mM HEPES, pH 7.5 with 10% (v/v) glycerol to remove free 
PLP.  Circular dichroism (CD) spectra were collected using an AVIV CD spectrometer 
calibrated for both wavelength maxima and signal intensity with an aqueous solution of 
D-10 camphorsulfonic acid (29).  CD spectra recorded from 190-240 nm were analyzed 
by the ridge regression method using a modified version of the computer program 
CONTIN developed by Provencher and Glöckner (30).  Protein concentrations were 10 
M and 100 M for the near and far CD spectra, respectively.  The final concentration of 
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succinyl-CoA was 100 M, giving a 1:1 molar ratio of enzyme to ligand for collection of 
the latter spectra.  At least three CD spectra were collected per experiment and averaged, 
using a 0.1 cm path length cuvette with a total volume of 300 l.  Blank CD spectra 
contained all components of the solution except enzyme.  CD spectra containing the 
enzyme samples were collected immediately after adding the enzyme.  The spectra of the 
samples containing enzyme were analyzed after substracting the blank spectra.  Co-factor 
fluorescence spectra were collected on a Shimadzu RF-5301 PC spectrofluorophotometer 
using protein concentrations of 2 μM.  Spectra were measured at pH 7.5, 50 mM HEPES, 
and 20% (v/v) glycerol. Excitation was at 331 nm and the excitation and emission slit 
widths were each set to 10 nm.  Emission was measured over the wavelength range 350 
to 600 nm.  Buffer blanks were subtracted from the spectra. 
Stopped-flow spectroscopy. All of the experiments were carried out at 30°C in 100 
mM HEPES, pH 7.5 and 10% (v/v) glycerol.  The concentration of reactants loaded into 
the syringes were always 2-fold greater than that present in the cell compartment after 
mixing. Because of the difference in Km for succinyl-CoA between the two variant 
enzymes, two different succinyl-CoA concentrations were used to ensure the 
identification of a single enzyme-catalyzed event.  For the S254A-catalyzed reaction, the 
final concentrations were:  120 μM S254A, 130 mM glycine, and 30 μM succinyl-CoA.  
The final concentrations of the reactants for S254T were:  50 μM S254T, 130 mM 
glycine, and 10 μM succinyl-CoA. Rapid scanning stopped-flow kinetic measurements 
were conducted using an OLIS model RSM-1000 stopped-flow spectrophotometer. The 
dead time of this instrument is approximately 2 ms, and the observation chamber optical 
path length is 4.0 mm.  Scans covering the wavelength region 270-550 nm were acquired 
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at a rate of either 62 or 31 scans per second in order to condense the resulting data files to 
a tractable size for data fitting analysis. An external water bath was utilized to maintain 
constant temperature of the syringes and observation chamber.  Specifically, spectral data 
covering the 270 – 550 nm range were analyzed by global fitting to a triple exponential 
using the SIFIT program supplied with the stopped-flow instrument (OLIS, Inc.).(31).  
The quality of fits were judged by visual analysis of the calculated residuals in 
conjunction with the Durbin-Watson statistic (32).  Single turnover data were interpreted 
using a three kinetic step mechanism as described by Equation 2.1. 
(Equation 2.1)    
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The observed rate constants were determined from at least three replicate 
experiments, and the reported values represent the average and standard error of 
measurement for each experimental condition.  The forward and reverse rate constants 
depicted in the kinetic mechanism (Figure 2.7) were obtained by modeling single 
wavelength kinetic traces at 510 nm with KinTekSim (Austin, TX) kinetic simulation 
software (33). The eight interior rate constants were allowed to float, while the KD values 
were held constant as determined separately. 
Transient kinetics of the reaction of glycine with the variant enzymes. The 
reactions of the murine eALAS variants with glycine were performed using the same 
instrument as was described for the single turnover reactions with the enzyme-glycine 
complex and succinyl-CoA.  The final enzyme concentration was 60 μM. The glycine 
concentration was always at least 10-fold greater than the enzyme concentration to ensure 
that pseudo-first order kinetics were observed. The treatment of the data was performed 
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using the fitting software supplied with the instrument.  The time courses at 420 nm were 
fitted to Equation 2.2 
(Equation 2. 2)    

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tk
it ceaA i     
where At is the absorbance at time t, a is the amplitude of each phase, k is the observed 
rate constant for each phase, and c is the final absorbance.  The quality associated with 
the fit was determined by the calculated residuals and from the Durbin-Watson ratio (32).  
The observed rate constants were plotted against increasing concentrations of glycine and 
the resulting data were fitted to a two step reaction process represented by Equation 2.3.  
Data fitting to Equation 2.4 used the nonlinear regression analysis program SigmaPlot10 
(Systat, San Jose, CA) 
(Equation 2.3)    
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where S is the concentration of substrate, k1 and k-1 are the forward and reverse rate 
constants, KD is the dissociation constant and kobs, the observed rate constant. 
Intrinsic protein fluorescence quenching. The pre-steady state kinetics of the 
product binding reaction of ALAS and the two serine variants were examined by 
measuring changes in the intrinsic protein fluorescence intensity. An OLIS RSM-1000F 
rapid mixing spectrofluorimeter, equipped with a high-intensity xenon arc lamp, was 
used to monitor the reaction. The enzyme and ligand in 20 mM HEPES (pH 7.5) and 10% 
glycerol were maintained at 30oC in separate syringes prior to their mixing in the reaction 
chamber.  The concentrations of enzyme and ligand in the reaction chamber were 1/2 of 
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those in the syringes.  The intrinsic protein fluorescence, as measured with 5 μM enzyme, 
was evaluated in the presence of increasing concentrations of the product, ALA.  The 
excitation wavelength and the slit width were 280 and 5 mm, respectively. The emitted 
light was filtered using a cutoff filter (WG 320; 80% transmittance at 320 nm, (Edmund 
Optics, Barrington, NJ)).  Typically, 500 time points were collected for varying lengths 
of time, and three or more experiments were averaged. Each averaged data set was then 
fitted to Equation 2.5, using the Global fitting software provided with the instrument. 
(Equation 2.5)    01)( AeAtF
tk
obs
obs    
where Fobs(t) is the observed fluorescence change (in arbitrary units) at time t, kobs is the 
observed first-order rate constant, A1 is the pre-exponential factor and A0 is the offset. The 
observed rate constants were then plotted against ligand concentration and the data were 
fitted to Equation 2.6 by nonlinear regression. The rates of dissociation (koff) and 
association (kon) as well as the ligand binding constants (KD) were calculated from the 
asymptotic maximal observed rate, the ordinate intercept, and the ligand concentration (x) 
in Equation 2.6.   
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Results 
Kinetic characterization of the S254 variants.  The steady-state kinetic parameters 
of the S254 variants were determined and the results are summarized in Table 2.1.  The 
mutation of serine-254 to alanine resulted in a kcat 2-fold higher than that of the wild-type 
ALAS value.   The Km for succinyl-CoA was increased 25-fold relative to ALAS, while 
the Km for glycine was not significantly affected.  The overall catalytic efficiency for 
succinyl-CoA decreased 36-fold, while the value for glycine remained unchanged as 
compared to ALAS values.   The replacement of serine-254 with threonine caused a 2-
fold decrease in the wild-type kcat value.  The Michaelis constants for both substrates 
were indistinguishable from those of the wild-type enzyme. 
Spectroscopy.  The orientation and average positioning of the PLP cofactor 
relative to the conserved serine and the active site were perturbed by the replacement of 
the serine with either an alanine or a threonine.  Gross structural changes evidenced by 
changes in the alpha helix and beta sheet content of proteins can be identified from CD 
spectroscopic changes in the far-UV (ultraviolet) (34).  The analysis of the UV CD 
spectra (Figure 2.3A) by CONTIN-CD indicates any changes in the secondary structure 
between wild-type ALAS and the two ALAS variants are negligible.  Locally chiral 
substructures that comprise the PLP microenvironment modulate the visible CD 
characteristics of the chromophore.  Spectra for the wild-type and variant enzymes, as 
holo- and succinyl-CoA-bound enzymes, were collected (Figure 2.3).  The spectra for 
wild-type ALAS and S254T holoenzymes displayed positive dichroic bands at 330 and 
420 nm.  However, in relation to the wild-type ALAS, the S254A variant showed a 
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decrease in amplitude of the 330 nm band, while the amplitude in the 420 region 
increased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1:  Summary of steady-state kinetic parameters 
Enzyme 
Gly
mK  
(mM) 
SCoA
mK  
(µM) 
catk  
(s-1) 
catk /
Gly
mK  
(mM·s-1) 
catk /
SCoA
mK  
(µM·s-1) 
Wild-type 25 ± 4.2 1.3 ± 0.9 0.14 ± 0.02 0.01 0.11 
S254A 18 ± 1.7 32 ± 7.7 0.27 ± 0.01 0.02 9.0 x 10-3 
S254T 27 ± 2.9 1.2 ± 0.3 0.050 ± 0.004 2.0 x 10-3 0.05 
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Figure 2.3.  Circular dichroism and fluorescence emission spectra of ALAS and the 
S254 variants.  Spectra of wild-type ALAS (—), S254A (····) and S254T (---) (A) and 
(B) Holoenzymes; (C) in the the presence of 100 μM succinyl-CoA; (D) upon excitation 
of the cofactor at 331 nm. 
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(Figure 2.3B).  Wild-type ALAS and variant enzymes responded differently to the 
presence of 100 μM ligand (Figure 2.3C).  Comparison of the CD spectra for the 
holoenzymes with succinyl-CoA showed that spectra of wild-type and S254T changed in 
the presence of substrate, while that of S254A maintained dichroic characteristics that 
were indistinguishable from those observed under ligand-free conditions.  Specifically, in 
wild-type and S254T, the amplitude of both dichroic bands decreased and the 330 nm 
peak red shifted to ~350 nm.  The cofactor fluorescence spectra obtained at pH 7.5 for the 
S254T variant enzyme with excitation at 331 nm is similar to that of the wild-type 
enzyme with a well-formed emission maximum ~385 nm (Figure 2.3D).   A notable 
deviation in emission maximum is observed for the S254A variant.  Specifically, 
excitation of S254A at 331 nm results in a broader fluorescence emission band centered 
around 450 nm.  The changes in the fluorescence emission profile for the alanine variant 
suggest that the tautomeric equilibrium between at least two forms of the PLP cofactor 
aldimine linkage with the catalytic lysine is perturbed.   
Reaction of glycine with the S254 variants.  The reaction of 60 M S254 variants 
with increasing amounts of glycine resulted in an increased absorbance at 420 nm (Figure 
2.4).  A global fit of the data for the reaction of S254A with glycine yielded values for k1 
of 0.159 ± 0.04 s-1, k-1 of 0.072 ± 0.001 s-1, and a KD of 6.6 ± 0.57 mM.  The fitting of the 
data corresponding to the reaction of the S254T variant with glycine provided parameters 
of   k1 of 0.11 ± 0.01 s-1, and k-1 of 0.070 ±0.004, and a KD of 1.5 ± 0.39 mM. 
ALA binding kinetics monitored by intrinsic protein fluorescence.  The observed 
rates of intrinsic protein fluorescence quenching were determined as a function of ALA 
concentration, and the results are presented in Figure 2.5.  The hyperbolic nature of the
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Figure 2.4.  Reaction of the S254 variants (60 µM) with increasing concentrations of 
glycine.  Data were fit to Equation 2.2 for a two-exponential process, yielding 
equilibrium and rate constants for S254A of KD = 6.6 ± 0.57 mM, k1 = 0.159 ± 0.04 s-
1, and k-1 = 0.072 ± 0.001 s-1.  The fitted constants for S254T were: KD =1.5 ± 0.39 mM,  
k1 = 0.11 ± 0.01 s-1 and k-1 =  0.070 ± 0.004 s-1. 
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Figure 2.5.  Reaction of wild-type 
ALAS and the S254 variants (5 µM) 
with ALA.  The observed rate constants 
were calculated by fitting the decrease in 
intrinsic protein fluorescence over time 
to Equation 2.3 for a single-exponential 
process. The resolved equilibrium and 
rate constants for wild-type ALAS (A) 
were:  KD = 500 ± 16 µM, 
k1 = 0.120 ± 0.015 s 1, and k-1 = 0.140 
± 0.05 s-1.  For the S254A variant (B) the 
constants were:  KD = 855 ± 66 µM, 
k1 = 0.235 ± 0.006 s 1, and k-1 = 0.29 
± 0.02 s-1, and  for the S254T variant 
were:  KD = 832 ± 49 µM, k1 = 0.19 
± 0.09 s-1, and k-1 = 0.057 ± 0.007 s 1.   
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binding data indicate a two-step process, and may be ascribed to formation of a collision 
complex followed by the conformational change associated with ALA binding (7).  
Significantly, for each of the three enzymes the resolved rate constants for the off rate 
conformational change (k-1) coincide with the kcat values determined through steady-state 
kinetics.  The dissociation constants of the variants for ALA are increased by 
approximately 60% over that of the wild-type enzyme.     
Pre-steady-state reaction of the variant enzyme-glycine complexes with succinyl-
CoA.  ALAS catalysis involves the sequential binding of glycine first (I-II), then 
succinyl-CoA (III-IV), followed by formation of an enol-quinonoid equilibrium (VI-VII) 
after the liberation of CO2 (Scheme 2.1) (7).  In order to determine the microscopic rates 
associated with the lifetime of the quinonoid intermediate we monitored the time course 
of the ALAS-catalyzed reaction under single turnover conditions.  The time courses of 
the absorbance change were best fit to a sequential, three-step mechanism outlined by 
Equation 3.1.  Among all the enzymes tested, a single step assigned to quinonoid 
intermediate formation, followed by a biphasic step of its decay were observed (Figure 
2.6). For each enzyme, the global fit of the spectral data at 510 nm is shown as a solid 
line overlaid with the time course data at 510 nm (dots).  The rate constants associated 
with quinonoid intermediate formation (Qf) differ between the two variants.  For S254A, 
the value is  4.8 ± 0.2 s-1, a rate similar to that of the wild-type enzyme (7).  However, the 
rate value for the S254T variant was decreased, showing a 4-fold reduction with a rate of 
1.4 ± 0.3 s-1.  These data suggest that the loss of the hydroxyl group at position 254 has 
only a modest effect on quinonoid intermediate formation, and therefore does not appear 
to play any obvious role in active site chemistry during catalysis.  The rates assigned to  
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Figure 2.6.  Reaction of wild-type 
ALAS- and S254 variant-glycine 
complexes with succinyl-CoA under 
single turnover conditions.  The data for 
single turnover quinonoid intermediate 
formation and decay reaction kinetics 
were fitted with the SIFIT program (OLIS, 
Inc.).  The data (●●) are overlaid with the 
line representing the fitted data. (▬).  (A) 
The rate constants for the three step 
sequence in the wild-type enzyme were 
6.0 s-1, 2.0 s-1, and 0.075 s-1.  (B) The rate 
constants for the three steps in S254A-
catalyzed reaction were 4.8 s-1, 0.8 s-1, and 
0.19 s-1.  (C) The rate constants for the 
three steps in S254T-catalyzed reaction 
were 1.4 s-1, 0.2 s-1, and 0.037 s-1.
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the two-step quinonoid intermediate decay (Qd1 and Qd2) also differ among the variants.  
Both variants have initial quinonoid intermediate decay rates that are at least 2-fold lower 
than that of the wild-type enzyme (i.e., 0.8 s-1 and 0.25 s-1 vs. 2.0 s-1).  However, the 
second step of quinonoid intermediate decay, which most closely approximates kcat for 
the overall reaction, is 40% faster for the S254A variant, in comparison to that of the 
wild-type enzyme.  This increased value agrees with the greater kcat that was determined 
from the steady-state kinetic analysis (Table 2.1).  As such, the rates for S254A observed 
during the lifetime of the quinonoid intermediate indicate fast transformation of the 
enzyme-substrate complex to the enzyme-product complex (Qf and Qd1), followed by a 
comparatively faster rate of product dissociation and the return of the conformational 
equilibrium to the catalytically favored open conformation (Qd2).  
 74
Discussion 
The spectroscopic and kinetic properties of the S254A and S254T murine ALAS 
variants were examined and compared to those of the wild-type enzyme in an effort to 
better understand the role of this residue in the catalytic process.  Mutation of serine to 
alanine removes the side chain oxygen atom and eliminates the possibility of hydrogen 
bond formation with the PLP cofactor and succinyl-CoA.  The conservative S254T 
mutation adds a methyl group, and is predicted to allow for hydrogen bonding, although 
some steric constraints may be introduced due to the tight packing in this region of the 
active site.  Comparison of the steady-state kinetic parameters of the variants to those of 
the wild-type enzyme determined under similar conditions reveals the unusual kinetic 
significance of S254 (Table 2.1).  Point mutations typically result in increased Michaelis 
constants and decreased turnover numbers, but significantly, in the S254A variant both of 
these parameters are increased.  The Km for succinyl-CoA is increased 25-fold over that 
of the wild-type enzyme, while kcat is increased 2-fold.  It is notable that mutation of an 
evolutionarily conserved residue in such a metabolically important enzyme leads to an 
enhanced kcat, even though the effect is not dramatic.   
The kcat for murine eALAS is considered to be defined by a conformational 
change of the enzyme accompanying ALA release (7).  This is further supported here by 
the stopped-flow data in Figure 6, where the protein fluorescence associated ALA off 
rates (k-1) are indistinguishable from the steady-state kcat values (Table 2.1).  These data 
also indicate that the rate-limiting step of the reaction cycle is unaltered in the mutated 
enzymes.  The increase in kcat observed for the S254A variant may be attributable to 
diminished stability of the closed conformation, leading to faster reversion to the open 
 75
conformation and product release.  In this interpretation, the large concomitant increase 
in Km for succinyl-CoA in the S254A variant would result not only from the direct effect 
of loss of hydrogen bonding to the substrate, but also from the less direct effect of 
impaired enzyme conformational responsiveness to the substrate that is believed to be 
required for optimal binding.  The three-fold decrease in kcat without any effect on the Km 
for succinyl-CoA resulting from the more conservative S254T mutation would then arise 
primarily from enhanced stability of the closed conformation.  Both mutations 
substantially diminish the catalytic efficiency with succinyl-CoA (kcat/ SCoAmK ), but in 
different ways, and while the effects of these very conservative mutations on the steady-
state kinetic parameters may appear relatively modest, they are presumably sufficient to 
have metabolically harmful effects in vivo, given the strong evolutionary selection for 
serine at this position. 
The S254A mutation has significant effects on the cofactor microenvironment, as 
determined by fluorescence and CD spectroscopies.  The fluorescence spectra suggest a 
rather dramatic alteration in cofactor tautomeric equilibria occurs upon loss of hydrogen 
bonding interactions between the phenolic oxygen of PLP and the side chain of S254 
(Fig. 2.3D).  The diminished enolamine tautomer emission at 386 nm in the S254A 
mutant is consistent with loss of hydrogen bonding at the cofactor phenolic oxygen, and 
an increased proportion of the cofactor maybe in the ketoenamine (35).  CD 
spectroscopic evaluations of the conformational effects of the S254A and S254T 
mutations in the far-UV region verify the mutations do not significantly alter the overall 
secondary structure of the enzymes (Fig. 2.3A).  Any alterations in the conformational 
equilibria of the active site loop, which adopts an extended conformation and is thus not 
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CD active, are not apparent in these spectra, but the visible CD spectra of the S254A 
variant does diverge substantially from those of the wild-type and the S254T variant.   
The S254A holoenzyme maximum at 435 nm is blue shifted towards ~420 nm, and the 
ratio of the mean residual ellipticity at this wavelength to the one at 330 nm was 
increased (Fig. 2.3B).  These ellipticities arise from Cotton effects associated with the 
ketoenamine (435 nm) and enolamine (330 nm) cofactor aldimine bond tautomers, and 
are indicative of the microenvironment surrounding this linkage between the cofactor and 
the active site lysine (36).  Succinyl-CoA binding to the wild-type and S254T variants 
induce decreases in asymmetry of the cofactor, while the S254A mutant is relatively 
unchanged under similar conditions (Fig. 2.3C).  A logical interpretation is that the 
decrease in asymmetry observed for the wild-type and S254T variants arises from partial 
conversion of the internal aldimine to free PLP aldehyde bound at the active site, as is 
observed in three out of four R. capsulatus crystal structure active sites upon succinyl-
CoA binding (8).  In the crystal structures these events are accompanied by transition to a 
closed conformation, from which it might be concluded that the S254A variant retains the 
internal aldimine in the presence of succinyl-CoA, and may not be induced to adopt a 
closed conformation upon binding of this substrate.   
The quinonoid intermediate single-turnover profiles of the two S254 variants 
indicate that they follow a chemical mechanism similar to that of the wild-type enzyme 
(Fig. 2.6A, B).  A rapid step of ALA-bound quinonoid intermediate formation upon 
decarboxylation is followed by two successively slower decay steps, associated with 
protonation of the ALA-quinonoid intermediate and ALA release, respectively (7).  The 
quinonoid intermediate formation rate decreased 4-fold for the S254T variant, which 
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could be explained by a change in the flow of electrons from the site of bond scission 
throughout the cofactor, precipitated by a shift in the conformational equilibrium towards 
closed.  In the ALAS crystal structure, PLP is noted to change position by 15 degrees 
when substrate is bound (8).  Changes to the stereoelectronic relationship between the 
cofactor and the α-carbon bonds of the external aldimine can influence the chemical 
mechanism dramatically (7).  Therefore, it is possible that the hydrogen bond between 
serine-254 and the phenolic oxygen of PLP may be an influential part of maintaining the 
angle of PLP during not only formation and decay of the quinonoid intermediate, but also 
during the complete reaction cycle.  The increase observed in the second step of 
quinonoid intermediate decay in the S254A variant is also consistent with the increases in 
kcat and the ALA off rate determined from enzyme fluorescence quenching.   
By utilizing the microscopic parameters obtained from the single turnover 
reactions of the variant enzymes, coupled with the product and substrate reaction data, we 
were able to model the kinetic mechanisms as shown in Figure 2.7.  Additionally, the 
Gibb’s free energy associated with the glycine and ALA were calculated (Table 2.2).  
The kinetic simulations revealed that the S254T mutation significantly retards the 
chemical mechanism.  Conversely, the modeled pathway for S254A highlights the 
increases observed in the kinetics of the variant.  Overall, the mechanistic data for both 
variants support the hypothesis that the interaction between S254 and the O3’ of PLP is a 
limiting factor in enforcing an induced fit mechanism by coupling substrate recognition 
to conformational equilibria.  However, how the structural differences between the 
variant enzymes with ligand bound accomplish this, awaits three-dimensional structural 
information. 
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Figure 2.7.  Kinetic mechanisms of the S254 variant enzymes. The single turnover 
quinonoid formation and decay reaction kinetics of the variant enzymes and the reactions 
with glycine and ALA and were used to model the kinetic mechanisms. The fits ((A) 
S254A) and ((B) S254T) were indistinguishable from those completed based on the 
global fit of spectral data. E, ALAS; G, glycine; EG, ALAS-glycine complex; SCoA, 
succinyl-CoA; EGSCoA, ALAS-glycine-succinyl-CoA complex; EQ, observable 
quinonoid intermediate; EALA1, ALAS-ALA internal aldimine with active site loop 
closed; and EALA2, ALAS-ALA internal aldimine with active site loop open. 
 
Table 2.2.  Gibb’s free energy associated with the wild-type ALAS- and S254 
variant-catalyzed reactions. 
Enzyme ΔG
ALA 
(kcal/mol) 
ΔGGly 
(kcal/mol) 
Wild-type 4.18 3.34 
S254A 4.08 3.97 
S254T 4.07 2.78 
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Chapter Three 
Arg-85 and Thr-430 in murine 5-aminolevulinate synthase coordinate acyl-CoA-
binding and contribute to substrate specificity 
Abstract 
5-Aminolevulinate synthase (ALAS) catalyzes the rate-limiting step of heme 
biosynthesis in mammals through the condensation of succinyl-Coenzyme A and glycine 
to produce 5-aminolevulinate, Coenzyme-A (CoA) and carbon dioxide.  ALAS is a 
member of the α-oxoamine synthase family of pyridoxal 5'-phosphate (PLP)-dependent 
enzymes and shares high degree of structural similarity and reaction mechanism with the 
other members of the family.  The X-ray crystal structure of ALAS from Rhodobacter 
capsulatus reveals that the alkanoate component of succinyl-CoA is coordinated by a 
conserved arginine and a threonine. The functions of the corresponding acyl-CoA-
binding residues in murine erythroid ALAS (R85 and T430) in relation to acyl-CoA 
binding and substrate discrimination were examined using site-directed mutagenesis and 
a series of CoA-derivatives.  The catalytic efficiency of the R85L variant with octanoyl-
CoA was 66-fold higher than that of the wild-type protein, supporting the proposal of this 
residue as key in discriminating substrate binding.  Substitution of the acyl-CoA-binding 
residues with hydrophobic amino acids caused a ligand-induced negative dichroic band at 
420 nm in the CD spectra, suggesting that these residues affect substrate-mediated 
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changes to the PLP microenvironment.  Transient kinetic analyses of the R85K variant-
catalyzed reactions confirm that this substitution decreases microscopic rates associated 
with formation and decay of a key reaction intermediate and show that the nature of the 
acyl-CoA tail seriously affect product binding.  These results show that the bifurcate 
interaction of the carboxylate moiety of succinyl-CoA with R85 and T430 is an important 
determinant in ALAS function and may play a role in substrate specificity. 
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Introduction 
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’-phosphate 
(PLP)-dependent enzyme consisting of two identical subunits, each containing one 
molecule of covalently bound PLP.  ALAS catalyzes the Claisen-like condensation of 
glycine and succinyl-CoA to yield carbon dioxide (CO2), CoA, and 5-amino-4-
oxopentanoate (5-aminolevulinate; ALA), and represents the first step of porphyrin 
biosynthesis in animals, fungi, and some bacteria.  The structural and mechanistic 
properties of ALAS are markedly similar to those of 8-amino-7-oxononanoate synthase 
(AONS), serine palmitoyl transferase (SPT), and 2-amino-3-ketobutyrate-CoA ligase 
(KBL) (1-3).  
The x-ray crystal structure of the holo form of Rhodobacter capsulatus ALAS 
was solved at 2.1 Å resolution and also as enzyme-substrate complexes with either 
glycine (2.7 Å) or succinyl-CoA (2.8 Å) (4).   ALAS is classified as a member of the α-
oxoamine synthase subfamily of fold type I PLP-dependent enzymes.  AONS, SPT, and 
KBL are the other members and represent the closest structural relatives, with the 
enzymes of the subfamily sharing a Cα root mean square deviation of approximately 1.5 
Å (5, 6).   The reaction chemistries are also highly similar, all involving small amino 
acids, CoA esters, and 1,3-aminoketones.  AONS catalyzes the committed step in biotin 
biosynthesis,(7) SPT catalyzes the first step of sphingolipid biosynthesis,(8) and KBL 
catalyzes the degradation of threonine (9).   
Despite the remarkable structural and mechanistic similarities in this important 
group of enzymes the molecular mechanisms underlying substrate specificity remain 
largely unexplored.  SPTs utilize palmitoyl-CoA as the preferred physiological substrate 
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(10), however, Han et. al. have shown that the SPT of a Coccolithovirus is more active 
when utilizing myristoyl-CoA, a substrate similar to palmitoyl-CoA, but shorter by two 
carbons (11).  Prior to the elucidation of the X-ray crystal structure of R. capsulatus 
ALAS, the bacterial enzyme-catalyzed reaction was examined with non-physiological 
acyl-CoA derivatives as substrates (12).  Results of this investigation indicate that some 
naturally occurring three, four, and five carbon CoA thioesters can act as substrates and 
that both acyl chain length and hydrophilicity of the acyl-CoA substrate are important 
factors in determining specificity.  The CoA substrate specificity of ALAS is of interest 
due to localization of the eukaryotic enzyme in the inner mitochondrial matrix.  
Specifically, 90% of cellular acetyl-CoA and between 92- and 97% of short and long 
chain acyl-CoAs are located within this organelle, providing an abundant supply of 
possible alternative substrates for meALAS.  As such, promiscuous reactions with 
alternative CoA substrates would produce highly reactive 1-3-aminoketones of unknown 
biological significance, that are potentially capable of dimerizing to form toxic 
dihydropyrazines (13, 14). 
Previous investigations regarding the binding of the amino acid substrate of 
ALAS and substrate specificity led to the conclusion that the ALAS active site only 
accommodates the smallest naturally occurring amino acid, namely glycine (15).  
Variants of R.  sphaeroides ALAS in which the glycine-binding threonine (T83) is 
mutated to the subtly smaller amino acid serine show a dramatic improvement in 
acceptance of non-physiological amino acid substrates (15).  This finding along with the 
crystal structures suggest that steric factors within the glycine-binding region of the 
active site are the major determinants of amino acid substrate specificity. 
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The ALAS active site is within a cleft at the subunit interface and is delimited by 
a β-strand bent around the PLP cofactor, in which the pyridinium ring of the cofactor lies 
at the bottom of the cavity (4).  Connection between the surface of the enzyme and the 
active site is by an amphipathic channel, which is occupied by succinyl-CoA in the 
substrate-bound structure (Figure 3.1).  Two distinct moieties of succinyl-CoA interact 
with the enzyme: the solvent accessible adenosyl component and the buried succinate.  
The alkanoic acid moiety of succinyl-CoA is bound to the active site via a strong 
hydrogen bond network that stabilizes a closed enzyme conformation (Lendrihas et. al., 
submitted) (4, 16).  At the end of a hydrophobic tunnel, the guanidino group of the highly 
conserved R21 (R85 in murine erythroid ALAS (meALAS)) donates a hydrogen bond to 
the carboxylate constituent of succinyl-CoA (Figure 3.1).  Simultaneously, the hydroxyl 
group of the conserved T365 (T430 in meALAS), which is positioned at the apex of a 
conformationally dynamic active site loop, bridges both the carboxylic acid moiety of 
succinyl-CoA and the side chain of R21 to complete a hydrogen bonding triad (Figure 
3.1) (4).  Accordingly, the chemical characteristics of the acyl-tail of the CoA substrate 
may be a determining factor for the enzyme in discriminating substrate entry into the 
active site. 
In this study, we investigate the role of the conserved R85 and T430 residues of 
meALAS in recognition and binding of the acyl-CoA substrate in relation to catalysis.  
Substitutions of the conserved residues with more hydrophobic amino acids (i.e., R85L 
and T430V) were introduced to examine the effect of hydrophobicity and steric hindrance 
on specificity toward the CoA-derived substrate.  Such a difference would alter the 
aliphaticity of the substrate-binding cleft, which, in turn, could affect the acyl chain-
 87
Figure 3.1  The acyl-CoA binding cleft in R. capsulatus ALAS.  The ALAS dimer 
appears above the hydrogen bond network maintained between the alkanoic acid 
component of succinyl-CoA and the side chains of the conserved residues (R21 and 
T365) is indicated by dashed yellow lines.  The PLP cofactor, succinyl-CoA substrate 
and the corresponding R and T residues (R85 and T430) are shown in stick format. 
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binding properties of this channel.  The results presented here for the R85 and T430 
variants of meALAS show that these residues are involved in both the orientation and 
binding of the succinyl-CoA substrate in the active site and may also, following the 
substrate binding, assist in enzyme closure. 
 Materials 
Reagents.  The following reagents were purchased from Sigma-Aldrich Chemical 
Company (St. Louis, MO): ampicillin, DEAE-Sephacel, Ultrogel AcA-44, -
mercaptoethanol, PLP, bovine serum albumin, succinyl-CoA, ALA-hydrochloride, -
ketoglutaric acid, -ketoglutarate dehydrogenase, HEPES-free acid, MOPS, tricine, 
thiamine pyrophosphate, NAD+, and the bicinchoninic acid protein determination kit.  
Glucose, glycerol, glycine, disodium ethylenediamine tetraacetic acid dihydrate, 
ammonium sulfate, magnesium chloride hexahydrate, and potassium hydroxide were 
acquired from Fisher Scientific (Pittsburgh, PA).  Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis reagents were acquired from Bio-Rad.  Sal I, Blp I, Xho I, Bam HI 
restriction enzymes, Vent DNA Polymerase, and T4 DNA ligase were from New England 
Biolabs (Ipswich, MA).  Oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA). 
Methods 
Mutagenesis. The pGF23 expression plasmid encodes the full-length sequence for 
the murine, mature eALAS (17).  The R85L variant was generated using a previously 
described method (18).  The mutagenic primers used for the R85L mutation were 5’-
GAC CAC ACC TAC CTT GTG TTC AAG ACT GT-3’ and 5’-ACA GTC TTG AAC 
ACA AGG TAG GTG TGG TC-3’, with the introduced codon substitution underlined.  
 89
The PCR-generated fragment containing the R85L mutation was used as a megaprimer in 
an independent round of PCR.  The PCR-generated fragment was sequenced to verify the 
presence of the desired mutations.  Subsequently, the PCR product was then digested 
with Sal I and Bam HI and subcloned into pGF23 digested similarly.  The site-directed 
mutagenesis for the T430V variant was performed on the whole plasmid pGF23 using a 
previously described method (19).  The mutagenic oligonucleotide for T430V was:  5’-
ATC AAC TAC CCA GTT GTG CCT CTG GGT-3’, with the introduced codon 
substitution underlined. The PCR-generated DNA was sequenced between the Blp I and 
Bam HI restriction enzyme sites to confirm the presence of the mutation. The product 
was then digested with Blp I and Bam HI and subcloned into pGF23 digested similarly.  
The pMAL2 expression plasmid, described above, encodes the full-length sequence for 
the murine, mature eALAS, with the arginine at position 85 mutated to leucine.  The 
R85L/T430V double mutated variant was constructed by digesting the T430V-encoding 
plasmid (pTL30) with Xho I and Bam HI.  This T430V mutation-encoding fragment was 
subcloned into pMAL2 digested similarly. 
Protein purification, SDS-PAGE, protein determination and steady-state analysis. 
Recombinant murine eALAS and the R85 and R85/T430 variants were purified from 
DH5 Escherichia coli bacterial cells containing the overexpressed protein as previously 
described (17).  Sufficient expression of the T430V variant could not be obtained.   The 
protein purity was over 90% judged by SDS-PAGE (20) and protein concentration was 
determined by the bicinchoninic acid method using bovine serum albumin as the standard 
(21).  All protein concentrations are reported on the basis of a subunit molecular weight 
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of 56 kDa.  Enzymatic activity was determined by a continuous spectrophotometric assay 
at 30oC (22).  
Structural analyses.  The protein data base files 2BWN, 2BWO, and 2BWP, 
corresponding to the R. capsulatus ALAS holoenzyme, succinyl-CoA bound, and glycine 
bound crystal structures were used as templates to model the the murine eALAS 
Michaelis complex structure (4).  Hydrogen bond determinations were accomplished 
using Deepview/Swiss-PdbViewer software (23, 24). 
Circular dichroism spectroscopic measurements. Spectroscopic measurements 
were performed with enzyme that was dialyzed in 20 mM HEPES, pH 7.5 with 10% 
glycerol to remove free PLP. Circular dichroism (CD) spectra were obtained using an 
AVIV CD spectrometer calibrated for both wavelength maxima and signal intensity with 
an aqueous solution of D-10 camphorsulfonic acid (25).  Protein concentrations were 100 
μM for each enzyme tested.  The final concentration of each CoA-derivative was 100 
M, giving a 1:1 molar ratio of enzyme to ligand.  At least three CD spectra were 
collected per experiment and averaged, using a 0.1 cm path length cuvette with a total 
volume of 300 l.  Blank CD spectra contained all components of the solution except 
enzyme.  CD spectra containing the enzyme sample were collected immediately after 
adding the enzyme.  The spectra of the samples containing enzyme were analyzed after 
subtracting the blank spectra.     
Stopped-flow spectroscopy. All of the experiments were carried out at 30°C in 100 
mM HEPES, pH 7.5 and 10% (v/v) glycerol.  The concentration of reactants loaded into 
the two syringes was always 2-fold greater than that present in the cell compartment after 
mixing, with glycine and the enzyme pre-incubated in one syringe and the CoA-
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derivative in another.  Because of the difference in Km values for the CoA-derivatives 
among the two enzymes tested, different CoA-derivative concentrations were used to 
ensure the identification of a single enzyme catalyzed event.  For the wild-type reaction, 
the final concentrations were:  120 μM wild-type ALAS, and 130 mM glycine.  The final 
concentrations of each independently examined CoA-derivative were: succinyl-CoA, 10 
μM; octanoyl-CoA, 10 μM; butyryl-CoA, 20 μM; β-hydroxybutyryl-CoA, 30 μM; 
glutaryl-CoA, 30 μM.  For the R85K-catalyzed reaction, the final concentrations were:  
120 μM R85K, and 130 mM glycine.  The final concentrations of each independently 
examined CoA-derivative were:  succinyl-CoA, 20 μM; octanoyl-CoA, 10 μM; butyryl-
CoA, 10 μM; β-hydroxybutyryl-CoA, 10 μM; glutaryl-CoA, 20 μM.  Rapid scanning 
stopped-flow kinetic measurements were conducted using an OLIS model RSM-1000 
stopped-flow spectrophotometer. The dead time of this instrument is approximately 2 ms, 
and the observation chamber optical path length is 4.0 mm.  Scans covering the 
wavelength region 270-550 nm were acquired at a rate of 31, 7 or 3 scans per second in 
order to condense the resulting data files to a tractable size for data fitting analysis.  An 
external water bath was utilized to maintain constant temperature (30oC) of the syringes 
and observation chamber.  Observed rate constants were determined by global fitting of 
the acquired spectral data sets, using the single value decomposition software provided 
by OLIS, Inc.(26)  The quality of fits were judged by visual analysis of the calculated 
residuals in conjunction with the Durbin-Watson statistic (27).  Single turnover data were 
interpreted using a three kinetic step mechanism as described by Equation 3.1. 
(Equation 3.1)   
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The observed rate constants were determined from at least three replicate experiments, 
and the reported values represent the average and standard error of measurement for each 
experimental condition.  
Intrinsic protein fluorescence quenching.  The pre-steady state kinetics of the 
product binding reaction of ALAS and the R85 and T430 variants were examined by 
measuring changes in the intrinsic protein fluorescence intensity.  An OLIS RSM-1000F 
rapid mixing spectrofluorimeter, equipped with a high-intensity xenon arc lamp, was 
used to follow the reaction.  The enzyme and ligand in 20 mM HEPES (pH 7.5) and 10% 
glycerol were maintained at 30oC in separate syringes prior to their mixing in the reaction 
chamber.  The concentrations of enzyme and ligand in the reaction chamber were 1/2 of 
those in the syringes.  The intrinsic protein fluorescence, as measured with 5 μM enzyme, 
was evaluated in the presence of increasing concentrations of the product, ALA.  The 
excitation wavelength and the slit width were 280 and 5 mm, respectively.  Scheme 3.1 
illustrates the relationship between wavelength maximum and the dynamic process being 
monitored.  The emitted light was filtered using a cutoff filter (WG 320; 80% 
transmittance at 320 nm, (Edmund Optics, Barrington, NJ)).  Typically, 500 time points 
were collected for varying lengths of time, and three or more experiments were averaged. 
Each averaged data set was then fitted to Equation 3.2, using the global fitting software 
provided with the instrument. 
 
(Equation 3.2)   01)( AeAtF
tk
obs
obs      
where Fobs(t) is the observed fluorescence change (in arbitrary units) at time t, kobs1 is the 
observed first-order rate constant, A1 is the pre-exponential factor and A0 is the offset. The 
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observed rate constants were then plotted against ligand concentration and the data were 
fitted to Equation 3.2 by nonlinear regression. The rates of dissociation (koff) and 
association (kon) as well as the ligand binding constants (KD) were calculated from the 
asymptotic maximal observed rate, the ordinate intercept, and the ligand concentration (x) 
in Equation 3.3   
(Equation 3.3)   
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Results 
Kinetic characterization of the R85 and R85/T430 variants.  The steady-state 
kinetic parameters of the ALAS variants were determined and the results are summarized 
in Table 3.1. Wild-type ALAS was active with all of the CoA-derivatives tested.  The Km 
for octanoyl-CoA was the lowest with a value of 0.51 μM compared to 2.9 μM for 
succinyl-CoA.  This decreased value contributed to a catalytic efficiency value that was 
2-fold higher than the reaction completed with the physiological substrate succinyl-CoA.  
Glutaryl-CoA and β-hydroxybutyryl-CoA were the least catalytically efficient, due to 6-
fold increases in the Km for both substrates.  Changing R85 to leucine (R85L) imparted 
dramatic changes with respect to the physiological substrate succinyl-CoA.  The kcat 
associated with the R85L-catalyzed reaction using succinyl-CoA as the substrate 
decreased greater than 11-fold, while the SCoAmK  increased 7-fold.  The 66-fold increase in 
catalytic efficiency toward octanoyl-CoA as well as the 4-fold increase found with 
butyryl-CoA for the R85L variant highlight a shift toward acceptance of more 
hydrophobic CoA-derivatives within the acyl-CoA-binding cleft of this enzyme.  The 
replacement of R85 with lysine (R85K) yielded a turnover number that was similar to 
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that of the wild-type enzyme.  When the different acyl-CoA substrates were tested, this 
pattern continued with the exception of the reaction with glutaryl-CoA.  This CoA-
derivative reacted slower than the physiological substrate succinyl-CoA as evidenced by 
a 21-fold decrease in kcat.  Among the catalytic efficiencies calculated for R85K, 
octanoyl-CoA yielded the highest with a value 13-fold greater than that of the same 
reaction containing succinyl-CoA.  The steady-state data obtained from the double 
variant (R85L/T430V) suggest that steric hindrance as well as hydrophobicity of the 
active site are important determinants for preference of CoA-derivative.  Affinity for 
octanoyl-CoA in the double variant is diminished, resulting in a 2-fold higher Km.  
Conversely, the reaction of the double variant with butyryl-CoA gave a Km value of 0.54 
μM, a value indistinguishable from octanoyl-CoA in the R85L variant, and 31-fold lower 
than octanoyl-CoA in the double variant.  The double variant-catalyzed reaction with 
glutaryl-CoA, a derivative similar to succinyl-CoA but longer by one methylene carbon, 
showed undetectable activity as measured under the assay conditions tested.  These data 
are shown graphically as normalized specificity constants in Figure 3.2, in which the ratio 
of the catalytic efficiency of each variant for a particular substrate is compared to the 
catalytic efficiency of the variant with succinyl-CoA.  
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Table 3.1 Comparison of steady-state kinetic constants for wild-type ALAS, R85K, 
R85L, and R85L/T430V with CoA derivatives as substrates. 
Parameter Wild-Type ALAS R85K R85L R85L/T430V 
 Succinyl-CoA as a Substrate 
kcat, min-1 10.0 ± 0.2 6.4 ± 0.2 0.94 ± 0.10 0.11 ± 0.03 
CoA
appmK , , μM 2.9 ± 0.1 12.4 ± 0.6 20.3 ± 1.0 9.6 ± 0.8 
kcat/
CoA
appmK , , min-1· μM-1 3.6 ± 0.2  0.53 ±  0.04 0.050 ± 0.003 0.010 ± 0.002 
Gly
mK , mM 24.2  ± 0.4  20.0 ± 0.4 63.1 ± 2.2 98.4 ± 3.5 
kcat/
Gly
mK , min-1·mM-1 0.43 ± 0.04 0.32 ± 0.06 0.010 ± 0.002 0.001 ± 0.002 
 Octanoyl-CoA as a Substrate 
kcat, min-1 3.4 ± 0.2 10.3 ± 0.4 1.8 ± 0.3 (1.0 ± 0.1) x 10-3 
CoA
appmK , , μM 0.51 ± 0.04 1.5 ± 0.04 0.55 ± 0.03 17.2 ± 0.6 
kcat/
CoA
appmK , , min-1· μM-1 6.8 ± 0.8 7.0 ± 0.2 3.3 ± 0.1 (5.6 ± 0.2) x 10
-5 
Gly
mK , mM 17.1 ± 0.9 25.2 ± 1.1 55.2 ± 5.0 74.2 ± 3.3 
kcat/
Gly
mK , min-1·mM-1 0.14 ± 0.01 0.52 ± 0.02 0.030 ± 0.005 (1.0 ± 0.08) x 10
-5 
 Butyryl-CoA as a Substrate 
kcat, min-1 6.3 ± 0.3 10.2 ± 0.3 2.01 ± 0.08 0.060 ± 0.002 
CoA
appmK , , μM 6.1 ± 0.09 2.7 ± 0.1 9.3 ± 1.0 0.54 ± 0.03 
kcat/
CoA
appmK , , min-1· μM-1 1.0 ± 0.1 3.7 ± 0.4 0.21 ± 0.04 0.03 ± 0.002 
Gly
mK , mM 29.3 ± 4.6 17.2 ± 0.7 70.3 ± 6.6 88.2 ± 3.9 
kcat/
Gly
mK , min-1·mM-1 0.26 ± 0.03 0.50 ± 0.01 0.030 ± 0.005 (6.1 ±  0.8) x 10
-4 
 β-Hydroxybutyryl-CoA as a Substrate 
kcat, min-1 4.0 ± 0.8 2.8 ± 0.1 0.65 ± 0.03 (1.0 ± 0.2) x 10-4 
CoA
appmK , , μM 9.8 ± 1.0 5.5 ± 0.2 6.1 ± 0.8 74.2 ± 0.6 
kcat/
CoA
appmK , , min-1· μM-1 0.41 ± 0.04 0.51 ± 0.04 0.11 ± 0.02 (1.3 ± 0.4) x 10
-6 
Gly
mK , mM 22.1 ± 0.8 18.2 ± 3.2 59.1 ± 4.7 92.2 ± 6.0 
kcat/
Gly
mK , min-1·mM-1 0.17 ± 0.06 0.14 ± 0.03 0.011 ± 0.003 (1.0 ± 0.3) x 10
-6 
 Glutaryl-CoA as a Substrate  
kcat, min-1 7.0 ± 0.4 0.30 ± 0.03 2.2 ± 0.1 n/d 
CoA
appmK , , μM 17.0 ± 1.6 7.5 ± 0.6 30.1 ± 1.1 n/d 
kcat/
CoA
appmK , , min-1· μM-1 0.41 ± 0.05 0.04 ± 0.003 0.07 ± 0.006 n/d 
Gly
mK , mM 28.4 ± 0.8 21.2 ± 0.2 70.6 ± 4.2 n/d 
kcat/
Gly
mK , min-1·mM-1 0.29 ± 0.02 0.010 ± 0.002 (8.0 ± 0.7) x 10
-4 n/d 
n/d, not determined 
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Circular dichroism spectroscopy.  To verify whether the R85K, R85L or 
R85L/T430V amino acid substitutions introduced substantial changes in secondary 
structure, CD spectra in the far-UV region (200-270 nm) were recorded for the wild-type 
and variant enzymes (data not shown).  All enzymes displayed similar CD spectra 
indicating that the introduced residue exchanges did not result in gross differences in the 
overall conformation of the ALAS protein.  The enzyme-bound cofactor gives rise to a 
defined CD spectrum in the visible region (300-500 nm) because of anisotropic 
interactions between the amino acid side chains and the chromophore in the active site 
(Figure 3.3). The CD spectrum thus contains information about the asymmetric 
orientation of the bound PLP cofactor in the active site, including the aldimine linkage 
between the PLP cofactor and the active site lysine (Scheme 3.1)(28, 29).  The visible CD 
spectra of the WT ALAS (Figure 3.3A) show that in the presence of either succinyl- or 
octanoyl-CoA there is a positive Cotton effect.  However, close inspection of the results 
indicates that there is a distinct difference in the CD maximum in relation to that of the 
WT ALAS; the wavelength maximum for succinyl-CoA blue shifts 15 nm to ~420 nm, 
while the octanoyl-CoA dichroic band at ~435 nm increases.  The spectra observed for 
the R85K variant are different (Figure 3.3B).  The changes caused by succinyl-CoA 
binding to the R85K variant mimic those observed upon octanoyl-CoA interacting with 
WT ALAS, in that the spectral differences between the two are unremarkable.  
Substitutions of polar residues with non-polar amino acids yielded proteins (R85L and 
R85L/T430V) in which ligand binding induces changes in the PLP environment and, 
consequently, display CD spectra (visible region) that are markedly different from those 
of wild-type ALAS and the R85K variant.  Within the R85L enzyme, succinyl-CoA 
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binding does not cause a shift in the microenvironment of the chromophore (Figure 
3.3C).  However, all of the remaining CoA-derivatives cause a negative Cotton effect, 
decreasing the amplitude of the spectra ~5 θ.  Steric hindrance and enhanced 
hydrophobicity of the acyl-CoA-binding cleft are hypothesized to be the most 
exaggerated in the double variant.  This theory is supported by the CD data which suggest 
that R85L/T430V is affected most by the binding of octanoyl- and butyryl-CoA (Figure 
3.3D).  The positive Cotton effect observed in the spectra for the enzyme in the presence 
of these two hydrophobic ligands could suggest that the exclusion of water and degree of 
active site aliphaticity are crucial components for determining substrate specificity.  
Overall, a comparison of the CD spectra of the wild-type and R85K variant enzymes with 
those of the hydrophobic variants (R85L and R85L/T430V) show that the distinct change 
in the microenvironment of the PLP pocket correlates well with the degree of 
hydrophobicity inherent to the bound ligand. 
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Figure 3.2.  Comparison of normalized specificity constants for murine eALAS 
variants with different CoA substrates.  The specificity constant (kcat/ CoAappmK , ) with 
succinyl-CoA as substrate was arbitrarily defined as equal to 1.00 for each ALAS variant.   
 
 
 
 
 
 
 
 
 
Scheme 3.1.  The absorbance maxima of chemical species in the ALAS-catalyzed 
reaction. 
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Figure 3.3.  Visible circular dichroism spectra of wild-type ALAS and the R85 and 
R85/T430 variants.  (A) wild-type ALAS, (B) R85K, (C) R85L, and (D) R85L/T430V.  
Spectra of the holoenzymes are in purple.  Spectra of the holoenzymes (100μM) in the 
presence of 100 μM CoA derivative are indicated according to the following color 
scheme:  pink, succinyl-CoA; green, octanoyl-CoA; blue, β-hydroxybutyryl-CoA; black, 
butyryl-CoA; red, glutaryl-CoA. 
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 ALA-binding kinetics monitored by the transient intrinsic protein fluorescence.  
To determine whether a change in the degree of hydrophobicity of the acyl-CoA-binding  
pocket could influence the product binding and concomitant quenching of the intrinsic 
protein fluorescence, wild-type ALAS and the enzyme variants were rapidly mixed with 
excess ALA and the changes in intrinsic protein fluorescence were monitored.  The 
observed pseudo first-order decay rates of these kinetic traces were dependent on ALA 
concentration, and differed among the enzymes tested (Figure 3.4).  In all cases the 
change in observed rate as a function of ALA concentration was hyperbolic, indicating 
two binding steps.  Presumably these two steps are indicative of rapid formation of an 
initial collision complex followed by a slower shift to the closed conformation observed 
in the crystal structures of the R. capsulatus enzyme.  While the resolved ALA “off” rates 
(i.e. k-1) coincide with the kcat values determined through steady-state kinetics, suggesting 
that a conformational change associated with ALA release defines kcat for each enzyme, 
the collision complex dissociation constants of the variants are increased.  The resolved 
on and off rates for the reaction between ALA and wild-type ALAS were 
k1 = 0.120 ± 0.015 s-1 and k-1 = 0.140 ± 0.005 s-1, respectively, with a KD of 500 ± 16 μM.  
The rates for the reaction of the R85K variant with ALA were ~2-fold lower with 
k1= 0.090 ± 0.003 s-1 and k-1 0.079 ± 0.003 s-1; however, the dissociation constant was 3-
fold higher at 1470 ± 30 µM, indicating decreased affinity for ALA.  Among the more 
hydrophobic variants, the rates of protein quenching with ALA were the most rapid for 
R85L with on and off rates of 0.039 ± 0.009 s-1 and 0.024 ± 0.003 s-1, respectively, values 
3-fold lower that those of the wild-type enzyme.  A KD value of 1130 ± 27 μM 
corresponding to a 3-fold greater dissociation of ALA from the R85L variant than that of 
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wild-type ALAS was calculated.  The double variant bound ALA less tightly, with a KD 
13-fold lower than that for wild-type ALAS and an estimated value of 6710 ± 33 μM. 
Figure 3.4.  Reaction of wild-type ALAS, R85K, R85L and R85L/T430V (5 µM) with 
ALA. The observed rate constants were calculated by fitting the decrease in intrinsic 
protein fluorescence over time to Equation 3.2 for a single exponential process.  (A) wild-
type ALAS (B) R85K (C) R85L (D) R85L/T430V.
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The on and off rates for R85L/T430V were also the lowest of the enzymes tested, with 
rates measuring k1= 0.007 ± 0.0001 s-1, and k-1 0.005 ± 0.001 s-1, respectively 
Pre-steady-state reaction of the variant enzyme-glycine complexes with acyl-CoA-
derivatives.  The R85L and R85L/T430V variant enzyme-glycine complexes did not 
yield a measurable absorbance change at 510 nm, previously assigned to a quinonoid 
reaction intermediate (Scheme 3.1), when rapidly mixed in the presence of any of the 5 
acyl-CoA derivatives tested (16, 30, 31).  Consequently, the investigation of the transient 
kinetics associated with the formation and decay of the quinonoid intermediate was based 
upon the reactions catalyzed by wild-type ALAS and the R85K variant, both of which 
demonstrate a quantifiable absorbance change at 510 nm upon the addition of the acyl-
CoA substrates to the enzyme-glycine complexes.  The rates associated with the lifetime 
of the quinonoid intermediate, measured during the enzyme catalyzed reactions, were 
elucidated (Table 3.2).  The absorbance change timecourses were fitted to a sequential, 
three-step mechanism outlined by Equation 4.1.  An initial burst of quinonoid 
intermediate formation, followed by a two-step decay was characteristic of each of the 
enzymes tested (Figure 3.5).  Of all the acyl-CoA derivatives examined, only β-
hydroxybutyryl-CoA, when rapidly mixed with the wild-type enzyme-glycine complex, 
failed to produce an absorbance change at 510 nm.  Overall, faster rates of quinonoid 
intermediate formation were observed for the wild-type enzyme, as compared to the 
R85K variant (Table 3.2).  The rates of quinonoid formation when octanoyl-CoA was 
used as the substrate (2.3 s-1 and 1.9 s-1) were of the same order of magnitude as the 
values recorded for succinyl-CoA (6.0 s-1and 4.2 s-1) for both the wild-type and R85K 
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Table 3.2.  Rates of quinonoid intermediate formation and decay under single-
turnover conditions. 
 
Parameter succinyl octanoyl butyryl β-hydroxybutyryl glutaryl 
 Wild-type ALAS  
 (s-1) (s-1) (s-1)  (s-1) 
Qf 6.0 ± 0.6 2.3 ± 0.4 0.41 ± 0.04 n/d 0.220 ± 0.03 
Qd1 2.00 ± 0.30 0.071 ± 0.004 0.070 ± 0.005 n/d 0.091 ± 0.005 
Qd2 0.072 ± 0.005 0.020 ± 0.003 0.011 ± 0.003 n/d 0.0010 ± 0.0004 
 R85K 
 (s-1) (s-1) (s-1) (s-1) (s-1) 
Qf 4.20 ± 0.1 1.91 ± 0.20 0.323 ± 0.020 0.121 ± 0.021 0.192 ± 0.042 
Qd1 1.10 ± 0.1 0.11 ± 0.02 0.002 ± 0.0001 0.022 ± 0.005 0.134 ± 0.071 
Qd2 0.050 ± 0.004 0.070 ± 0.003 0.041 ± 0.007 0.013 ± 0.001 0.0010 ± 0.0001 
n/d, not determined; Qf, quinonoid intermediate formation; Qd1, first step of quinonoid 
intermediate decay; Qd2, second step of quinonoid intermediate decay  
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Figure 3.5.  Reaction of wild-type ALAS- and R85K-glycine complexes with 
different CoA derivatives under single turnover conditions.  The data (●●/●●) are 
overlaid with the line representing the best-fit curve (▬).  The rate constants for the three 
step sequence corresponding to both enzymes are listed in Table 3.2.  Green and red data 
points correspond with wild-type ALAS and the R85K variant, respectively.  (A) 
octanoyl-CoA, (B) butyryl-CoA, (C) succinyl-CoA, (D) glutaryl-CoA, (E) β-
hydroxybutyryl-CoA. 
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enzymes, respectively.  These data support the increased catalytic efficiency observed 
from the experiments performed in the steady-state.  Further comparison of the reaction 
catalyzed by wild-type ALAS with butyryl-CoA vs. glutaryl-CoA showed that quinonoid 
intermediate formation was accelerated 90%.  A similar enhancement was observed for 
the R85K-catalyzed reaction which showed a 70% increase in the rate of quinonoid 
intermediate formation with butyryl-CoA vs. glutaryl-CoA.  The preference for butyryl-
CoA over glutartyl CoA suggests that in addition to the hydrogen bonding properties of 
R85 and T430, the amino acids that line the hydrophobic tunnel leading to the terminal 
guanidino group may play a role in substrate acceptance and orientation.  Curiously, only 
the R85K-glycine complex, when rapidly mixed with β-hydroxybutyryl-CoA, gave a 
time-dependent absorbance change at 510 nm and rate associated with quinonoid 
intermediate formation (0.12 s-1).  This is in stark contrast to the observations made of 
wild-type ALAS, where no quantifiable change with this substrate was detected.  This 
slow rate may be explained by the mixed polarity of the substrate tail, an attribute which 
simultaneously imparts hydrogen bonding character, as well as aliphaticity to the acyl-
CoA-binding cleft of the variant enzyme. 
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Discussion 
The reactions catalyzed by the highly related members of the α-oxoamine 
synthase subfamily of PLP-dependent enzymes can be compared with respect to the 
specificity of the acyl-CoA substrate due to the elucidation of the three-dimensional 
structures of subfamily members together with mutagenesis, spectroscopic and kinetic 
methods (1, 4-6, 32).  Both of the variant enzymes constructed for the arginine residue 
(R85L and R85K) as well as the doubly mutated enzyme (R85L/T430V) were expressed, 
overproduced, and then purified as holoenzymes, indicating that cofactor binding by the 
apoprotein was not affected by the introduction of the amino acid substitutions.  
However, replacement of the invariant threonine residue with valine (T430V) resulted in 
a poorly expressed, unstable, and proteolytically susceptible enzyme that was never 
purified to homogeneity (data not shown).  All of the purifiable variants were active with 
the physiological substrate succinyl-CoA.  Since the threonine to valine replacement at 
position 430 appears to dramatically affect protein stability, we suggest that T430 is 
essential not only for optimal molecular recognition of succinyl-CoA, but also for stable 
folding.  R85 may be less crucial for proper enzyme function, a finding supported by the 
crystallographic data for SPT (6).  Given that this enzyme lacks the arginine residue 
implicated in salt bridge formation with the carboxylate group of CoA substrates in the 
other three members of the α-oxoamine synthase subfamily and utilizes palmitoyl-CoA, 
an acyl-CoA derivative of increased aliphaticity, it is proposed that acyl-CoA binding in 
ALAS may be driven by non-covalent interactions between the two residues and the 
substrate.  However, considering the structural and mechanistic data for ALAS and SPT, 
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turnover likely remains orchestrated by amino acids that are proximal to the site of α-
carbon bond scission (16, 33).   
Comparison of the active sites of AONS and ALAS showed that the coordination 
of the acyl-CoA substrate is assisted by way of pantetheine association with the enzyme 
face and tail interactions with the buried hydrophobic tunnel (1, 4, 6).  Both R85 and 
T430 coordinate the carboxylate tail of the acyl-CoA substrate in meALAS.  The steady-
state kinetic analysis of the variants (R85K, R85L, and R85L/T430V) with the family of 
CoA-derivatives showed that the apparent Michaelis parameters ( CoAappmK , ) are dramatically 
different when compared to those of wild-type ALAS.  Acyl-CoA substrates of increased 
hydrophobicity (e.g., octanoyl- and butyryl-CoA) demonstrated greater affinity for the 
variants where the substituted amino acid was aliphatic in nature (R85L and 
R85L/T430V).  The 36-fold decrease in the ( CoAappmK , ) for octanoyl-CoA in the R85L 
variant leads us to suggest that the exclusion of water from the acyl-CoA-binding tunnel 
is a determining feature of substrate binding.   Further, in the double variant, an 18-fold 
reduction in the Michaelis constant for butyryl-CoA also supports this hypothesis.  The 
introduction of valine at position 430 would reduce the diameter of the hydrophobic 
tunnel, making steric hindrance a more significant consideration for substrate binding.  
These differences identified between the variant enzymes and wild-type ALAS suggest 
that reaction specificity is driven by the chemical characteristics of the CoA-derived tail 
and the hydrogen-bonding potential of the invariant acyl-CoA-binding residues, a 
phenomenon recognized in the acyl-CoA thioesterases of the peroxisome (34, 35).    
The chemical characteristics of the acyl-CoA tail are a determining factor in the 
substrate specificity of another family of enzymes that utilize related substrates in 
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turnover, the crotonase family (36, 37).  Among those enzymes, octanoyl-CoA has been 
shown to bind in a characteristic bent conformation (36).  This substrate conformation is 
accomplished by two structurally conserved hydrogen bond-donating groups to the 
carbonyl moiety of the substrate and through the entropically driven loss of water 
coordinated by the hydrophobic amino acids that line the binding cleft (36).  The CD data 
for butyryl-CoA with the double variant in addition to the substrate configuration 
observed in enzymes that physiologically utilize octanoyl-CoA led us to suggest that 
octanoyl-CoA, which differs from butyryl-CoA by a four methylene bridge, most likely 
bends in the ALAS active site.  This hypothesis is further supported by the data obtained 
for both wild-type ALAS and R85L with octanoyl-CoA.  For wild-type ALAS, the 
catalytic efficiency for the non-physiological substrate octanoyl-CoA is ~100% greater 
than that of succinyl-CoA (Table 3.1 and Figure 3.2).  Congruently, the specificity 
constant for octanoyl-CoA compared to that of succinyl-CoA in the R85L variant is 66-
fold higher, indicating a significant change in substrate specificity.  Therefore, we 
hypothesize that octanoyl-CoA, devoid of a salt bridge to anchor with the guanidino 
group of R85, likely bends, excludes water from the active site, and assists in enzyme 
closure, a conformation postulated to be essential for turnover (16). 
Interestingly, the specificity constant for the wild-type enzyme with octanoyl-
CoA is higher than the physiological substrate, succinyl-CoA, albeit at the cost of a three-
fold reduction in the specificity constant for the other substrate, glycine.  Nevertheless, 
this finding and the activity of the enzyme with the other CoA esters tested here lead us 
to raise the question as to what extent ALAS may catalyze formation of 1,-3-
aminoketones other than ALA in vivo.  This is currently unknown, but may warrant 
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further investigation.  Conceivably, the potential toxicity, associated with the generation 
of other aminoketones rather than ALA, could be minimized through the action of a 
regulatory acyl-CoA-binding protein.  In fact, studies have demonstrated that the acyl-
CoA binding protein binds long-chain acyl-CoA esters with high specificity and affinity 
(with Kd values of 1–10 nM); hence by interacting with acyl-CoA utilizing enzymes, the 
acyl-CoA-binding protein may provide a mechanism for control of free acyl-CoA esters 
and regulation of the activity of acyl-CoA utilizing enzymes.  Further substrate 
specificity in vivo might be enhanced via a substrate channeling mechanism involving 
interaction of ALAS with succinyl-CoA synthetase (38).  The requirement for such a 
mechanism is emphasized by the evidence presented here.    
The chromophoric properties of PLP in ALAS provide a valuable probe for 
positional alterations to the amino acids that comprise the cofactor binding cleft.  Since 
PLP is not a chiral molecule, the Cotton effect of PLP bound in the active site must result 
from certain asymmetric distortion of the PLP molecule through interaction with the 
enzyme.  Binding of acyl-CoA substrates to ALAS (or ALAS variants) most likely 
induced changes, even if subtle, in the PLP-protein interaction, as reflected by the 
different visible CD spectra (Fig. 3).  Curiously, for each of the enzymes tested, the most 
noticeable spectral deviations from the spectra obtained in the absence of substrate were 
produced by CoA-derivatives with tails that matched the chemical nature of the amino 
acid substitution introduced in ALAS.   In the R85L/T430V double variant, binding of 
either octanoyl- and butyryl-CoA induced a marked positive Cotton effect (Figure 3.3).  
A definite interpretation for the relationship between substrate binding and induced 
Cotton effect of the PLP cofactor cannot be provided at this point.  Perhaps the observed 
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effects could be explained, in part, by a shift in the enzyme conformational equilibrium 
towards the closed conformation, which has been hypothesized for the wild-type enzyme 
to be energetically driven by succinyl-CoA binding (Lendrihas et al., unpublished data) 
(16, 18).  However, a decrease in active site diameter, triggered by the entropic loss of 
water upon the binding of a more hydrophobic substrate, could also explain the change in 
the cofactor microenvironment as evidenced by the CD data.  This scenario is supported 
by ligand binding to the asymmetric protein host.  It is therefore premature to assign the 
observed CD spectral differences to a particular molecular event (e.g., a protein 
conformational change, a PLP reorientation or a perturbation of the electronic system of 
the chromophore).   Nevertheless, the CD spectra in the UV region of all the variants 
were indistinguishable from that of the wild-type enzyme (data not shown), indicating no 
gross alterations in secondary structure, and thus suggesting that the differences observed 
in the visible CD spectra, upon substrate binding, are confined to the PLP-binding cleft.  
Although specific contributions by single amino acid substitutions cannot be easily 
disentangled using CD, the CD spectral differences in the visible range among ALAS 
variants with the family of CoA-derivatives of different hydrophobicities lead us to 
propose that interactions between key residues (e.g., R85 and T430) that bind the tail of 
CoA play a role in determining substrate specificity.  
The proposed kinetic mechanism of the ALAS-catalyzed reaction is limited by 
product release, or opening of the active site loop coincident with product release (16).  
Utilization of protein fluorescence to study the reverse catalytic reaction, i.e., the reaction 
of the enzyme with the product, resolves the ALA “off” rate, and confirms it to be 
indistinguishable from kcat (16).  With this in mind, we investigated whether mutations to 
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the acyl-CoA-binding residues affect the rates of product release and/or perturb the 
enzyme-product equilibrium (Figure 3.4).  Quenching of the ALAS intrinsic fluorescence 
with ALA obeyed first-order decay kinetics.  For all the variant catalyzed-reactions, rates 
of product release and capture are diminished.  The most dramatic decrease is seen in the 
double variant; this enzyme exhibited a 13-fold reduction in the “on” and “off” rates (kon 
and koff) for the reaction with ALA.  Since CoA-derivatives of increased hydrophobicity 
bind with greater affinity to the non-polar variants (R85L and R85L/T430V), it is 
possible that the decreased affinity for the product, a δ-aminoacid, may be reversed for 
aminoketones of decreased polarity.  In this scenario and in agreement with a mechanism 
in which a conformational step follows ligand binding, the affinity of the aminoketones 
towards ALAS would not be reduced.  The Kd values would either increase or remain 
unchanged; this hypothesis, however, awaits further experimentation with aminoketones 
of differing hydrophobicity.   
The three-dimensional structures of ALAS and AONS  revealed a hydrogen 
bonding network between the invariant arginine and threonine residues and the 
carboxylate moieties of acyl-CoA substrates (1, 4).  Accordingly, how the use of 
chemically different acyl-CoA-derivatives would affect the transient kinetic parameters 
of the enzymes was evaluated.  Single turnover reactions with a family of CoA-
derivatives were used to determine the rates of quinonoid intermediate formation and 
decay.  The reaction catalyzed by wild-type ALAS with glutaryl-CoA as the substrate 
exhibited a 30-fold lower rate corresponding to quinonoid intermediate formation vs. the 
rate calculated with succinyl-CoA.  One possible explanation for the retarded rate is that 
the binding of glutaryl-CoA affects the hydrophobic acyl-CoA-binding tunnel in such a 
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way that cofactor-mediated electron transfer from the site of bond scission to the 
resonance stabilized pyridinium ring of PLP is perturbed.  This phenonmenon is further 
supported by the dramatic 70-fold reduction in the second step of quinonoid intermediate 
decay, where the absorbance change at 510 nm appears to stabilize to a level that 
approaches a steady-state (Figure 3.5D).  The R85K variant demonstrated a change in the 
first step of quinonoid intermediate decay, with a 10-fold lower rate for both octanoyl-
CoA and glutaryl-CoA when compared to the physiological substrate succinyl-CoA.  
When R85 is mutated to a lysine, the enzyme is chemically similar to wild-type ALAS in 
many respects, presumably because this conservative replacement retains the positive 
charge and hydrogen bonding capabilities.  In addition, in silico protonation of the lysine 
amino group to create the ε-ammonium charge center would contribute charge and polar 
interactions characteristic of the guanidinium group (23, 24).  However, the molecular 
volume of the amino acid side chain is different, as is the electrostatic charge distribution.  
With respect to their n-alkyl moieties, the n-propylguanidine side chain of arginine is 
longer than the n-butylamine side chain of lysine by 1.6 Å (40).  The R85K substitution 
could therefore accommodate the additional sp3 hybridized carbon atom present in 
glutaryl-CoA, allowing for a reduction in steric strain and/or unfavorable Van der Waals 
interactions.  Further, the increased hydrophobic tunnel length could also assist the 
bending of octanoyl-CoA within the cleft, a circumstance rationalized above.     
In summary, the spectroscopic and kinetic studies detailed here demonstrate not 
only the role played by R85 and T430 in determining acyl-CoA substrate specificity, but 
also provide insight into the structure-function relationships in ALAS and the α-
oxoamine synthase subfamily as a whole.  Although R85 and T430 recognize a part of 
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the substrate that is distal from the bulk of the ligand and the active site, the ability of all 
the enzymes to turnover non-physiological substrates remains intact.  Changing these 
residues to leucine and valine abates succinyl-CoA binding and catalytic efficiency, as 
well as increases the affinity of the enzyme for CoA-derivatives of greater aliphaticity.  
These observations indicate that a mutation-mediated decrease in substrate binding 
energy could be accountable for the enhanced affinity measured for the hydrophobic 
CoA-derivatives, instead of a direct mechanistic linkage between these residues and the 
site of bond cleavage.  Certainly, the conserved amino acid duo (R85 and T430) are at 
some distance from the PLP-binding site, and therefore the coupling of substrate binding 
to di-α-carbon cleavage in the active site presumably involves coordinated movement of 
the enzyme upon acyl-CoA binding.  However, further experiments to prove this await 
the development of tractable fluorescent probes and the elucidation of three-dimensional 
crystal structures with CoA-derivatives bound. 
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Chapter Four 
 
Hyperactive enzyme variants engineered by synthetically shuffling a loop motif in 
murine 5-aminolevulinate synthase 
Abstract 
 The regulatory step of the heme biosynthetic pathway in mammals is catalyzed by 
the pyridoxal 5'-phosphate-dependent enzyme, 5-aminolevulinate synthase (EC 2.3.1.37).  
Aminolevulinate is biosynthesized by condensing succinyl-CoA and glycine to yield 
coenzyme-A and carbon dioxide.  A conserved active site lid was shown to change 
conformation 3.5 Å between the holoenzymic form and succinyl-CoA-bound forms of 
Rhodobacter capsulatus ALAS.  We employed synthetic shuffling and pre- and steady-
state kinetic analyses to determine the role of the lid motif in the ALAS-catalyzed 
reaction.  Functional variants containing mutations to residues that comprise the lid 
(Y422-R439) were isolated based on genetic complementation in Escherichia coli strain 
HU227 and fluorescence microscopy.  All of the positive isolates showed a spectrum of 
amino acid substitutions, a finding which validates our screening method.  Each of the lid 
variants examined showed increases in kcat and catalytic efficiency with both substrates, 
observations which support a crucial role for the active site lid in product turnover.  The 
single turnover reaction data for the shuffled variants reveal that this lid has an important 
role quinonoid intermediate decay and product release.  Energetically favorable 
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thermodynamic activation parameters for a library isolate also suggest that the entire 
active site lid is involved in stabilizing the reaction coordinate.  Overall, our data support 
a hypothesis whereby the lid closes over the active site during catalysis; once chemistry 
has taken place, lid dynamics determine the rate of product release. 
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Introduction 
 Aminolevulinate (ALA) is the universal building block of tetrapyrolle 
biosynthesis (1).  In eucaryotes and the α-subclass of purple bacteria the production of 
ALA is catalyzed by 5-aminolevulinate synthase (ALAS) (EC 2.3.1.37) (2).  ALAS is 
classified as a fold-type I pyridoxal 5’- phosphate (PLP)-dependent enzyme, and like the 
evolutionarily related transaminases (3) functions as a homodimer, with a PLP cofactor 
bound at each of the two active sites, which occur in clefts at the subunit interface (4).  
The reaction catalyzed by ALAS is the Claisen-like condensation of succinyl-Coenzyme-
A (CoA) and glycine to yield CoA, carbon dioxide (CO2) and ALA.  This reaction type, 
coupled with the structural information about the protein, include it as a member of the α-
oxoamine synthase subfamily of PLP-dependent enzymes; a family which includes 7-
amino-8-oxononanoate synthase (AONS) (5).  Genetic defects in the gene corresponding 
to the erythroid specific isoform of the enzyme are associated with a congenital disorder, 
X-linked sideroblastic anemia (XLSA) (6). 
X-ray crystal structures of ALAS and AONS reveal that they share similar active 
site geometry and proximal active site motifs (7, 8).  Whereas the three dimensional 
structure of ALAS contains the substrate succinyl-CoA, the AONS structure was co-
crystallized with the product 7-amino-8-oxononanoate (AON).  In both cases, each 
enzyme has an active site lid, comprised of amino acids which stretch from one hinge of 
the lid to other, with the apex of the lid coordinating the carboxylate group of the ligand.  
Comparison of holoenzymic ALAS and AONS, with the substrate and product bound 
forms of the enzymes indicate that binding of these ligands within the active site 
precipitates active site lid dynamics that may signify a change in conformation.  The 
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active site lid of ALAS contains 18 residues; 8 of these are completely conserved, while 
10 vary considerably according to nature.  One corresponding residue in murine erythroid 
ALAS (mALAS2) that is positioned at the apex of the lid, T430, generates pathological 
affects associated with XLSA when mutated in humans (9).  This residue appears crucial 
for catalysis and may be an important determinant of substrate specificity (Lendrihas et. 
al, in press) (7).  Two β-sheets flank the position of the lid (β12 and β13) in the C-
terminal domain of the enzyme, where further interactions between the carboxy terminal 
portion of the lid occur between two α-helices on the adjacent subunit (α2 and α3).   
While evidence is available for the role of discrete active site residues in ALAS-
function, no studies have been carried out on the role of the active site lid that surrounds 
the site of catalysis and interacts with the acyl-CoA substrate (10-12).  One glycine-rich 
loop identified in mALAS2 formed by residues 142-154, sandwiched between α3 and α4 
was proposed to be involved in cofactor binding (13).  Several residues of this sequence 
(G142, G144 and R149) did not tolerate mutation (13).  However, mutations to residues 
N150 and I151 in the same study generated variants with turnover numbers greater than 
that of wild-type ALAS.  Further, this loop is implicated in succinyl-CoA binding, and 
based on the position of these residues deep within the three dimensional structure, 
mutations are likely to acutely disrupt the mobility of the motif (7). 
The importance of the active site lid in the condensation mechanism of an acyl-
CoA substrate and amino acid donor was first identified in AONS (8).  According to the 
X-ray crystal structures the β-sheet of the C-terminal domain undergoes a conformational 
transition.  This conformational change includes the 5.5 Å displacement of the active site 
lid.  From the ALAS crystal structure with succinyl-CoA bound the change in position of 
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the outermost top of the lid moves inward by 3.5 Å when compared to the position of the 
lid in the holoenzymic form (Figure 4.1) (7).  Accordingly, the poor electron density 
evidenced in the corresponding AONS motif coupled with the non-covalent interactions 
identified between the lid and the residues that comprise the active site indicate that these 
active site lids are probably disordered during unliganded conditions, a circumstance 
likely reversed in the presence of substrate or product. 
In order to examine the role of the active site lid in the ALAS-catalyzed reaction, 
we used synthetic shuffling to identify functional amino acid mutations and to evaluate 
the contribution of lid residues to catalysis.  The reported analysis of the catalytic role of 
the active site lid in the mechanism of ALA production suggests that the ALAS chemical 
mechanism may have evolved so as to be limited by a conformational change.  The lid 
presumably closes over the active site during catalysis, thereby facilitating enzyme-
mediated chemistry.  Once chemistry occurs, the dynamics of the active site lid determine 
the rate of product release. 
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Figure 4.1.  The position of the active site loop in the R. capsulatus ALAS crystal 
structure.  In (A), the overlap of one monomer of holoenzymic (magenta) and succinyl-
CoA-bound (green) ALAS from R. capsulatus.  In (B) the active site lid in the closed 
position (teal) is perched above the catalytic cleft of the enzyme.  Succinyl-CoA and the 
co-factor PLP are shown as sticks. The image was constructed using Pymol and PDB 
entries 2BWN and 2BWO. 
 
 
    
 
 
The primary amino acid sequence of the lid is 
+NH3—YVQAINYPTVPRGEELLR—COO- 
A B
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Materials 
Reagents.  DEAE-Sephacel, -mercaptoethanol, PLP, bovine serum albumin, 
succinyl-CoA, ALA-hydrochloride, -keto-glutarate, -ketoglutarate dehydrogenase, 
Bis-Tris, HEPES-free acid, MOPS, thiamin pyrophosphate, NAD+, and the bicinchoninic 
acid protein determination kit were purchased from Sigma-Aldrich Chemical Company.  
Ultrogel AcA 44 was from IBF Biotechnics.  Glycerol, glycine, disodium 
ethylenediamine tetraacetic acid dihydrate, ammonium sulfate, ascorbic acid and 
magnesium chloride hexahydrate were acquired from Fisher Scientific.  Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis reagents were acquired from Bio-Rad.  PD-10 
columns were from Amersham Biosciences.  Restriction enzymes and polymerases were 
from New England Biolabs.  Synthetic oligonucleotides were obtained from Integrated 
DNA Technologies. 
Methods 
Construction of the ALAS synthetic shuffled library.  The design and experimental 
approach for construction of the synthetic shuffled library was based on previously 
described methods (14-16).  Codons for 10 of the 18-amino acid loop were targeted for 
mutagenesis using synthetic shuffling, so that multiple amino acid variations could be 
introduced in these 10 positions (Table 4.1).  The ALAS active site loop-encoding 
fragment was reconstituted from partially overlapping oligonucleotides using PCR, with 
each of the codons for the 10 positions harboring, in addition to the wild-type amino acid, 
alternative amino acids encoded by nucleotide degeneracies (Table 4.1).  Following the 
assembly by PCR, the reaction product was amplified with another round of PCR having 
as primers oligonucleotides which annealed against the 5’ and 3’ ends of the generated 
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Table 4.1.  Designed mutations for incorporation at indicated positions within the ALAS active site loop1. 
Position WT V 
1 
V 
2 
V 
3 
V 
4 
V 
5 
V 
6 
V 
7 
V 
8 
V 
9 
V 
10 
V 
11 
V 
12 
Codon 
423 V2 L1 I2 M1          (M/G)TK 
425 A2 S2 P2 G2 R2 W1 C1       (M/G)SS 
428 Y2 F2 H2 S2 C2 I2 L2 N2 R2     (M/T)(A/K)Y 
432 P3 A3 G3 T3 D2 S2 H2 N2 R1 E1 K1   (M/G)(M/G)(S/T) 
433 R6 V4 G4 L4 I3 S2 K2 D2 E2 H2 N2 Q2 M1 (M/G)(A/K)N 
434 G2 K1 D1 E1 N1 R1 S1       RRW 
435 E1 R4 T3 A3 G3 P3 D2 S2 H2 N2 Q1 K1  (M/G)(M/G)(S/T) 
436 E1 L1 Q1 V1          SWG 
437 L3 R5 L3 K2 I2 Q2 M1 H1 N1 S1    M(R/T)(M/G) 
438 L3 F1            YTK 
1WT denotes amino acid found in mALAS2 active site loop, while V refers to variants encoded within the library.  Bold amino acids indicate amino 
acids that are found in ALASs from different species.  Codon indicates the nucleotide codon used to obtain the indicated mixture of amino acid residues.  
Subscripts following amino acid designations are the number of different codons for that amino acid.  Nucleotide degeneracies are represented in the 
IUB code:  Y, C/T; M, A/C; K, G/T; R, G/A; S, C/G; W, A/T; N, A/C/G/T. 
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PCR product and covered the sequence for restriction enzyme sites used in subsequent 
subcloning (i.e., Xba I and Bam HI).  To minimize the wild-type ALAS “background” 
during the screening of the library for functional ALAS variants, the synthetic shuffling 
library was subcloned into a mock ALAS expression vector.  The mock vector contained 
the wild-type ALAS-encoding sequence from the pGF23 expression plasmid (17), with 
the exception of the region encoding the active site loop and flanked by the Xba I and 
Bam HI restriction enzyme sites, which was replaced with a non-ALAS related sequence.  
The primers, conditions for the annealing reaction and PCR, and mock vector used in this 
study are described in supplemental experimental procedures.  The ligation reactions and 
DNA digestions with restriction endonucleases were according to standard protocols in 
molecular biology (18). 
Screening of the ALAS synthetic shuffled library and isolation of functional   
ALAS variants.  Library screening and selection of functional variants was accomplished 
by reversing the phenotype of E. coli hemA- (HU227) (19, 20).  HemA- cells can only 
survive if harboring a functional ALAS or when ALA (or hemin) is added to the medium 
(20).  Electrocompetent E. coli HU227 cells were transformed with the library and plated 
onto LB/ampicillin medium without ALA to allow selection of the active ALAS variants 
as previously described (19) (Figure 4.2).   To score the total number of colonies 
produced and assess transformation efficiency, one-tenth of each transformation reaction 
was spread onto LB/ampicillin plates containing 10 g/ml ALA.  Functional ALAS 
clones (i.e., isolated from the ALA minus plates) were then picked and plated onto 
defined MOPS medium to induce protein overexpression (17) and screened for porphyrin 
overproduction using fluorescence microscopy.  Briefly, the plates with the functional
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Figure 4.2.  The generation and screening of the library.  A library of over 330,000 
possible ALAS variants was constructed with PCR using a series of degenerate mixed 
base oligonucleotides.  The PCR product was ligated into an expression vector.  The 
resulting plasmids were transformed into Escherichia coli strain HU227 and plated on LB 
+ ampicillin agar with and without ALA.  The colonies that grew in the absence of ALA 
were identified as functional variants.  Functional variants were screened for porphyrin 
overproduction by fluorescence microscopy. 
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ALAS clones were examined with a Nikon Eclipse E1000 fluorescence 
microscope (Nikon, Tokyo) fitted with either a Nikon Triple Band filter set for excitation 
at 385-400 nm and emission at 450-465 nm for 4′,6-diamidino-2-phenylindole (DAPI) 
detection or a Nikon Cube BV2A excitation filter set for excitation at 400–440 nm and 
emission at 450-465 nm with a 610 nm long pass filter and a band pass filter at  550 nm ± 
20 nm for porphyrin detection.  Photographs were taken with a CCIR high performance 
COHU CCD camera and the images were processed with Image software Genus 2.81 
from Applied Imaging.  The level of porphyrin accumulated in the functional ALAS 
clones was compared to that of bacterial cells harboring wild-type ALAS and grown 
under the same experimental conditions (Figure 4.3).  Bacterial cells harboring ALAS 
variants, which accumulated greater porphyrin levels than bacterial cells with wild-type 
ALAS, were grown in LB/ampicillin medium in 96-well plates, and the glycerol stocks 
generated from overnight cultures were submitted to the ICBR Genomics Core at the 
University of Florida for DNA sequencing of the corresponding plasmids.  
Overexpression, purification and spectroscopic analyses of ALAS active site loop 
variants.  Overexpression was from the alkaline phosphatase (phoA) promoter, and the 
conditions for promoter induction were as previously described for mALAS2 (17).  
However, induction of the phoA promoter controlling the expression of the F1, SS2, F10 
and H1 variants was accomplished by growing the bacterial cells harboring the 
expression plasmids for these variants in MOPS, a low phosphate concentration and 
defined medium (17), supplemented with 10mg/L ascorbic acid for 30 hours at  20oC.  
Purification, storage, handling, and spectroscopic analysis of the mALAS2 variants were 
conducted as described previously (21).  Protein concentrations were determined by the
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Figure 4.3.  Differential fluorescence of ALAS variant isolates streaked on 
expression agar.  1.  DAPI visualized cells containing:  K313A (negative control) (A), 
wild-type ALAS (B), hyperactive variant SS2 (C).   2.  Cells visualized for red 
fluorescence containing:  K313A (negative control) (A), wild-type ALAS (B), 
hyperactive variant SS2 (C).  3.  Overlay of DAPI and red fluorescence visualized cells:  
K313A (negative control) (A), wild-type ALAS (B), hyperactive variant SS2 (C).   
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bicinchoninic acid method using bovine serum albumin as the standard (17).  Reported 
enzyme concentrations are based on the monomeric molecular mass of 56 kDa (17). 
Protein purity was assessed using SDS-PAGE. 
Steady-state and pre-steady-state kinetic characterization of ALAS active site loop 
variants.  ALAS steady-state activity of the ALAS active site loop variants was 
determined at 20°C using a continuous spectrophotometric assay as described previously 
for wild-type ALAS (22).  The ALAS activity data, acquired using a Shimadzu UV 2100 
dual-beam spectrophotometer, were plotted vs. substrate concentration in which one of 
the substrate concentrations varied, while the second was kept constant.  The steady-state 
kinetic parameters were determined by fitting the data to the Michaelis-Menten equation 
using non-linear regression analysis software as reported in (10).  The ALAS steady-state 
kinetic parameters of wild-type ALAS and the SS2 variant activity assays were also 
determined at 15, 25, 30 and 35 ºC.    
Rapid scanning stopped-flow measurements were performed using a model RSM-
100 stopped-flow spectrophotometer (OLIS, Inc.).  This instrument has a dead-time of 
approximately 2-ms and an observation chamber path length of 4 mm.  Spectral scans 
covering a wavelength range of 300-510 nm were collected at a rate of 1000 scans/s and 
then averaged to 62 scans/s to reduce the data files to an appropriate size for global fit 
analyses. The temperature of the syringes and the stopped-flow cell compartment was 
maintained at 20oC by an external water bath.  Pre-steady-state kinetic reactions of the 
variant enzymes were examined under single turnover conditions, using final 
concentrations of 60 μM enzyme, 120 mM glycine and 10 μM succinyl-CoA in 100 mM 
HEPES, pH 7.5 and 10% (v/v) glycerol as previously described (23).  Single turnover 
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data were evaluated using either a three-kinetic-step, or a two-step kinetic mechanism as 
described by Equations 4.1 and 4.2, respectively (23).   
 
(Equation 4.1) 
 
(Equation 4.2) 
    
Observed rate constants were determined by Robust Global Fitting of the spectral data 
using the single value decomposition software provided by OLIS, Inc. as previously 
reported (21, 23).  Quality of the calculated fits was judged by analysis of the calculated 
residuals, and the simplest mechanism that described the experimental data was used.  
Determination of the dissociation constants for the binding of glycine and ALA.   
The equilibrium dissociation constant (KD) for the binding of glycine to the SS2 variant 
was determined in 20 mM HEPES (pH 7.5) and 10% glycerol at 20oC and by titrating the 
SS2 variant (60 μM) with increasing concentrations of glycine (0.6 mM-60 mM) and 
monitoring the increase in absorbance at 420 nm upon formation of the external aldimine 
between PLP and glycine (10).  The KD value was determined by fitting the data to 
Equation 4.3, where Y is the absorbance increase at 420 nm, Ymax is the maximum 
increase in absorbance, and [Ligand] is the glycine concentration, using non-linear 
regression analysis software.   
(Equation 4.3) 
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Binding of ALA to the SS2 variant resulted in quenching of the fluorescence emission at 
428 nm upon excitation at 330 nm due to formation of an external aldimine with the PLP-
cofactor.  Thus to determine the dissociation constant for the binding of ALA to SS2, the 
change in fluorescence emission at 428 nm (exc = 330 nm) was monitored upon titration 
of SS2 (60 μM) with increasing concentrations of ALA (0.5 mM-128 mM).  The changes 
in fluorescence at 428 nm were plotted as a function of ALA concentration, and the KD 
value was determined by fitting the data to Equation 4.3, using non-linear regression 
analysis software.     In Equation 4.3, Y is the total change in fluorescence at 428 nm, 
Ymax is the initial fluorescence, and [Ligand] is the ALA concentration. 
Determination of the thermodynamic activation parameters.  The temperature 
dependence of the steady-state kinetic parameters of wild-type ALAS and the SS2 variant 
were examined using the same experimental conditions as described above and covering 
the temperature range of 15-35 C.  The natural log the calculated values for the turnover 
numbers (lnkcat) were plotted vs. the inverse of temperature and the data were fit to the 
Arrhenius equation (Equation 4.4).  
(Equation 4.4)     
)ln(1)ln( A
TR
Ek aobs   
where Ea is the activation energy, R is the universal gas constant, T is the absolute 
temperature, and A is the frequency factor.  The determined activation energies were then 
used to calculate the thermodynamic activation parameters, ΔH, ΔG and ΔS, as 
previously described (23).  
Data analysis for the definition of the minimal kinetic mechanism of a selected 
ALAS active site loop variant.  The KinTekSim kinetic simulation software (24) was used 
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to model the single wavelength kinetic traces at 510 nm for the reaction catalyzed by the 
SS2 variant and thus estimate the forward and reverse rate constants.  The interior rate 
constants were allowed to float, while the previously determined KD values for binding of 
glycine and ALA to the SS2 variant and wild-type ALAS were maintained constant (21).  
Results 
Construction of the synthetically shuffled library and screening of functional 
ALAS variants.  To the extent that the conserved active site lid in mALAS2 may limit 
catalysis, synthetic shuffling was used to evaluate the contribution of amino acids that 
comprise the lid make to motif dynamics and enzyme turnover.  If all 18 amino acid 
residues on the active site lid were mutated to all possible substitutions, there would be a 
total of 1820 possibilities, an intractable number of combinations for our experimental 
approach.  Therefore, instead of a random mutagenesis approach, the number of potential 
mutations at a single position was limited by utilizing mixed base oligonucleotides that 
encode specific changes to the cDNA.  Mixed base oligonucleotide primers encoding 
amino acids that have a precedent in nature were incorporated into the primary sequence 
of wild-type ALAS, from Y422-R439 (Table 4.1).    A multiple sequence alignment 
quantifying the naturally occurring amino acid diversity present at specific positions in 
the lid was performed (Figure 4.4).  These ALAS sequences were incorporated into the 
library.  To preserve the functional integrity of ALAS, we always included the wild-type 
nucleotides in the primers.    Further, the conserved residues of the active site lid were not 
mutated; an additional consideration employed to reduce the possibility of recovering 
inactive variants.  Screening of the synthetically shuffled library included a two-pronged 
approach (Figure 4.2).  First, E. coli strain HU227 need aminolevulinate to thrive (25); 
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mutants transformed into this strain are able to provide the depleted metabolite required 
for colony formation on agar plates lacking ALA.  Next, to elucidate which variants are 
catalyzing the production of ALA at a rate faster than wild-type ALAS, the appearance of 
fluorescence associated with excess porphyrin biosynthesis was used (Figure 4.3).   
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Figure 4.4.  Multiple alignment of the amino acid sequences of the ALAS loop region. 
 
                      Active Site Loop  
      Y422...............R439 
    1 ALAS_DELLEU          486    LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLAAWTEVGLPLQD -VSIAACNFCRRPVH 
FELMSEWERSYFGNM    573 
    2 ALAS_DLLLEU          486    LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLAAWTEVGLPLQD -VSIAACNFCRRPVH 
FELMSEWERSYFGNM    573 
    3 ALAS_HOMSAP          491    LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLLAWTAVGLPLQD -VSVAACNFCRRPVH 
FELMSEWERSYFGNM    578 
    4 ALAS_RATNOR         491    LLLAKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCRRPVH 
FELMSEWERSYFGNM    578 
    5 ALAS_RATRAT          491    LLLAKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCRRPVH 
FELMSEWERSYFGNM    578 
    6 ALAS_MUSMUS          491    LLLSKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCHRPVH 
FELMSEWERSYFGNM    578 
    7 ALAS_DANRER          486    ILLEKHNIYVQAINY PTVPRG-EELLRLAP SPFH-NPIMMNYFAE KLLDVWQEVGLPLNG -PAQASCTFCDRPLH 
FDLMSEWEKSYFGNM    573 
    8 ALAS_DANROS          486    ILLEKHNIYVQAINY PTVPRG-EELLRLAP SPFH-NPIMMNYFAE KLLDVWQEVGLPLNG -PAQASCTFCDRPLH 
FDLMSEWEKSYFGNM    573 
    9 ALAS_OPSTAU          486    SLLEKHNIYVQAINY PTVPRG-QELLRLAP SPHH-HPAMMEYFVD KLVEVWQEAGLLLNG -PATVSCTFCDRPLH 
FDLMSEWEKSYFGNM    573 
   10 ALAS_HOMSPN          545    ELMSRHNIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMNYFLE NLLVTWKQVGLELKP -HSSAECNFCRRPLH 
FEVMSEREKSYFSGL    632 
   11 ALAS_DELDEL          545    ELMSRHNIYVQAINY PTVRRG-EELLRIAP TPHH-TPQMMNYFVE NLLATWKRVGLELKP -HSSAECNFCRRPLH 
FEVMSEREKSYFFGM    632 
   12 ALAS_MOUDOM          546    ELMTRHNIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMNFFVE KLLVTWKRVGLELKP -HSSAECNFCRRPLH 
FEVMSEREKAYFSGM    633 
   13 ALAS_GALVAR          540    KLMSQHSIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMSYFLE KLLATWKDVGLELKP -HSSAECNFCRRPLH 
FEVMSERERSYFSGM    627 
   14 ALAS_XENLAE          308    KLMRDYSIYVQAINY PTVPRG-EELLRIAP TPHH-NPQ------- --------------- --------------- -------------
--    344 
   15 ALAS_OPSBET          532    LMMSHHNIYVQAINY PTVARG-DELLRIAP TPHH-TPEMMKYFVD RLVQTWKEVGLELKP -HSSAECTFCQQPLH 
FEVMNEREKSYFSGL    619 
   16 ALAS_OPSPAR          532    LMMSHHNIYVQAINY PTVARG-DELLRIAP TPHH-TPEMMKYFVD RLVQTWKEVGLELKP -HSSAECTFCQQPLH 
FEVMNEREKSYFSGL    619 
   17 ALAS_DANDAN          518    IMMSRYNIYVQAINY PTVARG-EELLRIAP TPHH-TPQMMKYFVD KLTQTWTEVGLPLKP -HSSAECNFCRQPLH 
FEIMSEREKSYFSGL    605 
   18 ALAS_MYXGLU          565    ELMSRHNIYVQAINY PTVPRG-EEMLRVVV TPHH-TPQMMQYFVE HLTNSWKDIGLNLRP -HASAECNYCKMPIH 
FELMSEHDQVYFDGM    652 
   19 ALAS_STRDRO          512    SLLEEHNIYVQAINS PTVPSG-EEKLRIAP SPXH-TPDMMDRFVA SLSEVWAKSGLRFNT PICPRECEFCKNPEK 
FEELSSRERSFAEES    578 
   20 ALAS_DROMEL          463    VLIEQFGHYLQSINY PTVARG-QEKLRLAP TPFH-TFEMMNALVT DLKKVWEMVDLSTNV PLSPNACMFCNSESC 
WHQDTSPDLECGIPN    529 
 135
   21 ALAS_LIMPOL          494    ELISMHGHYVQAINY PTVPRG-EEKLRIAP TPFH-TRPMMEAFVR DLVSVWRGLKLPLRD GICEKKCEFCEKPLY FEHLESRVL----
--    560 
   22 ALAS_SEPOFF          540    DLLIKHNIYVQAINY PTVARG-EEKLRVAA TPHH-TKEMMDHFVD CVVKVWLEHGLTLNP -DSTRPAEFNVKFKK FSI----------
--    603 
   23 ALAS_GLYDIB          516    ELMEEHGIYVQPINY PTVPRG-QELLRVAP TPHH-TKEMMDSFVN ATLSVFLNNNIELKS -TCGINCLYCHQPMK CEAFTNRER----
--    586 
   24 ALAS_GALGAL          420    ALLEEHGLYVQAINH PTVPRGQELLLRIAP TPHH-SPPMLENLAD KLSECWGAVGLPRED -PPGPSCSSCHRPLH LSLLSPLER----
--    508 
   25 ALAS_SINMEL          346    LLLDNFGIYVQPINY PTVPKK-TERLRITP TPMH-SDADIDHLVS ALHSLWSRCALARAV A-------------- -------------
--    405 
   26 ALAS_SMRMEL          275    LLLDNFGIYVQPINY PTVPKK-TERLRITP TPMH-SDADIDHLVS ALHSLWSRCALARAV A-------------- -------------
--    334 
   27 ALAS_AGRTUM          364    ILLDNHGVYVQPINY PTVPRK-TERLRITP TPLH-TDADIEQLVG ALHQLWSHCALARAV A-------------- -------------
--    423 
   28 ALAS_AGRRAD          346    ILLDSHGVYVQPINY PTVPRK-TERLRITP TPLH-SDADIEHLVG ALHQLWSHCALARAV A-------------- -------------
--    405 
   29 ALAS_RHIRAD          276    ILLDSHGVYVQPINY PTVPRK-TERLRITP TPLH-SDADIEHLVG ALHQLWSHCALARAV A-------------- -------------
--    335 
   30 ALAS_RHOPSE          344    ELINRYGIYVQPINY PTVPRG-TERLRITP SPQH-TDADIEHLVQ ALSEIWARVGLAKAA --------------- -------------
--    403 
   31 ALAS_RHOPSE          346    ALLARHAIYVQPINY PTVARG-QERFRLTP TPFH-TTSHMEALVE ALLAVGRDLGWAMSR RAA------------ -------------
--    407 
   32 ALAS_EUGGRA          343    LLLKRFQIYVQPINY PTVDVG-TERLRITV SPVH-TNEHMATLIT ALLQVWEELGLPLRP PVFDTEGYPEVEAAE WLPNSAMWR----
--    409 
   33 ALAS_BRAJAP          348    LLLEEHGIYIQPINY PTVAKG-SERLRITP SPYH-DDGLIDQLAE ALLQVWDRLGLPLKQ KSLAAE--------- -------------
--    409 
   34 ALAS_BRAJAP          275    LLLEEHGIYIQPINY PTVAKG-SERLRITP SPYH-DDGLIDQLAE ALLQVWDRLGLPLKQ KSLAAE--------- -------------
--    339 
   35 ALAS_BRUMEL          345    RLLEVHGIYIQPINY PTVPRG-TERLRITP SPLH-DDKLIDGLKD ALLEVWNELGIPFAE PSAPQAANSDRIIPL MVSKAGG------
--    425 
   36 ALAS_ZYMMOB          287    ILLNEYGAYVQPINF PTVPRG-TERLRFTP GPTH-NEAMLRELTD SLVAIWHRLDMRFAA --------------- -------------
--    345 
   37 ALAS_RHOCAP          348    MLLSDYGVYVQPINF PTVPRG-TERLRFTP SPVH-DLKQIDGLVH AMDLLWARCA----- --------------- -------------
--    401 
   38 ALAS_RHOCAP          278    MLLSDYGVYVQPINF PTVPRG-TERLRFTP SPVH-DLKQIDGLVH AMDLLWARCA----- --------------- -------------
--    331 
   39 ALAS_PARDEN          292    MLLADFSIYVQPINF PTVPRG-TERLRFTA SPVH-DPKQIDHLVK AMDSLWSQCKLNRST SAA------------ -------------
--    339 
   40 ALAS_PARZEA          360    MLLADFSIYVQPINF PTVPRG-TERLRFTA SPVH-DPKQIDHLVK AMDSLWSQCKLNRST SAA------------ -------------
--    409 
   41 ALAS_RHOPSE          364    MLLIHFGIYVQPINF PTVPRG-TERLRFTP SPVH-DSGMIDHLVK AMDVLWQHCALNRAE VVA------------ -------------
--    407 
   42 ALAS_EMENID          510    KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA AELENQPIWT---
--    598 
    
Figure 4.4.  Continued 
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   43 ALAS_EMENID          440    KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA 
AELENQPIWTDAQLN    528 
   44 ALAS_ASPNID          440    KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA 
AELENQPIWTDAQLN    528 
   45 ALAS_ASPORI          508    KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-IKEHRDHLVQ AVQTVWNELGIKRTS DWEAQGGFVGVGVDG 
AEAENQPIWNDVQLG    596 
   46 ALAS_NEUCRA          334    KLLNDHQIYVQSINY PTVPVG-QERLRITP TPGH-TKQFRDHLVA ALDSIWTELGIKRTS DWAAEGGFIGVGEAE A-
EPVAPLWTDEQLG    421 
   47 ALAS_GIBFUJ          393    MLLNDYGIYVQAINY PTVPVG-QERLRVTP TPGH-IKEYRDQLVE AIDEIWTRLDIKRTS DWAAEGGFIGVGEQD --
NVQEPLWTDKQLN    479 
   48 ALAS_YARLIP          404    LLLTKHQIYVQAINF PTVPIG-QERLRVTP TPGH-HEGLCDELVA ALEDVWQELDLKRVE DWTAEGGLCGVGEGV --E-
VEPLWSEEQLS    489 
   49 ALAS_CANALB          451    LLLNKHDIYVQAINF PTVPIG-EERLRITP TPGH-GPELSKQLVE AVDSVFTELNLNRIN DWKKLGGLVGVGVEG -
AAKVEHIWTEEQLA    538 
   50 ALAS_CANALB          381    LLLNKHDIYVQAINF PTVPIG-EERLRITP TPGH-GPELSKQLVE AVDSVFTELNLNRIN DWKKLGGLVGVGVEG -
AAKVEHIWTEEQLA    468 
   51 ALAS_DEBHAN          392    LLLDKYNIYVQAINF PTVPIG-QERLRITP TPGH-GPELSNQLIG ALDSVFNELSLSRIG DWEGKGGLCGVGEPD -
IEPIEHIWTSEQLA    479 
   52 ALAS_SACCER          435    ILINKHQIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILIN AVDDVFNELQLPRVR DWESQGGLLGVGESG -
FVEESNLWTSSQLS    522 
   53 ALAS_SACCAS          365    ILINKHQIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILIN AVDDVFNELQLPRVR DWESQGGLLGVGESG -
FVEESNLWTSSQLS    452 
   54 ALAS_CANGLA          347    ILMEKHRIYVQAINF PTVSRG-TERLRITP TPGH-TNDLSDILIA AVDDVFNELQLPRIR DWEMQGGLLGVGDKN -
FVPEPNLWTEEQLS    434 
   55 ALAS_KLULAC          387    ILMDKHRIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILMD ALEDVWSTLQLPRVR DWEAQGGLLGVGDPN -
HVPQPNLWTKDQLT    474 
   56 ALAS_EREGOS          373    ILMEKHRIYVQAINF PTVPRG-TERLRITP TPGH-TNDLSDVLLD AMDDVWKTLQLPRVS DWAAHGGLLGVGEPD -
YVPEANLWTEEQMS    460 
   57 ALAS_AGABIS          460    KLLSEHDIYVQAINY PTVARG-EERLRITV TPRH-TMEQMEGLIR SLNQVFEELNINRLS DWKLAGGRAGVGIPG 
AADDVQPIWTDEQIG    548 
   58 ALAS_AGADIV          390    KLLSEHDIYVQAINY PTVARG-EERLRITV TPRH-TMEQMEGLIR SLNQVFEELNINRLS DWKLAGGRAGVGIPG 
AADDVQPIWTDEQIG    478 
   59 ALAS_SCHPOM          475    SLLHDHNIYVQSINF PTVSVG-TERLRITP TPAHNTEHYVQSLTN AMNDVWSKFNINRID GWEKRGIDVGRLCKF PVLPFTTTH----
--    558 
   60 ALAS_SCHMIK          405    SLLHDHNIYVQSINF PTVSVG-TERLRITP TPAHNTEHYVQSLTN AMNDVWSKFNINRID GWEKRGIDVGRLCKF PVLPFTTTH----
--    488 
   61 ALAS_RICPRO          342    MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFDELDIELSS AKELNKEVRLHLIA- -------------
--    414 
   62 ALAS_RICTYP          342    MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFAELDIELSS TKELNKEVRLHLIA- -------------
--    414 
   63 ALAS_RICPRO          272    MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFDELDIELSS AKELNKEVRLHLIA- -------------
--    344 
   64 ALAS_RICCON          354    MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLSV ALVQIFAELDIELSS AKELNEEVRLNLIA- -------------
--    426 
   65 ALAS_CHRVIO          354    RLLEEFDIYVQPINY PSVPRG-GERFRLTV GPRR-SHEEIQRFVA ALKHCLA-------- --------------- -------------
--  
Figure 4.4.  Continued 
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Figure 4.4.  Multiple alignment of the amino acid sequences of the ALAS loop region.  The amino acid sequences were 
obtained from public databases (NCBI) using a BLAST search and aligned using CLUSTAL W (1).  The 10 positions within 
the 18-amino acid sequence targeted for synthetic shuffling are high-lighted in cyan.  The amino acid numbering in red refers 
to that of murine erythroid ALAS (mALAS2).   
Represented proteins are: ALAS_DELLEU: Delphinapterus leucas ALAS (20138447); ALAS_DLLLEU: Delphinapterus leucas cook inlet subspecies 
2 (5281116); ALAS_HOMSAP, Homo sapiens ALAS erythroid (4557299); ALAS_RATNOR, Rattus norvegicus erythroid ALAS (51980582); 
ALAS_RATRAT, Rattus rattus erythroid ALAS (6978485); ALAS2_MUSMUS, Mus musculus erythroid ALAS (33859502); ALAS_DANRER, Danio 
rerio ALAS (18858263); ALAS_DANROS, Danio roseus ALAS (20138448); ALAS_OPSTAU, Opsanus tau ALAS (1170202); ALAS_ORYLAT, 
Oryzias latipes ALAS (49022596); ALAS_HOMSPN, Homo sapiens erythroid ALAS (4502025); ALAS_DELDEL, Delphinus delphis erythroid ALAS 
(20138445); ALAS_MOUDOM, Mus musculus domesticus erythroid ALAS  (23956102); ALAS_GALVAR, Gallus varius erythroid ALAS (122821); 
ALAS_XENLAE, Xenopus laevis erythroid ALAS (44968228); ALAS_OPSBET, Opsanus beta ALAS (1170206); ALAS_OPSPAR, Opsanus pardus 
ALAS (532630); ALAS_DANDAN, Danio danglia ALAS (32451642); ALAS2_MYXGLU, Myxine glutinosa erythroid ALAS (4433550); 
ALAS1_BRALAN, Branchiostoma lanceolatum ALAS 1 (28630217); ALAS1_STRDRO, Strongylocentrotus droebachiensis ALAS 1 (4433548); 
ALAS1_DROMEL, Drosophila melanogaster ALAS 1 (2330591); LAS1_LIMPOL, Limulus polyphemus ALAS 1 (4433540); ALAS1_SEPOFF, Sepia 
officinalis ALAS 1 (4433546); ALAS2_GLYDIB, Glycera dibranchiate ALAS 2 (4433544); ALAS2_GALGAL, Gallus gallus gallus ALAS 2 
(1170201); ALAS_SINMEL, Sinorhizobium meliloti 1021 ALAS (15966742); ALAS_SMRMEL, Sinorhizobium meliloti ALAS (18266808); 
ALAS_AGRTUM, Agrobacterium tumefaciens ALAS (889869); ALAS_AGRRAD, Agrobacterium radiobacter ALAS (95069); ALAS_AGRTUM, 
Agrobacterium tumefaciens ALAS (122818); ALAS_RHOPAL, Rhodopseudomonas palustris ALAS (4001678); ALAS_RHOSPO, Rhodobacter 
sporagenes ALAS (541302); ALAS_EUGGRA, Euglena gracilis ALAS (12620813); ALAS_BRAELK, Bradyrhizobium elkanii ALAS (66534); 
ALAS_BRAJAP, Bradyrhizobium japonicum ALAS (30179569); ALAS_BRUMEL, Brucella melitensis ALAS (25286547); ALAS_ZYMMOB, 
Zymomonas mobilis ALAS (4511998); ALAS_RHOGLU, Rhodobacter gluconicum ALAS (97435); ALAS_RHOCAP, Rhodobacter capsulatus ALAS 
(122828); ALAS_PARDEN, Paracoccus denitrificans ALAS (1170207); ALAS_PARZEA, Paracoccus zeaxanthinifaciens ALAS (537435); 
ALAS_RHOSPH, Rhodobacter sphaeroides ALAS (541301); ALAS_EMENID, Emericella nidulans ALAS (418756); ALAS_EMCNID, Emericella 
nidulans ALAS (585244); ALAS_ASPNID Aspergillus nidulans ALAS (40745239); ALAS_ASPORY, Aspergillus oryzae ALAS (5051989); 
ALAS_NEUCRA, Neurospora crassa ALAS (52782908); ALAS_GIBFUJ, Gibberella fujikuroi ALAS (15721883); ALAS_YARLIP, Yarrowia 
lipolytica ALAS (52782857); ALAS_CANBER, Candida berate ALAS (7493758); ALAS_CANALB, Candida albicans ALAS (10720014); 
ALAS_DEBHAN, Debaryomyces hansenii ALAS (52782855); ALAS_SACCER, Saccharomyces cerevisiae ALAS (6320438); ALAS_SACCAS, 
Saccharomyces castellii ALAS (122831); ALAS_CANGLA, Candida glabrata ALAS (52782865); ALAS_KLULAC, Kluyveromyces lactis ALAS 
(52788271); ALAS_EREGOS, Eremothecium gossypii ALAS (52782894); ALAS_ASPBIS, Agaricus bisporus ALAS (1679599); ALAS_AGADIV, 
Agaricus divoniensus ALAS (2492846); ALAS_SCHPOM, Schizosaccharomyces pombe ALAS (7492336); ALAS_SCHMIK, Schizosaccharomyces 
mikatae ALAS (52782853); ALAS_RICCON, Rickettsia conorii ALAS (7433712); ALAS_RICTYP, Rickettsia typhi ALAS (51474008); 
ALAS_RICPRO, Rickettsia prowazekii ALAS (6225494); ALAS_RICRIC, Rickettsia rickettsia ALAS (2528635); ALAS _CHRVIO, 
Chromobacterium violaceum ALAS (34102112). 
(1)  Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673-4680 
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Under these conditions, it was possible to isolate ALAS variants with turnover numbers 
greater than that of wild-type ALAS.  In panels (A1, B1 and C1) of Figure 4.3 cells are 
visualized with a DAPI filter, which was used a means of assaying for single colony 
isolates.  The magnification for each image was identical, implying that colony size 
differed between those cells harboring a hyperactive variant compared to wild-type and 
the negative control (K313A) (26).  This decrease is colonial diameter is likely due to 
ALA toxicity (27).  The contrast between those cells harboring the inactive ALAS 
(K313A) and those complemented with wild-type ALAS show clearly the lack of 
porphyrin-derived red fluorescence in the negative control (Figure 4.3 Panels A2 and 
B2).  The dissimilarity in accumulated porphyrin levels between wild-type ALAS and the 
SS2 variant is highlighted by the considerably greater red fluorescence present in the 
library isolate compared to wild-type ALAS (Figure 2 Panels B3 and C3).  In summary, 
comparison of accumulated porphyrin levels present in cells as visualized by 
fluorescence microscopy of bacterial colonies on expression agar proved a reliable 
method for obtaining hyperactive isolates.   
Qualitative analysis of the isolated active site lid variants.  The mutations present 
among the active site lid variants is shown in Table 4.2.  Functional mutations were 
detected at 9 of the 18 positions that comprise the lid.  Based on our experimental design 
it can be concluded that the mutation of Asn427 to His is most likely an artifact of the 
primer design and PCR.  Amino acid substitutions observed among the variants included 
highly disruptive changes (e.g., A425P, P432E, L437K, E435K) as well as more 
conservative variations (e.g., V423L, A425G, Y428H, R433K).  This suggests that non-
covalent forces including hydrogen bonding as well as Van der Waals and electrostatic
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Table 4.2.  Amino acids substitutions in active site lid variants.  Shuffled positions 
are indicated in red. 
Wild-type 
ALAS Y V Q A I N Y P T V P R G E E L L R
Single variants                   
A8    T               
D8                Q   
G7      H             
Quadruple 
variant                   
F1            K K Q  Q   
Penta variant                   
F10       I     Q N T  N   
Hexa variants                   
A4  I  P   C    R K  N     
F3    G   H     H N K  K   
H1       N    N I E K  K   
Hepta variant                   
SS2  L     R    E I N Q  K   
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interactions may be perturbed in the variants.  Replacements at residues toward the 
carboxy terminus of the lid, (P432-R439) favored conversion to basic amino acids, likely 
positively charged at physiological pH, while residues that comprised the portion of the 
lid proximal to the amino terminus (Y422-V431) showed less restriction toward which 
amino acid was permissible.  Several positions showed a propensity for a particular 
substitution as demonstrated by the frequency of the observed mutation.  At position 423, 
valine was found substituted three times for leucine, indicating that hydrophobicity may 
be a necessary characteristic at this position in the lid.  Toward the C-terminal end of the 
lid, E435 was found mutated twice to both glutamine and lysine, L437 was substituted for 
lysine three times and glutamine twice.  This indicates that the presence of positively 
charged residues in this area of the lid may facilitate lid dynamics. 
Steady-state kinetic analysis of the active site lid variants.  The steady-state 
kinetic characterization of 9 variants from the library was carried out at 20oC (Table 4.3).  
Compared to wild-type ALAS, all of enzymes had higher turnover numbers.  The SS2 
variant showed a kcat 16-fold higher than that of the wild-type enzyme.  Similarly, the kcat 
values for the quadruply, quintuply and hextuply mutated F1, F10 and H1 variants were 
also markedly higher compared to wild-type ALAS.  The remaining variants, including 
the single point variants, also showed enhanced turnover, ranging from a 50% increase 
observed in D8 to an 8-fold increased displayed by the A4 isolate.  While the turnover 
number data suggest that a single amino acid substitution is enough to increase enzyme 
activity, it is the combination of amino acids substitutions toward the carboxy terminal 
region of the lid that elicit the greatest increases in turnover number.  As compared to that 
of wild-type ALAS, the Michaelis constant for succinyl-CoA was notably different 
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Table 4.3.  Kinetic parameters for the reactions of hyperactive ALAS enzymes1 
 Steady-state parameters Pre-steady-state 
parameters 
Enzyme kcat 
s-1 
Gly
mK  
mM 
SCoA
mK  
μM 
kcat/
Gly
mK  
mM-1 s-1 
kcat/
SCoA
mK  
μM-1 s-1 
Qf 2 
s-1 
Qd1 3 
s-1 
Qd2 4 
s-1 
WT 0.02 ± 0.01 14 ± 2.0 11 ± 1.0 1.1x10-3 1.5x10-3 0.8 0.53 0.01 
SS2 0.31 ± 0.06 12 ± 1.2 3.0 ± 0.3 0.02 0.10 16 1.7 N/A 
A4 0.16 ± 0.01 14 ± 1.1 2.3 ± 0.4 0.01 0.07 7.1 1.7 0.07 
F3 0.20 ± 0.01 13 ± 1.1 2.6 ± 0.4 0.02 0.08 7.7 1.1 0.17 
H1 0.23 ± 0.14 13 ± 1.4 2.0 ± 0.3 0.02 0.11 10 1.5 N/A 
F10 0.17 ± 0.01 16 ± 1.8 1.1 ± 0.7 0.01 0.16 3.7 0.98 0.15 
F1 0.20 ± 0.02 16 ± 1.2 2.9 ± 0.4 0.01 0.07 4.0 1.1 N/A 
A8 0.07 ± 0.01 25 ± 3.7 2.3 ± 0.4 2.5x10-3 0.03 4.8 0.81 0.12 
D8 0.03 ± 0.01 24 ± 3.1 1.7 ± 0.7 1.3x10-3 2.0x10-3 5.4 0.44 0.02 
G7 0.07 ± 0.01 15 ± 1.7 1.5 ± 0.1 4.4x10-3 0.05 4.4 0.87 0.12 
1Enzymatic reactions monitored at 20 °C; 2Rate for quinonoid intermediate formation; 
3Rate for first step of quinonoid intermediate decay; 4Rate for second step of quinonoid 
intermediate decay. 
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among the active site lid variants.  All of the variants showed at least a 3-fold reduction in 
the SCoAmK .  Accordingly, due to the enhanced turnover evident among the multiply 
mutated variants, the catalytic efficiency with respect to succinyl-CoA increased no less 
than 10-fold.  For the same reason, because the Km for glycine was relatively unaltered, 
the catalytic efficiency with glycine also increased among the isolated variants.  The 
increase in affinity observed among the active site lid variants with respect to succinyl-
CoA supports a hypothesis whereby the binding of this substrate switches a pre-existing 
protein conformational equilibrium towards a closed, catalytically competent, 
conformation (Lendrihas, et. al., submitted) (28).   
Pre-steady-state reaction of the active site lid variant enzyme-glycine complexes 
with succinyl-CoA.  To understand the contribution that the active site lid makes toward 
the reaction catalyzed by ALAS, the transient kinetic parameters of the library variants 
were elucidated.  The formation and decay rates of a key step in the chemical mechanism 
were obtained (Table 4.3).  Under single turnover reaction conditions, the lifetime of a 
transient quinonoid intermediate was observed with respect to time as a change in 
absorbance at 510 nm.  The absorbance change timecourses were fit to a sequential 
mechanism with either two or three-steps, equations 1 and 2, respectively.  An initial 
burst of quinonoid intermediate formation, followed by a two-step rate of decay was 
characteristic to 6 of the enzymes tested (Figure 4.5A-F).  Compared to wild-type ALAS 
(0.8 s-1), the A4 and F3 multiply mutated lid variants, showed a 9-fold increase in the rate 
of quinonoid intermediate formation (7.1 s-1 and 7.7 s-1, respectively).  Additionally, the 
rates corresponding with the first step of quinonoid intermediate decay in these variants 
(1.7 s-1 and 1.1 s-1) were also increased over that of wild-type ALAS (0.53 s-1). 
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Figure 4.5.  The single turnover 
reactions of isolated hyperactive 
ALAS variants.  The pre-steady state 
kinetic parameters were calculated under 
single turnover conditions (60μM 
enzyme, 10μM succinyl-CoA, and 120 
mM glycine) at 20oC and by monitoring 
absorbance changes at 510 nm.  The 
reaction catalyzed by the wild-type 
enzyme is characterized by a single step 
of quinonoid intermediate formation and 
2-step process of decay.  The reactions 
catalyzed by the F10 and H1 variants 
(panels G, and H, respectively) are 
markedly different, they follow a single 
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step of intermediate formation and 
single step of intermediate decay.  The 
remaining variant catalyzed reactions:  
A4, D8, G7, A8, F3 and F1 (panels A-F, 
respectively) resemble that of the wild-
type enzyme.  
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Accordingly, the second step of quinonoid intermediate decay, a step hypothesized to 
include the dissociation of product and opening of the putative active site lid was 
markedly increased in these variants, with values of 0.07 s-1 and .017 s-1, rates 7- and 17-
fold higher when compared to 0.01 s-1 for wild-type ALAS.  These data support the 
increased catalytic efficiency observed from the experiments performed in the steady-
state.  The singly mutated variants A8, D8 and G7 also formed the quinonoid 
intermediate at least 4-fold faster when compared to wild-type ALAS (4.8 s-1, 5.4 s-1, 4.4 
s-1, respectively).  However, the first rate of biphasic quinonoid intermediate decay was 
similar.  The rates for all three proteins did not exceed that displayed by wild-type ALAS.  
This suggests that the coordinated action of more than one residue may be responsible for 
initiating active site lid dynamics, and altering the kinetic mechanism.  In the remaining 3 
variants, the lifetime of the transient quinonoid intermediate was dramatically different 
(Figure 4.5H, 4.5I and 4.6A). Instead of proceeding by a mechanism similar to wild-type 
ALAS, these enzymes appear to condense the biphasic rate of decay into a single step.  
Consequently, the data are fitted to a two step sequential mechanism.  SS2, H1, and F1 all 
form the quinonoid intermediate faster than wild-type ALAS.  Most notably, SS2 does so 
at a rate that is 20-fold faster (16 s-1 vs.0.8 s-1 for wild-type ALAS) (Figure 4A).  This 
group of variants also show the greatest enhancement in the rate associated with 
quinonoid intermediate decay.  SS2, H1, F10 and F1 all display at least a 2-fold increase 
in the rate of quinonoid decay.  However, since the second step of quinonoid intermediate 
decay is not observed among these variants it is possible that as the rate of decay 
becomes monophasic and shows an observed rate that is significantly greater than that 
measured for the slower second phase observed in wild-type ALAS, the true rate of 
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quinonoid intermediate decay is no longer conformationally dependent, and approximates 
the rate of product release. 
Equilibrium Constants for the SS2 variant. The dissociation constants for the 
binding of glycine and ALA to the SS2 variant at pH 7.5 and 20oC were used to model 
the kinetic mechanism (Figure 4.6B and 4.6C).  Schiff base formation between the 
cofactor of the SS2 variant and glycine was monitored spectroscopically at 420 nm.  The 
glycine concentration dependent data were fit to a standard hyperbola and the KD for 
glycine was found to be 4.12 ± 0.57.  This value is 50% lower than that of the wild-type 
enzyme.  The increased affinity of SS2 for glycine suggests that the active site lid 
mutations facilitate substrate binding, a finding coincident with increased catalytic 
efficiency.  The dissociation constant for ALA, as measured in the SS2 variant, was 
determined by monitoring the change in fluorescence emitted at 428 nm upon excitation 
at 330 nm.  To determine the KD for the product, the enzyme was reacted with increasing 
concentrations of ALA.  The dissociation constant for ALA was determined to be 1.82 ± 
0.19 mM, a value 62% higher compared to that of wild-type ALAS.  This value, a notable 
decrease in affinity between the product and the SS2 variant may be attributable to 
increased active site lid flexibility, a circumstance supported by the hyperactivity 
measured for SS2 in the steady- and pre-steady-state.   
Thermodynamic properties of wild-type ALAS and the SS2 variant.  The 
dependence of the turnover number (kcat) on temperature was characterized over the range 
288–308 K for both wild-type ALAS and the SS2 variant (Figure 4.7).  The kcat values 
were calculated using the same experimental method and data treatment as was described 
for the reported steady-state kinetic parameters.  The turnover numbers for each enzyme
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Figure 4.6.  The SS2 variant 
catalyzed reaction.  The pre-steady 
state kinetic parameters for SS2 were 
calculated under single turnover 
conditions at 20oC and by:  (A) 
monitoring quinonoid intermediate 
absorbance changes at 510 nm; (B) 
monitoring internal aldimine formation 
absorbance changes at 420 nm, and; 
(C) monitoring the change in 
fluorescence emission at 428nm upon 
excitation at 330 nm upon the addition 
of ALA. 
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were used to construct an Arrhenius plot, from which the thermodynamic activation 
parameters were derived (Table 4.4).   The Arrhenius plot of the experimental data 
showed a linear dependence in the temperature range for both enzymes.  From the slope 
of the straight line, an activation energy (Ea) of 0.5 kcal/mol was calculated for the wild-
type enzyme.  For the SS2 enzyme, Ea was determined to be 0.1 kcal/mol, a value 80% 
lower compared to that of wild-type ALAS.  This suggests that the SS2-catalyzed 
reaction may decrease the energy barrier for enzyme motions that are coupled to the 
reaction.  Different slope values were calculated from the linear relationship between the 
kcat values for both enzymes and temperature. The slope value associated with wild-type 
ALAS was -24, compared to -9.2 for the SS2 variant.  These two dissimilar values 
suggest that the SS2-catalyzed reaction proceeds by an alternate reaction pathway, where 
chemistry and lid mobility determines the rate limiting step.   
Figure 4.7.  The thermal dependence of the SS2 variant catalyzed reaction.  kcat 
values were calculated by performing steady-state kinetics at different temperatures. (A) 
an Arrhenius plot depicting the difference between the wild-type (●) and the SS2 variant 
catalyzed (○) reactions at 288, 292, 297, 302 and 308K.  Error bars are plotted over and 
partially obscured by the data points.   
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Table 4.4.  Thermodynamic activation parameters of wild-type ALAS and the 
SS2 variant. 
Enzyme Slope Ea (kcal/mol) 
H  
(kcal/mol) 
G  
(kcal/mol) 
S  
(kcal/mol·K)
SS2 -9.2 0.01 ± 0.003 -0.58 16 -56 
WTALAS -24 0.05 ± 0.002 -0.55 17 -58 
 
Figure 4.8.  The simulated kinetic mechanism of the SS2 variant catalyzed reaction.  
Transition from an internal aldimine with lysine 313 to an external aldimine with glycine 
is the first step.  Succinyl-CoA binds second which is followed by quinonoid formation, 
protonation of the quinonoid to yield an aldimine bound molecule of ALA.  Finally, the 
release of ALA from the active site is the rate limiting step. 
E; SS2: G; glycine: EG; enzyme-glycine complex: SCoA; Succinyl-CoA: EGSCoA; 
ALAS-glycine-Succinyl-CoA complex: EQ; enzyme bound to protonated quinonoid: 
EALA; enzyme-ALA complex. 
KD = 4.28 mM 
E+G  EG+SCoA  EGSCoA EALA  E+ALA 
KD = 1.82 mM 
1.7 s-116 s-1 2.2 μM-1· s-1
1.5 s-10.22 s-111 s-1 
EQ 
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Discussion 
Comparison of the X-ray crystal structures of holoenzymic ALAS and AONS 
with the succinyl-CoA- and AON-bound structures, revealed the presence of a 
conformationally mobile active site lid.  The outermost part of the active site lid of ALAS 
undergoes a 3.5 Å change in conformation in the presence of succinyl-CoA (Figure 4.1).  
To address the role of this dynamic structure in the enzyme-catalyzed reaction we 
employed synthetic shuffling to alter the amino acid composition of the active site lid in 
mALAS2 (Y422-R439).  Our results suggest that amino acid substitutions within the 
active site lid lead to altered lid dynamics, a circumstance affecting enzymatic turnover, 
and one that ultimately liberates the enzyme from a conformationally limited rate 
determining step. 
The approach used to evaluate the active site lid of ALAS utilized a mutagenic 
technique called synthetic shuffling (14).  Non-conserved amino acids that comprise the 
lid vis á vis the multiple sequence alignment, tolerated sequence substitutions differently 
based on their position in the motif (Figure 4.4 and Table 4.1).  Shuffled residues 
proximal to the amino terminus (V423, A425, Y428) were found to be mutated a total of 
12 times in the isolated variants.  This is in stark contrast to the 31 mutations identified 
among the residues that comprise the carboxy terminal portion of the lid (P432, R433, 
G434, E435, L437).  The imbalance in mutational frequency evident between the two 
halves of the lid suggest that the role of the carboxy terminal half of the lid may be less 
structural in nature, as demonstrated by ability of drastically mutated variants such as SS2 
and F1 to not only retain activity, but turnover product at rates 10- and 15-fold faster 
compared to wild-type ALAS.  All of the singly mutated variants had replacements in 
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both halves of the lid (A8, D8 and G7).  While the isolation of G7 may be an artifact of 
the mutational approach, G7, coupled with A8 and D8 contained substitutions whereby 
non-polar amino acids were swapped with residues capable of forming a hydrogen bond.  
The A425T mutation present in the A8 variant could affect the orientation of the amino 
terminal portion of the lid with the two α-helices (α2 and α3) of the adjacent monomer, a 
scenario also possible in the multiply mutated variants SS2, A4, and F3.  In fact, the 
contribution of these abutting helical residues to ALAS function has been previously 
addressed (19).  Gong et. al., found that mutating N150 to lysine, and I151 to 
phenylalanine and leucine, in mALAS2, increased the Vmax over that of wild-type ALAS.  
Indeed, the active site lid library data, coupled with the mutational data on residues N150 
and I151 agrees with three previous models where specific interactions that drive ligand-
induced closure and catalysis are proposed to be interdomain in nature (29-31).   
Two characteristics are shared among all of the variants in the library with respect 
to steady-state kinetic parameters (Table 4.3).  First, all of the enzymes examined showed 
an increase in turnover number.  Second, the catalytic efficiency for both substrates was 
enhanced.  These characteristics indicate that the reaction catalyzed by ALAS may be 
limited by a conformational change leading to product release, a mechanism evaluated 
among other enzymes (32, 33).  Accordingly, mutations that affect the mobility of a 
conformationally mobile enzyme structure lead to consequences for reactions in which 
the physical step of product release, rather than chemistry, is rate limiting.  Therefore the 
enhanced turnover observed among the active site lid variants potentially validates our 
ALAS catalytic mechanism in which the enzyme conformation switches between closed 
and open to stabilize reaction intermediates and release product, respectively; a 
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mechanism recently proposed for another PLP-dependent enzyme, diaminopimelate 
decarboxylase (34).  The majority of variants which showed an increase in kcat were 
found to have mutations that occur toward the carboxy terminal portion of the active site 
lid.  At position 433, the A4 and F1 variants contained mutations to lysine, compounded 
with multiple mutations to the motif.  A previous study investigating single point 
mutations to R433 (R433L and R433K), found that the kcat values increased 20% and 
100% for the respective substitutions (11).  Those data coupled with the findings of this 
study suggest that position 433 may significantly contribute to lid mobility and the 
dissociation of ALA from the enzyme.   However, the variants that had the largest 
increases in turnover number and catalytic efficiency were those with mutations to both 
regions of the lid, e.g., SS2 and F3.  These data support the hypothesis, based on the 
crystal structure of R. capsulatus ALAS, that variation to both regions of the active site 
lid leads to relaxation of helices α2 and α3, with concomitant disruption of the active site 
lid interaction with the aldimine-bound product, likely resulting in acceleration of the 
conformationally limited release of ALA.  Conversely, the single point mutant identified 
in D8 (L437Q) showed only a modest increase in kcat compared to wild-type ALAS.  This 
finding implies that mutations to L437 alone are not sufficient to accelerate product 
turnover.  Supportively, since mutations to this residue were identified in concert with 
multiple replacements in 5 variants, we believe that the major effect of enhancing the kcat 
value for enzymes in the library was due to multiplex variation to the amino acid 
composition of the motif. 
With regard to the nature of the rate limiting step in variants isolated from the 
library, a conformational change is likely the predominant kinetic barrier in the single-
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turnover reaction. That is, in a process that can only be limited by the second phase of 
quinonoid intermediate decay or by the rate of product release, the latter must be the 
more rapid, as evidenced by steady-state turnover numbers.  The rate limiting step in 6 of 
the variants from the library is identified as the opening of the active site lid triggered by 
product formation (Figure 4.5A-F).  The function of this change in structure likely 
disrupts the interaction between the carboxylate moiety of ALA, so that the aldimine 
bond formed between the product and PLP can be strongly polarized, and ultimately 
lysed.  Additionally, lid opening enhances product dissociation (compared to wild-type 
ALAS, the SS2 variant showed a 4-fold increase in the ALADK ) by potentially: uncovering 
ALA from within a catalytic vacuole, restoring electron density to the site of α-carbon 
bond scission, and minimizing contact between product and enzyme.  Further, since the 
second rate of quinonoid intermediate decay approximates kcat in wild-type ALAS and 
these 6 variants it is likely that the there is a single dominant energy barrier, and that it is 
thermodynamically advantageous to limit turnover by equalizing the energy of quinonoid 
intermediate decay in the enzyme-catalyzed reaction.   
The pre-steady-state behavior of three variants from the library differs from that 
observed with the wild-type and other library isolates (Figure 4.5G, 4.5H and 4.6A). For 
these three library isolates (SS2, F1 and H1) the observed rate of quinonoid intermediate 
decay is condensed into a single step.  The quinonoid intermediate formation rate 
immediately after mixing the SS2-glycine complex with succinyl-CoA is ~20-fold faster 
than the corresponding rate in wild-type ALAS, suggesting that a step after catalysis is 
only partially rate determining for this variant under these conditions.  This model is 
consistent with the decrease in the kcat-derived slope and Ea for this mutant when the 
 154
temperature is varied (Table 4.4).  Together with the greater dissociation constant 
determined for ALA with these specific mutations, the data suggest that a conformational 
change leading to product release may no longer be rate limiting for the SS2-catalyzed 
reaction.  In several other enzymes where chemistry has been implicated as rate limiting 
(35-37) it was suggested that the effects of conformational change on kcat were the result 
of a thermodynamically driven commitment to catalysis.  In the three variants that appear 
condensed with respect to the rate of quinonoid intermediate decay, Qd is greater than 
that of wild-type ALAS and all the active site lid variants tested (Table 4.3). This finding 
suggests that the reactions catalyzed by SS2, F1 and H1 are energetically favorable.  
Indeed a scenario that the increases in exothermy and positive differential activation 
entropy identified in the SS2 variant strongly support.   
Based on the kinetic simulation of the single turnover data corresponding to SS2, 
quinonoid intermediate decay has condensed into a single step, indicating that the 
opening of the active site lid to allow ALA dissociation is no longer a kinetically relevant 
part of the mechanism (Figure 4.8).   Thermodynamic data further support this 
spectroscopic observation (Figure 4.7 and Table 4.4).  Comparison of the wild-type 
ALAS- and SS2-catalyzed reactions indicates that there is a 6% difference in the Gibb's 
free energy of the reaction.  The decrease of net energy observed for the SS2-variant 
catalyzed reaction, supports the loss of the kinetic step, as the excess energy required by 
the wild-type enzyme will have to be absorbed from the environment, a circumstance 
whereby the ALAS-catalyzed reaction compensates by requiring an additional step.  This 
interpretation is supported by the refined mechanism of the ALAS-catalyzed reaction by 
Hunter et. al., wherein the reverse rate of enzyme-ALA1 conversion to enzyme-
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quinonoid is greater than the forward rate of enzyme-ALA1 conversion to enzyme-ALA2 
(28).  Overall the transient kinetic data suggest that active site lid flexibility and enzyme 
activity are tightly coupled and that both the rate limitation to the enzyme reaction and 
conformational motion are the same process dependent, in part, upon the spectrum of 
amino acids that comprise the motif.  
In conclusion, a mutational analysis of the active site lid of mALAS2, identified 
by structural investigation, reveals a role of the lid in determining the rate limiting step of 
the enzyme-catalyzed reaction. Variants isolated from the library contained mutations to 
the non-conserved residues that comprise the active site lid, with a marked preference for 
substitutions toward the carboxy terminal region of the motif.  Kinetic characterization of 
library isolates showed that mutations to the lid result in turnover numbers and catalytic 
efficiencies that were always greater than those of wild-type ALAS; strongly suggesting 
that the active site lid is a crucial determinant of both substrate binding and product 
turnover.  Additionally, in a subset of variants, the rate associated with product release 
appears independent of a conformational change.  The development of tractable 
fluorescent probes as well as solvent viscosity studies with the variants should prove 
useful in determining the conformational dynamics of the ALAS-catalyzed reaction. 
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Chapter Five 
Summary and Conclusion 
 The three-dimensional structures of Rhodobacter capsulatus ALAS holoenzyme 
and succinyl-CoA bound ALAS revealed “open” and “closed” conformational states of 
the enzyme, respectively (1).  The presence of these two conformational forms agrees 
with a previous proposal, based on the transient kinetic characterization of the ALAS 
pathway, in which the enzyme undergoes a transition from the open to the closed state 
upon succinyl-CoA binding and returns to the open conformation upon ALA release (2, 
3).  A closer look at the active site shows that a conserved serine residue (S189 in R. 
capsulatus ALAS and S254 in meALAS) changes the orientation of its hydrogen-
bonding pattern in a succinyl-CoA-dependent manner (1).  Succinyl-CoA binding 
induced dramatic changes in the visible CD spectra of both the wild-type and S254A 
proteins. Additionally, this amino acid substitution elicited a 2-fold increase in enzyme 
activity, while simultaneously increasing the Km for succinyl-CoA 25-fold.  These 
experimental findings coupled with the structural data suggest that this residue is an 
important determinant in conformer equilibrium by promoting energetically favorable 
interactions between the chromophore and succinyl-CoA, and by stabilizing a closed 
Michaelis-complex configuration.   
 To address the functionality of S254 in the ALAS-catalyzed reaction, kinetics 
experiments were performed on wild-type ALAS and two ALAS variants (S254A and 
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S254T).  Substitution of serine with alanine eliminates hydrogen bond formation between 
the amino acid and the phenolic oxygen of PLP and succinyl-CoA.  Notably, steady-state 
kinetic parameters calculated for this variant indicate that both the turnover number and 
the Michaelis constant for succinyl-CoA increased.  This finding implies unusual 
functional complexity regarding the correlation between this mutation and the enzyme-
catalyzed reaction.  The means by which the enzyme manages to increase activity despite 
a reduction in affinity for the more complex of the two substrates may include a 
mechanism whereby the equilibrium is predominantly shifted toward the closed 
conformational state. 
 The S254A mutation has notable effects on the cofactor microenvironment as 
determined by CD spectroscopy. CD spectroscopic evaluations of the conformational 
effects of the S254A and S254T mutations illustrate the differences between the two 
amino acid substitutions.  Succinyl-CoA binding to the wild-type and S254T variant 
induced changes in the CD spectra associated with the microenvironment of the 
chromophore, while CD spectra corresponding to the S254A mutant were unchanged 
under similar conditions.  This dissimilarity between wild-type ALAS and S254A may be 
the result of a partial conversion of the internal aldimine to free PLP aldehyde present in 
the active site, a circumstance which is observed in three out of the four R. capsulatus 
crystal structure active sites upon succinyl-CoA binding (1).  In the crystal structures 
these events are coincident with the closed conformation, from which it might be 
concluded that the S254A variant retains the internal aldimine in the presence of 
succinyl-CoA, and may not be induced to adopt a closed conformation upon binding of 
this substrate.    
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 Pre-steady-state kinetic analyses of both the wild-type ALAS- and variant-
catalyzed reactions show that upon decarboxylation, the ALA-bound quinonoid 
intermediate is formed followed by two successively slower steps in which the 
intermediate decays.  These two steps are assigned to protonation of the ALA-quinonoid 
intermediate and ALA release, respectively (3).  For the S254T variant, the rate of 
quinonoid intermediate formation decreased 4-fold compared to that of wild-type 
enzyme.  This reduction may indicate a change in the flow of electrons from the site of 
bond scission to the resonance stabilized carbanion, induced by a shift of the 
conformational equilibrium towards the closed conformation.  Changes in the position of 
PLP observed in the three-dimensional structures available for ALAS show a shift of 15 
degrees when substrate is bound (1).  These observations, coupled with experimental 
evidence suggesting that even subtle changes to the stereoelectronic parameters of the 
external aldimine and PLP modulate catalysis, indicate that the hydrogen bonding 
potential of position 254 in ALAS may be an important feature in the regulation of the 
transition from the open to the closed conformation (4, 5).  Together the data for both 
ALAS variants support a postulate whereby non-covalent forces between S254 and the 
phenolic oxygen influence an induced fit mechanism in which substrate recognition is 
coupled to conformational equilibria. 
 ALAS is a member of the -oxoamine synthase subfamily of pyridoxal 5'-
phosphate (PLP)-dependent enzymes and shares a high degree of structural similarity and 
reactivity with the other members of the family (6).  Despite the remarkable structural 
and mechanistic similarities in this important group of enzymes the molecular 
mechanisms underlying substrate specificity remain largely unexplored.  The X-ray 
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crystal structure of ALAS from Rhodobacter capsulatus reveals that the alkanoate 
component of succinyl-CoA is coordinated by a conserved arginine and a threonine (1).  
The functions of the corresponding acyl-CoA-binding residues in murine erythroid ALAS 
(R85 and T430) in relation to acyl-CoA binding and substrate discrimination were 
examined using site-directed mutagenesis and a series of CoA-derivatives. 
 The acyl-CoA substrate binds to the enzyme through an interaction between the 
pantetheine moiety of CoA with the enzyme surface and via hydrogen-bonding 
interactions between the terminal alkanoate group and R85 and T430 (1). The steady-
state kinetic analysis of the variants (R85K, R85L, and R85L/T430V) with the family of 
CoA-derivatives showed that the apparent Michaelis parameters are dramatically 
different when compared to those of wild-type ALAS.  Acyl-CoA substrates of increased 
hydrophobicity (e.g., octanoyl- and butyryl-CoA) bound with higher affinity to variants 
where the substituted amino acid was aliphatic in nature (R85L and R85L/T430V).  The 
36-fold decrease in substrate binding for octanoyl-CoA in the R85L variant suggests that 
the exclusion of water from the acyl-CoA-binding cleft is an important feature of 
substrate binding.  It is likely that reaction specificity is driven by the chemical 
characteristics of the CoA-derived tail and the hydrogen-bonding potential of the 
invariant acyl-CoA-binding residues, a circumstance which has been proposed for the 
acyl-CoA thioesterases of the peroxisome (7, 8). 
 The use of chemically different acyl-CoA-derivatives affects the transient kinetic 
parameters of a variant enzyme (R85K) signifying potential alterations to a key 
mechanistic step in the ALAS-catalyzed reaction.  Single turnover reactions with a family 
of CoA-derivatives were used to determine the rates of quinonoid intermediate formation 
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and decay for the R85K variant.  The R85K variant-catalyzed reaction was decelerated in 
the first step of quinonoid intermediate decay, with a 10-fold lower rate for both 
octanoyl-CoA and glutaryl-CoA when compared to the physiological substrate succinyl-
CoA.  When R85 is mutated to a lysine, the enzyme is chemically similar to wild-type 
ALAS in many respects, presumably because this conservative replacement retains the 
positive charge and hydrogen bonding capabilities.  However, the molecular volume of 
the amino acid side chain is different.  With respect to their n-alkyl moieties, the n-
propylguanidine side chain of arginine is longer than the n-butylamine side chain of 
lysine by 1.6 Å (9).  The R85K substitution could therefore accommodate the additional 
sp3 hybridized carbon atom present in glutaryl-CoA, allowing for a reduction in steric 
strain and/or unfavorable van der Waals interactions.  Both of these possibilities could be 
contributing factors in molecular recognition of the physiological substrate succinyl-CoA.  
In all, the experimental data support multifunctional roles for these amino acids (R85 and 
T430) in regulating substrate specificity, and linking the bifurcate coordination of the 
acyl-CoA tail with the mechanistic chemistry of the active site.   
 In X-ray crystal structures of 8-amino-7-oxononanoate synthase from E. coli and R. 
capsulatus ALAS, a loop, covering a conserved sequence of amino acids, was shown to 
migrate 3.5 and 5.5 Å between the holoenzymic forms and acyl-CoA-bound forms of the 
two enzymes, respectively (1, 10).  Comparison of holoenzymic ALAS and AONS with 
the substrate- and product-bound forms of the enzymes indicates that binding of these 
ligands within the active site precipitates movement of the loop.  These structural 
observations suggest, but do not prove, that the dynamics of this active site lid may 
signify a change in conformation.  In order to examine the role of this active site loop (or 
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“lid”) in the ALAS-catalyzed reaction, we used genetic manipulation to identify 
functional amino acid mutations and to evaluate the contribution of lid residues to 
catalysis.  The approach used to evaluate the active site lid of ALAS utilized a mutagenic 
technique called synthetic shuffling (11).  The active site lid of ALAS contains 18 
residues; 8 of these are completely conserved, while the remaining amino acids show no 
pattern with respect to evolution (1).  Mutations were observed throughout the entire 
motif.  However, more mutations were found in the carboxy-terminal portion of the lid 
compared to the segment closer to the amino-terminus (31 to 12, respectively).  This 
inequality suggests that greater plasticity is associated with the C-terminal part of the 
loop. 
 Each of the isolated variants was shown to have increased turnover numbers and 
enhanced catalytic efficiency with both substrates.  These characteristics, identified 
among active site lid variants, indicate that the reaction catalyzed by ALAS may be 
limited by the amino acid composition of the lid.  Further, conformational changes 
centered in active site loops have been reported to have important mechanistic roles in 
other enzymes (12, 13).  Accordingly, mutations that affect the mobility of a 
conformationally mobile enzyme structure may have consequences in which the physical 
step of product release, rather than chemistry, becomes rate limiting.  Therefore the 
enhanced turnover observed among the active site lid variants potentially validates our 
ALAS catalytic mechanism in which the enzyme conformation switches between closed 
and open to stabilize reaction intermediates and release product, respectively, a 
mechanism recently proposed for another PLP-dependent enzyme, diaminopimelate 
decarboxylase (14).   
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 The pre-steady-state behaviors of three variants from the library (SS2, F1 and 
H1)differed from that observed with the wild-type enzyme and other library isolates: the 
two steps associated with the quinonoid intermediate decay were condensed into a single 
step.  For the SS2 variant-catalyzed reaction, quinonoid intermediate formation is ~20-
fold faster than the corresponding rate in wild-type ALAS, suggesting that a step after 
catalysis is only partially rate-determining for this variant. Together with the greater 
dissociation constant of the SS2 variant for ALA (Table?), the data suggest that a 
conformational change leading to product release no longer is rate-limiting for the SS2-
catalyzed reaction.  Indeed, studies on several other enzymes where a chemical step has 
been implicated as rate-limiting show that the effects of conformational changes on kcat 
were the result of a thermodynamically driven commitment to catalysis (15-17).  In fact, 
increases in exothermy and positive differential activation entropy were also determined 
for the SS2 variant-catalyzed reaction.    
 Based on the kinetic simulation of the single turnover data for the reaction 
catalyzed by SS2, quinonoid intermediate decay has condensed into a single step, 
indicating that the opening of the active site lid to allow ALA dissociation is no longer a 
kinetically relevant part of the mechanism.  Thermodynamic data further support this 
spectroscopy-derived observation.  The decrease of net energy observed for the SS2 
variant-catalyzed reaction, supports the loss of this kinetic step.  Conversely, the excess 
energy required by the wild-type enzyme would likely have to be absorbed from the 
environment, a circumstance whereby the ALAS-catalyzed reaction would compensate 
by requiring an additional step (3).  This interpretation is supported by the refined 
mechanism of the ALAS-catalyzed reaction by Hunter et. al., wherein the reverse rate of 
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enzyme-ALA1 conversion to enzyme-quinonoid is greater than the forward rate of 
enzyme-ALA1 conversion to enzyme-ALA2 (3).  Overall the transient kinetic data 
suggest that active site lid flexibility and enzyme activity are tightly coupled and that 
both the rate limitation to the enzyme reaction and conformational motion are the same 
process, dependent, in part, upon the spectrum of amino acids that comprise the motif.   
 The kinetic parameters calculated for the library isolates show that these mutations 
confer hyperactivity.  Through these investigations, hypotheses pertaining to the reaction 
mechanism of ALAS have implications in the pathways of disease involving both iron 
metabolism and porphyrin biogenesis.  Data presented here and conclusions set forth 
regarding limits to ALA turnover and individual steps associated with substrate binding 
and rates of reaction, specifically address facets of XLSA and the recently discovered 
erythroid ALAS-related porphyria, X-linked dominant protoporphyria (19).  Many 
mutations associated with diminished ALAS activity in vivo are located in the PLP-
binding cleft (1, 19).  Significantly, the conformationally responsive S254 residue forms 
a hydrogen bond with the phenolic oxygen of the cofactor.  Enhanced turnover of ALA, 
and subsequent biosynthesis of porphyrins and porphyrin precursors are the foreseeable 
consequences of the reactions catalyzed by isolates from the active site lid library.  
Indeed, these circumstances resemble the pathology that is associated with X-linked 
dominant protoporphyria (18).   
The knowledge related to ALAS from the studies presented here contribute to the 
goal of therapeutic intervention of porphyrin-accumulative diseases, like cancer.   
Further, biochemical developments in the field of biotechnology will also be enhanced 
through this research by addressing the molecular requirements of treatments like 
 167
photodynamic therapy.  In conclusion, these data are likely to provide insight into the 
rate-determining step of enzymes limited by a product release, or a conformational 
change leading to product release. 
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